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An appropriate inflammatory immune response requires the effective orchestration of molecular 
and cellular effectors. Interleukin-17 (IL-17) is a cytokine, small signaling proteins, made by 
immune cells to communicate with mainly non-immune cells.  IL-17 signaling engages its 
receptor (IL-17R) to induce inflammation by stabilizing transcripts or by inducing expression of 
target genes. IL-17R downstream intermediate proteins activate and downregulate intracellular 
signaling. IL-17R shares some, but not all, intracellular intermediate proteins with Toll-like 
receptor (TLR) and Tumor necrosis factor α receptor (TNFR) signaling.  Previous research has 
shown that not all intermediates from TLR or TNFR1 pathways participate of IL-17R signaling. 
We aimed to identify novel intermediate proteins acting downstream in IL-17R by using 
molecular and cellular biology and biochemical techniques. After identifying five possible novel 
intermediates that either activate (caveolin-1 and AnapC3) or inhibit (ABIN-1, CYLD, Otulin) 
IL-17R signaling, we aimed to describe the mechanism of action of two of them, ABIN-1 and 
caveolin-1. We described the molecular mechanisms by which ubiquitin-binding protein ABIN-1 
and membrane-bound scaffolding protein Caveolin-1 control IL-17 signaling. Interestingly, as 
previous research on other signaling intermediates of IL-17R signaling has shown, IL-17R 
signaling also regulates the expression of these two proteins in what we propose is a self-
modulatory signaling mechanism. Specifically, we identified that ABIN-1 inhibits baseline and 
IL-17-activated signaling by binding polyubiquitin independently of A20. Moreover, we showed 
that IL-17 signaling induced degradation of ABIN-1. For caveolin-1, we observed a different 
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mechanism of regulation. Thus, Caveolin-1 interacted with a subunit of IL-17R and regulated 
trafficking of IL-17R to the cell surface. Interestingly, caveolin-1 regulatory functions correlated 
with an activating role of caveolin-1 in IL-17R signaling. Lastly, caveolin-1 was downregulated 
by IL-17 signaling. In this thesis we report novel functions for ABIN-1 and caveolin-1 
downstream of IL-17R. These results provide insight into the mechanism by which ABIN-1 and 
caveolin-1 regulate IL-17R signaling, and how IL-17R signaling self-regulates by modulating the 
expression or degradation of these two proteins. The results from this thesis contribute to the 
understanding of IL-17-mediated inflammatory signaling, and set the groundwork for future 
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1.0  CHAPTER ONE: INTRODUCTION 
1.1 INFLAMMATION IS MEDIATED BY INTERLEUKIN-17 AND ITS RECEPTOR 
The immune system uses inflammation as an effective tool to protect the host against microbial 
pathogens and harmful foreign molecules. An optimal immune response requires the 
orchestration of molecular and cellular effectors to regulate inflammation. Since inflammation 
causes tissue damage, initiation and termination of the inflammatory response is tightly regulated 
by lymphocytes. A mechanism by which lymphocytes control inflammation is through their 
production of cytokines, master signaling proteins that regulate the inflammatory response. The 
Interleukin-17 (IL-17) family of cytokines induce inflammation to fight pathogens, and 
dysregulated IL-17-mediated inflammation is associated with the development of autoimmune 
disorders (1,2). IL-17-mediated inflammation is achieved by activating intracellular signaling of 
the IL-17 receptor (IL-17R). Thus, IL-17 signaling promotes expression of inflammatory genes 
either by inducing their de novo transcription or by stabilizing their mRNAs (3–7).  This thesis 
focuses on understanding the intracellular regulation of the IL-17 response, and describing the 
mechanisms of action of two novel regulators downstream of IL-17R. 
IL-17A and its receptor are the best studied members of the IL-17 cytokine and receptor 
sub-families, comprising six cytokines (IL-17A through IL-17F) and five receptors (IL-17RA 
through IL-17RE). IL-17A forms a homodimer or heterodimer with IL-17F to engage its receptor 
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(8–10). In this thesis, I studied the signaling of the IL-17A homodimer, which from hereon I 
refer to as IL-17. All IL-17 receptors contain extracellular domains formed by fibronectin type-
III (FN) domains and cytoplasmic SEF/IL-17R (SEFIR) domains (figure 1.1) (11–13). IL-17RA 
and IL-17RC are the only two receptors in their family that express an extended C-terminal 
SEFIR (SEFEX) domain required for intracellular signaling (14,15). In addition to the SEFEX 
domain, IL-17RA is the only subunit to express an additional C-terminal domain, the distal 
CCAAT/enhancer binding protein β (C/EBPβ) activation domain (CBAD). Our group and others 
have shown that the CBAD is required for inhibitory signaling of IL-17. The CBAD regulates 
sequential phosphorylation and inactivation of C/EBPβ by regulating the activation of glycogen 
synthase kinase-3 beta (GSK-3β), and also binds A20 and TRAF3 to inhibit IL-17 signaling (16–
19). IL-17 signals through a heterodimeric receptor formed by IL-17RA and IL-17RC. The 
intracellular regulation of signaling downstream of this heterodimeric IL-17RA/IL-17RC 




Figure 1.1: Domains and subunits of the IL-17R. 
Schematic diagram of domains and subunits of the heterodimeric interleukin-17 receptor (IL-17R). This diagram 
depicts the heterodimer formed by IL-17RA (green) and IL-17RC (brown). Known domains of IL-17RA are 
annotated on the left side of the figure. Many of these domains have homology in the IL-17RC subunit. Acronyms: 
FN1/2: Fibronectin-III-like domain 1 or 2; TM: transmembrane region; SEFIR: SEF/IL-17R domain; SEFEX:  
SEFIR extension; CBAD: C/EBPβ activation domain. 
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1.2 THE TYPE 17 RESPONSE: IL-17-PRODUCING CELLS 
Lymphocytes are subdivided into different lineages. T cells are typically described as adaptive 
immune cells that are activated by engaging a specific antigen through their T-cell receptor 
(TCR). Two important defining characteristics of adaptive T cells are their specificity in 
recognizing an antigen and their ability to form memory (20,21). T cells are further categorized 
based on their functional specialization and their expression of specific surface receptors or 
markers. T cells with direct cytotoxic activity and expressing CD8 are classified as cytotoxic T 
cells. On the other hand, T cells that produce cytokines, help other immune cells, and express 
CD4 on the cell surface are classified as T Helper (TH) cells. In 1989, Mossman and Coffman 
hypothesized that two types of TH cells could be differentiated based on their ability to make 
cytokines: interferon-γ (IFNγ)-producing TH1 cells, and IL-4-producing TH2 cells (22). More 
than twenty years later, the TH1- TH2 hypothesis was expanded to include TH17 cells as an 
additional subset of CD4+ T cells (23,24). TH17 cells are characterized by the IL-23-dependent 
activation of the Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) 
pathway, and by their production of IL-17 (25–28).  
More recently, several types of innate immune cells have also been found to respond to 
IL-23 to produce IL-17 (29–33). Currently, IL-17-producing cells are characterized by their 
expression of the transcription factor retinoic acid receptor-related orphan receptor-γt (RORγt, 
encoded by Rorc). IL-17-producing cells can be either innate or adaptive immune cells, and 
include conventional TH17 cells, mucosal CD8+ T cells or Tc17, “natural” TH17 cells that are 
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innate as they do not require TCR activation, innate lymphoid cells Type 3 (ILC3), γδ T cells, 
natural killer T (NKT) cells, and invariant NKT  (iNKT) cells (33–35). Together, these cells are 
termed “type 17” cells. The innate type 17 cells in non-lymphoid tissues quickly respond to 
tissue injury or pathogenic insults, producing type 17 signature cytokines like IL-17, IL-22, and 
granulocyte-macrophage colony stimulating factor (GM-CSF) (34,36–38).    
Innate type 17 immunity depends on IL-1β and IL23 to activate the JAK/STAT3 
pathway. JAK1 phosphorylates and activates STAT3 to induce its translocation to the nucleus to 
act together with RORγt (2,39–42). Furthermore, STAT3 controls the expression of Rorc and 
other TH17-specific transcription factors like interferon-regulatory factor 4 (Irf4) and basic 
leucine zipper transcription factor ATF-like (Batf) (43–45). Therefore, STAT3, RORγt, IRF4, 
and BATF function coordinately to initiate and maintain the IL-17-producing phenotype. The 
differentiation, initiation and activation of TH17 cells is the most well-studied of all IL-17-
producing cells, and although I will not investigate TH17 cells themselves in this thesis, I will 
briefly mention the knowledge accumulated from previous studies on TH17 cells to provide a 
framework for appreciating the upstream events that ultimately lead to activation of IL-17-
producing cells (figure 1.2).  
TH17 differentiation is driven by additional factors such as transforming growth factor β 
(TGFβ) and IL-6, during initial T cell recognition of cognate antigen. The contribution of TGFβ 
signaling to differentiation is complicated by the fact that TGFβ could either control TH17-
inducing factors or indirectly restrict alternative cell fates. In contrast, the contribution of IL-6 to 
the TH17-phenoytpe is better understood. IL-6 activates STAT3, which directly drives 
transcription of Rorc, IL23r, and Il17. Additionally, STAT3 inhibits TGFβ-induced forkhead box 
P3 (FOXP3) expression, and consequently suppresses the differentiation of undifferentiated T 
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cells to a regulatory T (Treg) cell phenotype (46,47). Besides initiating T cell differentiation, IL-6 
induces expression of the IL-1β receptor (IL-1R) in TH17 cells. Activation of IL-1R signaling 
induces the phosphorylation of mammalian target of rapamycin (mTOR), activating IRF4 and 
enhancing the metabolic fitness of the dividing TH17 cells (48). For maturation and maintenance 
of the IL-17-producing phenotype, IL-23R signaling is essential, and the pathogenicity of TH17 
cells is promoted by IL-23. Genetic studies that link IL-23R polymorphisms to autoimmune 
disorders like psoriasis, ankylosing spondylitis, multiple sclerosis, and Crohn’s disease 
(described in more detail, below) support the pathologic role of IL-23R signaling in the type 17 
immunity (49–51). In this pathologic context, dysregulated TH17 cells make IL-17, which 
induces downstream signaling in responder cells to drive inflammation and tissue destruction. 
1.3 THE TYPE 17 RESPONSE: IL-17-RESPONDING CELLS 
The IL-17-responding cells are mainly non-immune cells. Their response to IL-17 is dependent 
on cell surface expression of the heterodimeric IL-17RA/IL-17RC receptor. The IL-17RA 
subunit is ubiquitously expressed across most cell types. However, the IL-17RC subunit is 
mostly expressed in non-immune cells, and provides specificity in terms of the ability to respond 
to IL-17 (52).  Furthermore, IL-17RC contributes to intracellular signaling of IL-17 through its 
SEFIR/SEFEX domain, which is absolutely required for intracellular signal transduction in vitro 
and in vivo (15,53,54). Selective expression of IL-17RC restricts the IL-17-responding cells to 
include epithelial cells, stromal cells and osteoclasts.  Indeed, IL-17-induces osteoclastogenesis, 
the differentiation of monocytic precursors into osteoclasts, which drives bone resorption. 
Osteoclasts, in turn, have a key role in rheumatoid arthritis by regulating IL-17-dependent matrix 
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metalloproteinases and RANKL production that modulates joint tissue remodeling. Additionally, 
recent evidence suggests that neutrophils and natural killer (NK) cells may also respond to IL-17 
via an induced expression of IL-17RC (55,56) although these findings are controversial In sum, 
primarily non-immune cells express IL-17RC to form a functional IL-17R that responds to IL-17 




Figure 1.2: Type 17 immunity connects immune and non-immune cell compartments. 
IL-17 is secreted by immune cells after differentiation and activation. IL-17 signals through the IL-17 receptor 
located on the surface of stromal, epithelial, and tissue-forming cells. (A) Antigen Presenting Cells (APC) sense 
PAMPs or DAMPS and make IL-6, IL-23, and IL-1β. (B) Adaptive IL-17-producing cells respond to IL-23, IL-6 
and IL-1β to make IL-17. In addition, innate IL-17-producing cells respond to IL-23 and other environmental factors 
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(e.g., other cytokines and/or directly responding to PAMP or DAMP) and make IL-17. (C) IL-17-responding cells 
produce effector molecules to respond to the initial insult. Additionally, IL-17-producing cells secrete chemokines 
that attract effector cells like neutrophils or monocytes to amplify the response. (D) Effector molecules and cells. 
This thesis focusses on the intracellular response of IL-17-responding cells highlighted in the orange box. 
Acronyms: PAMP: Pathogen-associated molecular patterns; DAMP: Damage-associated molecular pattern; APC: 
antigen-presenting cell; IL-6: interleukin-6 TH17: T helper-17; Tc17: T cytotoxic-17; NKT: natural killer T cells; 
iNKT: invariant NKT; ILC3: innate lymphoid cells-3; IL-17: interleukin-17; IL-17R: IL-17 receptor; ACT1: 
Nuclear factor-NF-kappaB activator 1; C/EBPβ: CCAAT/enhancer-binding protein beta; MAPK: Mitogen-activated 
protein kinase; NF-κB: Nuclear factor-kappaB; AP1: Activator protein 1; CXCL1/2: C-X-C motif chemokine 1 or 2; 






1.4 IL-17R SIGNALING, UBIQUITINATION AND IL-17-TARGET GENES 
Much effort has been dedicated to understanding the transcriptional regulation and cellular 
sources of IL-17. In this thesis, I aim to elucidate the regulation of IL-17R signaling occurring in 
IL-17-responding cells. Upon IL-17 secretion and binding to IL-17R, myriad intracellular events 
occur that induce gene expression and stabilize nascent transcripts, which ultimately leads to 
inflammation. 
Of these intracellular events, the post-translational protein modifications of 
phosphorylation and ubiquitination are the most relevant for IL-17R signaling. Phosphorylation 
on tyrosine (Y), serine (S), and threonine (T) residues regulates enzymatic activities and 
interactions of proteins by acting mainly as a bimodal on/off system. In contrast, ubiquitination is 
a multi-modal signaling system in the sense that addition of different ubiquitin chains to the 
same target protein has different outcomes. Each of ubiquitin’s seven lysine (K) residues can be 
joined to the N-terminal of a different ubiquitin molecule to form a wide array of ubiquitin 
chains. The functions of these covalently-bound ubiquitin chains on target proteins are diverse 
and depend on the type of K-linkage. For example, K48-pUb signals the proteasomal 
degradation of the target protein, whereas K63-pUb signals intracellular processes, such as 
interactions with other proteins, to activate or inhibit signaling pathways. This sophisticated 
coding system is mediated by E3-ligases (57). E3 ubiquitin ligases are important in IL-17R 
signaling due to their ubiquitination activity and concurrent function as scaffolding proteins. 
Ubiquitination is reversible and counter-regulated by deubiquitinases (DUBs). The human 
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genome is predicted to encode over 600 E3-ligases and nearly 100 DUBs. Thus, E3-ligases are 
thought to be more specific to their substrates than DUBs. The addition and removal of ubiquitin 
are key post-translational modifications of IL-17R (58) and its downstream proteins.  
IL-17R-mediated inflammatory signaling is initiated by recruiting the proximal adaptor 
ACT1 to the SEFIR domain of IL-17R. The primary function of ACT1 is to act as an adaptor 
connecting IL-17R to other downstream intermediates from the tumor necrosis factor-alpha 
(TNFα) receptor-associated factor (TRAF) family of proteins. In addition to its scaffolding 
function, ACT1 also catalyzes the addition of a K63-pUb chain on K124 of TRAF6 (59,60). 
ACT1 and TRAF6 are both E3-ligases that positively regulate IL-17-dependent nuclear factor 
kappa-B (NF-κB) signaling by binding to and adding pUb chains to downstream intermediates 
(61). One published report indicates that TRAF6 ubiquitinates IL-17R (58) and activates TGFβ-
activated kinase 1 (TAK1), which in turn interacts with ACT1. Next, TAK1 forms a complex 
with TAK1-binding protein-2 (TAB2) and -3 (TAB3) to interact with the SEFIR domain of IL-
17RA (62). Subsequently, TAK1 phosphorylates and activates the inhibitor of the κB (IκBα) 
kinase (IKK) complex formed by IKKα, IKKβ, and two subunits of IKKγ (also called NEMO). 
The activated IKK complex phosphorylates IκBα, inducing IκBα K48-ubiquitination and 
degradation. This degradation releases NF-κB transcription factor proteins to translocate to the 
nucleus and activate NF-κB-dependent genes.  
In addition to triggering NF-κB, IL-17R signaling also stabilizes mRNA transcripts, and 
initiates C/EBPβ/δ, IκBζ, and the mitogen-activate protein kinase (MAPK) pathways, including 
p38, JUN N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK) (figure 
1.3)(6,10,63,64). Upon IL-17 stimulation, p38 and JNK are activated by a mechanism involving 
the tumor progression locus 2 (TPL2) kinase. IL-17 activates the IKK complex, which in turns 
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phosphorylates p105 and releases TPL2 to activate p38 and JNK. TPL2 also binds, 
phosphorylates and activates TAK1, which subsequently activates the IKK complex, forming a 
positive-feedback loop (65). The mechanism of IL-17-dependent ERK activation is still unclear. 
In addition to MAPK proteins, C/EBPβ and C/EBPδ are also important effectors of IL-17 
signaling. In fact, synergy between IL-17 and TNFα signaling is partially mediated by C/EBP 
proteins (66). IL-17 induces transcription of Cebpd, while C/EBPβ is regulated post-
transcriptionally (via alternative splicing) and post-translationally (via phosphorylation) (17,67). 
C/EBPβ has three alternative start sites, and IL-17 induces the splicing and formation of the less 
dominant mRNAs. Additionally, C/EBPβ is sequentially phosphorylated on two serine residues 
to inhibit its transcriptional activity (17). Moreover, IκBζ is another effector of IL-17 signaling 
that contributes to IL-17/TNFα synergy. Karlsen et al. showed that TNFα induces Nfkibz 
(encoding IκBζ) and that IL-17 stabilizes the transcript, causing an increase of IκBζ. Then, IκBζ 
collaborates with NF-κB to enhance the expression of Lcn2, an iconic IL-17 target gene (68). 
Most of these signaling effector molecules converge to activate IL-17 target genes.  
IL-17 signaling induces different subsets of target genes. For example, IL-17 induces the 
expression of Cxcl1, Cxcl2, and Cxcl5 to recruit neutrophils to the target tissue. Ccl20 is also 
induced to promote trafficking of mucosal-associated cells expressing CCR6, a typical receptor 
of IL-17-producing cells like TH17 cells and ILC3s. IL-17 also induces Csf2 (encoding GM-
CSF) and Il6 to control survival, proliferation and recruitment of myeloid cells, especially 
neutrophils. Moreover, IL-17 signaling induces β-defensins, small cationic microbicidal peptides 
that directly destroy pathogens and prevent microbial colonization of epithelial surfaces. Lcn2 is 
another archetypal IL-17-target gene with antimicrobial activity encoding Lcn2 (also called 24p3 
or Ngal). Lcn2 limits bacterial growth by restricting access to dietary iron. The diversity of these 
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genes indicates that IL-17R signaling regulates several intracellular functions, and the different 
ways in which these genes are controlled demonstrate the different mechanisms by which IL17R 
signaling is regulated.  Binding sites for NF-κB, C/EBP, and the MAPK-dependent transcription 
factor AP-1 have been identified in the promoter regions of many of these IL-17 target genes 
(63), demonstrating that regulation of IL-17R signaling is mediated, in part, by activation and 
inhibition of C/EBP, MAPK and NF-κB. In this thesis, I focus mainly on the regulation of IL-17-
dependent NF-κB signaling.  
Some IL-17-dependent genes are fairly tissue-specific. For instance, IL-17 signaling in 
central nervous system (CNS) and gut epithelium induces expression of occludin proteins to 
maintain tight junctions and barrier integrity of these tissues (69,70). Another example of 
differentiated regulation and signaling of IL-17 is in oral and kidney epithelial cells, which 
express β-defensin and kallikrein proteins for antimicrobial activity and tissue protection (71,72). 
These examples demonstrate that in addition to driving inflammation, IL-17R signaling also 
drives specific gene expression in different tissues. Hence, the study of regulation of IL-17R 
signaling is vital to understanding the physiological consequences of tissue-specific type 17 
responses.  
Given that transcripts of many IL-17 target genes are highly unstable, IL-17 also 
regulates inflammation by stabilizing the mRNAs of these downstream target genes. The IL-17-
induced mRNA stability pathway is dependent on adaptor proteins ACT1, TRAF2 and TRAF5, 
but is independent of TRAF6. In the specific example of IL-17-induced Cxcl1 stability, for 
example, IL-17 signaling activates IKKε to phosphorylate ACT1 at S311. TRAF2 and TRAF5 
are then recruited to ACT1, which sequester the mRNA splicing regulatory factor (ASF/SF2) 
away from the 3’-untranslated region (UTR) of Cxcl1, promoting its stability (6,73). 
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Furthermore, IL-17 also recruits the human antigen R (HuR) protein to the 
ACT1/TRAF2/TRAF5 complex for ubiquitination and activation by ACT1. Activated HuR then 
binds to the 3’UTR of Cxcl1 and stabilizes the transcript by competing with ASF/SF2 to bind to 
similar sequences (74). However, studies of IL-17-mediated mRNA stability have mostly 
focused on understanding stability of chemokine transcripts such as Cxcl1 and Cxcl5. It is well-
known that IL-17 induces stability of other unstable inflammatory mRNAs, which suggests that 
IL-17 may activate other mRNA stability mechanisms. More details about this and other IL-17-
mediated mRNA stability pathways has been recently reviewed in Amatya et al. (11), and further 










Figure 1.3: Schematic representation of IL-17R signaling. 
Proposed model of IL-17R signaling including intermediate adaptor molecules, effectors and negative regulators. 
The red arrows with flat ends indicate inhibition and the black arrows with pointed ends indicate induction or 




1.5 REGULATION OF IL-17R SIGNALING 
Regulation of IL-17R signaling requires the coordination of activating and inhibitory factors at 
key intermediate signaling steps. As aforementioned, IL-17R proximal adaptor proteins ACT1 
and TRAF6 are crucial intermediates of IL-17 signaling, and both are regulated by post-
translational modifications. Moreover, phosphorylation and ubiquitination of ACT1 are key 
mechanisms for regulating IL-17R signaling. ACT1 has multiple sites of phosphorylation, and 
various kinases can target different sites to induce a specific response in IL-17R signaling. For 
example, ACT1 is phosphorylated to promote its K48-ubiquitination and degradation. 
Specifically, the ubiquitination of ACT1 is mediated by the SCFβ-TrCP complex formed by 
Skp1, Cdc53 and F-box protein Cdc4, plus the β-TrCP1 and β-TrCP2 proteins. This complex 
also K48-ubiquitinates IκBα, leading to its degradation (75).  Interestingly, although ACT1 and 
IκBα are degraded by similar mechanisms, the outcome of degradation of these proteins is 
different. These previously published results indicate that proteasomal degradation can 
coordinate activation of IL-17-dependent signaling by degrading intermediates at various levels 
in the signaling cascade.  
In addition to post-translational modification of ACT1, IL-17R signaling is also regulated 
by proteins that bind to ACT1 and TRAF6. TRAF6 ubiquitinates both itself and downstream 
proteins to activate signaling, and the lack of response to IL-17 observed in TRAF6-/- fibroblasts 
demonstrated that TRAF6 is a crucial component in the IL-17R pathway (52,76). For instance, 
one report by Wu et al. showed that the Syk kinase binds ACT1 and TRAF6 to enhance TRAF6 
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ubiquitination and expression of IL-17-dependent CCL20 (77). One report by Zepp et al. showed 
that TRAF4 interacts with ACT1 to activate ERK5 in keratinocytes. Moreover, these authors 
observed that IL-17-dependent activation of ERK5 could promote proliferation of keratinocytes 
(78). Indeed, Traf4 is overexpressed in skin cancer cells, suggesting that the overexpression of 
Traf4 in cancer cells causes IL-17R signaling to induce proliferation in a TRAF6-independent 
manner. 
There are also several examples showing that blocking the interaction of ACT1 with 
downstream proteins inhibits IL-17R signaling. For instance, the tank-binding kinase-1 (TBK1), 
another IKK-related kinase, directly phosphorylates and binds ACT1 to block the interaction of 
ACT1 with TRAF6, thus inhibiting IL-17 signaling (79). Similarly, TRAF3 and TRAF4 bind to 
ACT1 to block the ACT1/TRAF6 interaction (18,78). These studies show that IL-17 signaling is 
regulated by proteins controlling the binding of ACT1 to downstream intermediates.  
Notwithstanding the crucial role of ACT1 in the IL-17R signaling cascade, inhibition of 
IL-17R signaling may also occur further downstream of ACT1. For instance, our group 
described that IL-17 signaling activates GSK-3β, which together with ERK1/2, sequentially 
phosphorylates C/EBPβ. This sequential phosphorylation inhibits C/EBPβ nuclear translocation 
and activation of C/EBPβ-dependent genes. The mechanism of this regulation is only partially 
understood, and requires CBAD of IL-17RA to activate GSK-3β after IL-17 stimulation (17).  
These studies suggest that there might be other adaptor proteins proximal to IL-17R that activate 
GSK3β and that remain to be discovered. 
Inhibition of IL-17R signaling is also regulated at the mRNA level by a subset of IL-17-
target genes. Recently our group showed that endoribonucleases Roquin1/2 and MCPIP1 
degrade transcripts of genes such as Il6, Il17ra, Il17rc, and Nfkbz to decrease IL-17 signaling and 
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mediate inflammation in the setting of autoimmunity and lung inflammation (80,81). 
Interestingly, MCPIP1 recognizes loop structures in the 3’-UTR of these transcripts, 
destabilizing them and inducing their degradation. These results confirm that regulation of 
mRNA is another important arm of the regulatory mechanisms of IL-17R signaling. Moreover, 
microRNAs mIR30 and mIR23b also inhibit mRNA stability by directly binding to the 3’- UTR 
of the mRNA is encoding TAB2 and TAB3, destabilizing them and consequently decreasing 
activation of NF-κB signaling (82). Altogether, these reports indicate that there are many layers 
of complexity to the regulation of IL-17R signaling.  
Another potential regulatory mechanism of IL-17R signaling is the control of receptor 
localization to the plasma membrane. However, the full extent by which the IL-17R surface 
localization is regulated remains poorly understood. To date, most studies on IL-17R signaling 
have focused on activation of downstream signaling, whereas studies of receptor trafficking and 
localization have been comparatively limited (13). Nonetheless, several key early studies have 
revealed the significance of IL-17R domains and subunits in the context of receptor localization. 
For instance, IL-17RA mutants with mutations in the intracellular SEFIR/SEFEX domain exhibit 
normal protein folding and transport to the cell surface, however, they exhibit different effects on 
intracellular signaling (14). One particular mutant, the IL-17RAdelta665 mutant lacking the 
inhibitor CBAD domain, expresses IL-17R more robustly than other receptors, which correlates 
with its rather stronger signaling capability (17). Furthermore, another study from our group 
using fluorescence resonance energy transfer (FRET) microscopy indicates that IL-17 
stimulation induces disappearance of IL-17RA from the cell surface (83). Altogether, these 
observations demonstrate that intracellular signaling events and the capability of the receptor to 
signal could partially control IL-17R trafficking and localization. However, although the final 
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fate of IL-17RA after signaling is unknown, the fact that the receptor reappears on the cell 
surface ten to thirty minutes after removing IL-17 from the medium (Gaffen lab, unpublished), 
suggests that IL-17RA is recycled back to the plasma membrane. The mechanism of the possible 
receptor recycling is unknown, but may involve ubiquitination of IL-17RA, since and the IL-
17RA is ubiquitinated (58) and ubiquitination mediates recycling of epidermal growth factor 
receptor (EGFR) (84). Further studies to identify the mechanism by which IL-17R is transported 
to and from the cell surface and recycled after signaling may reveal the involvement of plasma 
membrane proteins that regulate intracellular trafficking, such as scaffolding proteins or 
ubiquitin-related proteins. In sum, these reports indicate that there are many layers of complexity 
to the regulation of IL-17R signaling and subcellular localization. 
1.6 INHIBITION OF IL-17R SIGNALING IS REGULATED BY UBIQUITINATION 
As described above, ubiquitination of TRAF6 is an important step in the regulation of IL-17R 
signaling.  Thus far, two DUBs, A20 and ubiquitin-specific protease 25 (USP25), have been 
described to remove K63-pUb chains from TRAF6 to inhibit IL-17R signaling via different 
mechanisms. Specifically, USP25 interacts with TRAF5 and TRAF6, and removes their ACT1-
mediated K63-pUb chains. USP25 requires its DUB activity to inhibit both IL-17-dependent NF-
κB activation and IL-17-mediated stabilization of Cxcl1 and Il6 transcripts. Consistently, 
USP25-/- mice exhibit elevated IL-17-mediated inflammation in a setting of lung and CNS 
inflammation (85). These findings demonstrate that the deubiquitination of K63-pUb is an 
important regulatory mechanism of IL-17R signaling, and suggest that other DUBs could 
potentially have roles in the regulation of IL-17-mediated inflammation. 
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Several reports indicate that A20 plays a role in IL-17R signaling, but this relationship 
appears to be different across cell types. In bone marrow stromal cells, our group showed that 
A20 inhibits IL-17R signaling by interacting with IL-17R to inhibit TRAF6 polyubiquitination 
and NF-κB activation. Additionally, IL-17 induces A20 expression via NF-κB (19). In 
astrocytes, although A20 also inhibits IL-17R signaling, IL-17 represses A20 expression by 
inducing A20-targeting microRNAs (miR-873 and miR-136-5p) (86–89). Lastly, in enterocytes, 
IL-17 does not regulate A20 expression, and A20 regulates TLR4 signaling without evidence of 
controlling IL-17R signaling in these cells (90). Together, these reports show that A20 functions 
downstream of different receptors, and that distinct cell types have different mechanisms to 
regulate A20. A possible explanation for these observations could be found by analyzing the 
differences in exposures among cell types. Enterocytes are constantly exposed to TLR ligands 
from gut microorganisms. Thus, there must be internal regulatory mechanisms that shift the 
inhibitory activity of A20 to control TLR signaling instead of IL-17R signaling. In contrast, the 
central nervous system (CNS) is rarely exposed to microbes or TLR4 ligands, so in homeostasis, 
inflammatory signaling in cells such as astrocytes is minimal and tightly regulated. However, if 
microbes enter the CNS, inflammation must be quickly invoked to control the microbial 
invasion. Thus, the expression of microRNAs that downregulate A20 is a mechanism to quickly 
increase type IL-17 immunity and eliminate microbes. Following this logic, stromal cells and 
fibroblasts have less exposure to the TLR4 ligand than enterocytes, so, additional regulatory 
mechanisms would make fibroblasts more responsive to IL-17 compared to enterocytes. 
Therefore, A20 inhibits IL-17R signaling because the IL-17 pathway is among the main 
inflammatory pathways to which fibroblasts and stromal cells respond. In summary, A20 is an 
anti-inflammatory molecule that inhibits, among other pathways, IL-17R signaling. Additionally, 
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regulation of A20 is diverse across different tissues, and A20-mediated inhibition of IL-17R 
signaling is coordinated by microRNAs and A20-related proteins specific for each tissue.  
ABIN-1 and CYLD are two examples of A20-related proteins. ABIN-1 binds A20 and 
contributes to the A20-mediated inhibition of TNF signaling, at least in part, by bridging the 
interaction of A20 with NEMO (91,92). Additionally, A20 is a DUB with overlapping functions 
to CYLD. Both DUBs remove K63-pUb chains from NEMO and RIP1 to act as negative 
regulators of TNF-dependent NF-κB signaling (93–96). Therefore, it is possible that ABIN-1 and 
CYLD may also contribute to A20-mediated inhibition of IL-17R signaling.  
Additionally, work by Draber et al. showed that the linear ubiquitin chain assembly 
complex (LUBAC) recruits CYLD and A20 to inhibit TNF signaling (97). Linear ubiquitination 
is an important process to regulate NF-κB signaling downstream of TNFα,  via activation of the 
IKK complex (98). Interestingly, there is only one known DUB that removes linear ubiquitin, 
Otulin, which a report has shown can bind LUBAC to prevent activation of the IKK complex 
downstream of TNFα signaling (99).  Moreover, another recent report has shown that in immune 
cells Otulin has cell-type-specific effects, including over-production of inflammatory cytokines, 
accumulation of linear-polyubiquitin chains and spontaneous NF-κB activation in myeloid cells 
(100). Based on these data, Otulin may be another inhibitor of IL-17R signaling.  
Despite all these lines of evidence indicating that ABIN-1, CYLD and Otulin inhibit 
inflammatory pathways that are used by IL-17, no mechanisms involving these proteins 
downstream of IL-17-mediated inflammation have been described. These findings raise the 
question of whether these, and maybe other ubiquitin-related proteins, inhibit IL-17R signaling. 
Understanding the role of ubiquitination, deubiquitination and the proteins that regulate these 
processes will lead to a more complete understanding of regulation of IL-17R signaling.   
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1.7 IL-17R SIGNALING IN CONTEXT WITH OTHER INFLAMMATORY 
PATHWAYS 
Ligands like LPS, IL-1β or TNFα strongly activate inflammatory signaling by binding to TLR4, 
IL-1βR1 and TNFR1, respectively.  IL-17 is a modest activator of signaling compared to these 
and other inflammatory ligands. Nevertheless, IL-17 cooperates with LPS, IL-1β, IFNγ, IL-22, 
lymphotoxin-beta (LT-β) and TNFα to induce inflammatory signaling. The molecular 
mechanisms of the cooperation of IL-17 with these inflammatory molecules are diverse and 
poorly understood.  However, cooperativity occurs because these pathways share some, but not 
all, intermediate adaptors that converge on the activation transcription factors to enhance 
signaling. An additional mechanism of synergy involves stabilization of gene transcripts. For 
instance, IL-17 and TNFα signaling synergize to activate the promoters of Lcn2 and Il6, but also 
to stabilize Il6 transcript. 
The differences and similarities among IL-17R, TLR4 and TNFR1 provide the basis to 
understand cooperation among these signaling pathways.  Both TNFR1 and TLR4 have the 
potential to signal on both the cell surface and inside the cell, but there are no studies indicating 
that the IL-17R signals on another subcellular compartment besides the cell surface.  
Additionally, both TNFR1 and TLR4 use different receptor-proximal adaptor proteins to activate 
their signaling. TNFR1 uses TNFR-associated death domain (TRADD), TRAF2, Receptor-
interacting protein (RIP) and Fas-associated death domain (FADD), while TLR4 uses MyD88 
(myeloid differentiation primary response protein 88) and Tirap (toll/interleukin-1 receptor 
domain-containing adapter protein), TRIF and TRAM. Except for TRAF2, none of the TNFR1- 
or TLR4-proximal adaptor proteins have been reported to function downstream of IL-17R.  In 
terms of differences between signaling effects, TNFR1 induces cell death, while TLR4 activates 
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several downstream pathways like IFN-responding factor 5 (IRF5) and TBK1/IKKε-dependent 
IRF3. The similarities among IL-17R, TNFR1 and TLR4 lie in their many shared signaling 
intermediates. IL-17R and TNFR1 activate the MAPK pathway and the IKK complex to induce 
NF-κB signaling. Both IL-17R and TLR4 activate TRAF6 to induce MAPK and NF-κB 
signaling.  As aforementioned, A20 and USP25 inhibit IL-17R signaling in addition to TLR4 
signaling. The cross-talk of these inhibitors suggest that other regulators from TLR4 and TNFR1 
may also play a role downstream of IL-17R signaling. Based on our current knowledge about 
TLR4 and TNFR1 signaling, I selected genes coding for some of their intermediate adaptors and 
tested the role of these genes in IL-17R signaling. I describe those results in chapter 3. In 
summary, insight from TLR4 and TNFR1 signaling can be used to guide research on IL-17R 
signaling. 
 
1.8 THE ROLE OF IL-17 IN INFECTIONS 
A functional IL-17-dependent inflammatory response is required for controlling a wide range of 
pathogenic organisms including parasites, extracellular and intracellular bacteria, and fungi. 
Elimination of these pathogens is organized by IL-17-induced antimicrobial peptides that 
directly kill pathogens, or by IL-17-induced chemokines that indirectly destroy pathogens 
through the recruitment of neutrophils and monocytes to the site of the infection. For example, 
IL-17 induces S100A8 and S100A9, which together form the heterodimeric protein calprotectin. 
Similar to Lcn2, which sequesters iron (as explained above in section 1.4), calprotectin limits 
microbial growth by restricting access to manganese and zinc.  
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IL-17-producing cells have been examined in the context of mucosal infection by fungi 
such as Candida albicans, Pneumocystis, and Cryptococcus neoformans, and bacteria such as 
Klebsiella pneumoniae, Staphylococcus aureus and Mycobacterium tuberculosis (101–103). The 
role of IL-17 signaling is less clear for the regulation of viral infections.  
Regarding fungal pathogens, humans with defects at various points along the Th17 
pathway are susceptible to mucosal, but usually not disseminated, candidiasis. Furthermore, 
human studies have shown that patients with complete deficiency in IL-17RA or IL-17RC, or 
partial deficiency in IL-17F (and consequently in IL-17F/F and IL-17A/F), have susceptibility to 
chronic mucocutaneous candidiasis infection (104,105). This not only ties IL-17 to the anti-
Candida response but also indicates that the dominant activity of IL-17 in humans is antifungal. 
Additionally, multiple studies have shown that a STAT1 gain-of-function (GOF) mutation and 
caspase recruitment domain-containing protein 9 (CARD9) deficiency increase susceptibility to 
Candida infections, and are associated with decreased IL-17 production. STAT1 GOF competes 
with and overcomes the binding of STAT3 to the Rorc promoter, decreasing expression of Rorc, 
Il17 and IL-17 target genes (106). Furthermore, patients with Job’s Syndrome/Hyper-IgE 
Syndrome (HIES) have autosomal dominant-negative mutations in STAT3 associated with 
reduction of TH17 cell frequencies. These patients are susceptible to chronic mucocutaneous 
candidiasis (CMC) (107). Similarly, mutations in the autoimmune regulator (AIRE) increase the 
susceptibility to CMC.  This is thought to be because AIRE-deficiency leads to production of 
autoantibodies against IFNs and TH17-related cytokines like IL-22, IL-17F and IL-17A, resulting 
in blockade of the type 17 response (108). Altogether, these finding with patients confirm the 
key role of IL-17 signaling in clearance of Candida albicans infection. Indeed, the robust 
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association of IL-17 signaling with Candida albicans infection allows murine models of 
candidiasis to be used as physiological read-outs of the type 17 immunity (28,81).  
In Pneumocystis infections, a recent study showed that while IL-17 production was 
increased in the lungs of infected mice, IL-17A-/- mice cleared Pneumocystis infection with 
kinetics similar to wild-type mice, suggesting that IL-17 is not required in all situations to control 
Pneumocystis infection (109). Despite these conflicting murine studies, Pneumocystis remains an 
important pathogen in immunosuppressed patients deficient in TH17 cells, which indicates that 
IL-17 signaling plays a role in the clearing of this infection. 
In both immunocompromised and immunocompetent individuals, Cryptococcus 
neoformans causes significant morbidity and mortality. Cryptococcus neoformans uses a PGE2- 
and IRF4-dependent mechanism to specifically inhibit induction of IL-17 during TH17 
differentiation (110). Experiments in IL-23 deficient mice have shown a reduction in IL-17 
increases susceptibility to infection by Cryptococcus neoformans (111). Thus, altogether, these 
findings suggest that Cryptococcus neoformans infection is regulated by type 17 immunity. 
IL-17 signaling is also involved in the inflammatory response to extracellular bacterial 
infections.  For example, deficiency in IL-17 signaling decreases pulmonary clearance of 
Klebsiella pneumoniae in mice. Extensive work performed by the Kolls group has shown that the 
regulation of Klebsiella pneumoniae is dependent on IL-17 receptor signaling in the lung 
epithelium, and that IL-17 signaling is crucial for inducing Lcn2 production and for mediating 
mucosal defense (112–114). As described above, Lcn2 restricts Klebsiella pneumoniae from 
accessing free iron, thereby limiting bacterial growth (113,115,116). These studies show the 
importance of the IL-17-dependent production of antimicrobial peptides in controlling bacterial 
burden.  Staphylococcus aureus infection is another bacterial infection that requires an IL-17-
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mediated immune response, as human and murine studies suggest. Patients with HIES have 
increased susceptibility to Staphylococcus aureus infection. In a Staphylococcus aureus infection 
murine model, the IL-17 response induces neutrophil recruitment and bacterial clearance, 
reducing mortality (40). In sum, gram-positive and gram-negative extracellular bacterial 
infections are regulated by IL-17 signaling.  
The IL-17 response also exhibits a protective role for intracellular bacteria in human 
studies and murine models. Notably, there is an apparent role for IL-17 in protective immunity 
against hypervirulent Mycobacterium tuberculosis infection. The Khader group showed that IL-
17 has a protective role against Mycobacterium tuberculosis infection by limiting hypoxia 
around bacterial granulomas, through inhibition of hypoxia-induced factor-1alpha (HIF1α). In 
vivo neutralization of IL-17 increased Mycobacterium tuberculosis susceptibility. This was 
consistent with results showing that a human polymorphism upstream of the IL17 promoter 
correlates with decreased IL-17 production and increased risk of tuberculosis (117).  
Additionally, the Khader group has found that IL-17 also mediates an unexpected protective 
immunity against Mycobacterium tuberculosis via the IL-17-dependent induction of CXCL13, 
which is required for localization of T cells within lung lymphoid follicles. Appropriate T cell 
localization within lung lymphoid follicles is, in turn, necessary for macrophage activation and 
control of Mycobacterium tuberculosis (118). 
Finally, a dual protective and pathogenic role has been associated with IL-17 in the 
clearance of Influenza virus and rhinovirus infections. Importantly, Influenza A co-infection has 
been shown to decrease IL-17, IL-22, and IL-23 production after Staphylococcus aureus 
infection (119), suggesting that the virus regulates type 17 immunity. In addition to a possible 
role in controlling viral infections, IL-17A is also related to viruses by homology with the 
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herpesvirus saimiri (HVS). Sequence alignment of mouse IL-17 molecule contains 147 amino 
acids and shares 57% identity to HSV13, an open reading frame (ORF) from HVS (120).  
In summary, IL-17 signaling is crucial for fighting certain fungal and bacterial pathogens, 
and might also play at least a limited role in response to some viral infections. The control of 
these pathogens requires the expression of IL-17-target genes to induce inflammation. 
Depending on the pathogen, the organization of different IL-17 target genes contributes to the 
clearing of the infection. Altogether, these studies suggest that type 17 immunity is key for 
clearing or controlling some pathogens, and that understanding how to enhance IL-17R signaling 




1.9 THE ROLE OF IL-17 SIGNALING IN AUTOIMMUNE DISEASES 
In autoimmune diseases, tolerance to self-antigens is compromised, triggering inflammation and 
tissue destruction, and the specific disease manifestation depends on the organ where this 
excessive inflammation is found. Dysregulation of IL-17 expression or signaling in different 
tissues is associated with the onset of different autoimmune diseases. A large body of evidence 
indicates that IL-17-mediated inflammation contributes to the pathology of autoimmune diseases 
such as psoriasis, multiple sclerosis, Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis 
and chronic noninfectious uveitis. In this section, I will discuss the roles of IL-17 in the 
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pathogenesis of a few autoimmune diseases, focusing on those that have animal models that 
could be used in future studies, and those that might benefit from IL-17-related therapies.  
 
1.9.1 Psoriasis 
Psoriasis is a chronic skin disease characterized by dermal hyperplasia that results from the 
dysregulation of inflammatory signaling between keratinocytes and infiltrating immune cells. In 
psoriasis, skin-resident IL-17-producing cells respond to inflammatory molecules producing IL-
17. Keratinocytes respond to IL-17-inducing inflammatory and chemoattracting molecules that 
recruit neutrophils to the local area (121). The IL-17-mediated inflammation induces rapid 
recycling of epidermal cells, leading to the formation of red, scaly lesions and chronic skin 
inflammation. A mechanism underlying the role of IL-17 in psoriasis may involve its propensity 
to synergize with other factors. For example, IL-17 synergizes with other cytokines like IFNγ, 
TNFα, and IL-22 to induce inflammatory cytokines and chemokines. IL-17, in combination with 
TNFα, induces inflammatory genes that are characteristic of psoriasis from human keratinocytes, 
such as IL-6, IL-8 and ICAM-1 (122,123). In addition, IL-17, together with IL-22, 
synergistically increases the expression of skin antimicrobial peptides, including β-defensin-2 
(BD-2) and the S100 proteins, S100A7, -8, and -9 (124). Consistent with the elevated production 
of antimicrobial peptides, psoriasis patients are more resistant to skin infections than healthy 
people (125). Furthermore, keratinocytes stimulated with IL-17, IL-22 and TNFα produce 
CCL20 (a ligand for CCR6), which is probably required for the continuous recruitment of 
CCR6-positive TH17 cells in the psoriasis lesions (126).   
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The success of inhibiting IL-17 as a therapy to reduce skin disease in patients with plaque 
psoriasis highlights the role of IL-17 in this disease. Therapeutically, blocking of IL-17 was 
found to be more effective than blocking TNFα for the treatment of psoriasis (127). Despite the 
clear association of IL-17 signaling with the onset of psoriasis, human genetic studies have found 
no link between psoriasis and polymorphisms in genes coding for IL-17 or its receptor. However, 
several polymorphisms in genes that regulate NF-κB signaling have been found, suggesting that 
the role of IL-17 on the onset of psoriasis might be to activate NF-κB-dependent inflammatory 
genes. 
Additional studies have shown that polymorphisms in NF-κB-inhibitory genes such as 
TNFAIP3 and TNIP1 are linked to the onset of psoriasis (128–131). Consistent with these 
findings from human studies, the mouse homologues Tnfaip3 and Tnip1 have been shown to 
regulate IL-17-mediated inflammation in murine models of psoriasis. Mechanistically, A20 
inhibits IL-17R signaling (19), which explains why the lack of A20 increases IL-17-mediated 
inflammation; however, the molecular mechanism of ABIN-1 (coded by Tnip1) function 
downstream of IL-17R signaling has not been solved.  
In addition to human genetic studies, skin biopsies from psoriatic patients provide 
evidence of the proteins involved in psoriasis. For example, patient biopsies have elevated levels 
of TGFα compared to controls (132,133), suggesting a role for TGFα in this disease. 
Additionally, a study comparing psoriatic with non-affected skin biopsies from the same patients 
showed that the psoriatic areas have decreased ABIN-1 protein (134), consistent with genetic 
associations mentioned above. Moreover, several studies have shown that caveolin-1 protein is 
dramatically downregulated in psoriatic skin lesions (135–139), suggesting that caveolin-1 has a 
role in the pathogenesis of psoriasis. However, no clear connections between caveolin-1 
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functions and the molecular pathways involved in the onset of psoriasis have been established.  
Thus, further mechanistic studies are required to understand the role of Caveolin-1 protein in the 
molecular pathways involved in the development of psoriasis.  
 
1.9.2 Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS. Patients 
with MS have more IL-17-producing cells in blood and cerebrospinal fluid (CSF) than healthy 
controls (140), and necropsy samples taken from the brains of patients with multiple sclerosis 
show increased IL-17 expression (141). Although these findings suggest a role for IL-17 in the 
CNS, more solid evidence of this comes from the murine experimental autoimmune encephalitis 
(EAE) model of MS.  
In EAE, TH17 cells accumulate in the CNS, and the production of IL-17 induces 
inflammation mediated by glial cells (142).  Furthermore, lack of IL-23 signaling arrests these 
TH17 cells in an early activation stage in which they do not cause EAE (143). An important 
pathogenic aspect of TH17 cells is the IL-23-driven production of GM-CSF, as evidenced by the 
observation that IL-23R-deficient TH17 cells do not cause disease (144,145). IL-23 signaling is 
also pathogenic because it induces IFNγ expression in TH17 cells, and these double IL-17/IFNγ-
producing cells have been shown to transfer EAE susceptibility (146–148).  
 As described in section 1.2, IL-6 and IL-1β signaling are important for the development 
of TH17 cells, which is exemplified by results showing that mice deficient in IL-6 signaling or 
IL-1β signaling have fewer TH17 cells, and consequently, are protected from developing EAE 
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(149,150).  Moreover, plasticity between Treg and TH17 cells has been observed in EAE and in 
patients with MS (147,151). 
Additionally, in EAE, IL-17 induces p38-MAPK activation, which in turn activates dual 
specificity protein phosphatase 1 (DUSP1) in CNS-resident cells to induce expression of 
chemokines that recruit TH17, TH1, and macrophages to the CNS. This mechanism maybe 
important for initiation of EAE (152), and possibly important for the initiation of MS. The 
relevance of IL-17 in the development of EAE makes it a commonly-used model for testing IL-
17 signaling under physiological conditions (81,153). As with other autoimmune diseases, MS is 
a multifactorial disease, and the use of the EAE model has contributed greatly to understanding 
the role of type 17 immunity in this disease.   
1.9.3 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a heterogeneous and chronic disease that also has an IL-17R 
signaling component in its etiology. The role of IL-17 signaling in this disease has not been 
clearly established, in part due to challenges arising from disease heterogeneity. RA is 
characterized by the proliferation of synovial fibroblasts, infiltration of CD4+ T-cells, and 
autoantibody-producing plasma cells into joint spaces, leading to joint and cartilage erosion. RA 
patients are diagnosed based on joint inflammation and autoantibody production, symptoms that 
can be caused by different etiologies. This heterogeneity is exemplified by the fact that there is 
no single therapy that works for all patients (something that is common to most autoimmune 
diseases). Instead, therapies work for subsets of patients, leading to the classification of them as 
responders or non-responders. Different pools of patients with RA respond differenty to 
treatments such as the small molecule methotrexate (MTX), anti-TNF blocking antibody, anti-
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CD20 antibody or anti-IL-17 blocking antibody.  Interestingly, in clinical trials, the beneficial 
effect of blocking IL-17 was not significantly greater than the effect of blocking TNF, a currently 
approved therapy (154,155). Thus, results from clinical studies show that although IL-17 may 
play a pathologic role in the development of RA, this effect is probably restricted to a subset of 
patients. Additionally, this suggests that the role of IL-17 signaling in RA is part of multiple 
underlying mechanisms for disease, but not all patients manifest disease due to the same 
mechanisms. The mechanisms of IL-17 in RA pathogenesis require cooperation between IL-17 
and TNFα to induce expression of chemokines, cytokines, and MMPs to destroy cartilage and 
remodel joint tissue (156,157). Specifically, osteoclasts respond to IL-17 stimulation by inducing 
expression of mediators like MMPs and RANKL. The expression of these inflammatory genes 
leads to cartilage and bone destruction, which destroys and remodels the joint tissue (158). 
Altogether, results from human studies of RA reveal that IL-17 signaling is one component of 
the multifactorial onset of disease.  
Additional evidence for a role of IL-17 in RA comes from experimental murine models. 
Collagen-induced arthritis (CIA), a mouse model of RA, is much more severe in mice lacking 
IL-12 or IFNγ, arguing against the importance of TH1 cells in this model. A key insight into this 
disease came from the discovery that IL-23 is more important for the development of CIA than 
IL-12 (159), suggesting an essential role for TH17 cells. Indeed, neutralizing IL-17 or its receptor 
in CIA mouse models reduces joint inflammation, cartilage destruction and bone erosion (160), 
whereas ectopic expression of IL-17 promotes collagen arthritis and aggravates joint destruction 
(161). IL-17-deficient mice were resistant to CIA, confirming the critical role of IL-17 in CIA 
(162). However, given differences between murine CIA and human RA, these findings do not 
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discredit the role of other mechanisms in human RA, but they do support a contributing role for 
IL-17 signaling in RA. 
 
 
1.9.4 Ankylosing Spondylitis 
Ankylosing spondylitis (AS) is a chronic immune-mediated inflammatory disease characterized 
by progressive spinal rigidity and chronic spinal inflammation initiating in the sacroiliac joints, 
presenting as chronic inflammation at the sites of ligamentous and tendinous insertions into bone 
(163). A successful treatment for AS is the use of anti-TNF blocking antibodies, which confirms 
that this disease is highly driven by TNFα-mediated inflammation. Furthermore, IL-17-mediated 
inflammation is also an important component for the development of AS. Recent clinical trials 
with anti-IL-17 antibodies have shown significant clinical efficacy in AS (164), superior to the 
effect of blocking TNFα.  Measured by clinically assessing disease severity and changes in 
baseline in the high-sensitivity C-reactive protein (CRP) level in serum, they showed that 
blocking IL-17 is not only is effective in patients who have not received TNF agents previously 
but also may be effective in patients in whom previous anti-TNF treatment failed (165).  
Consistent with a model in which IL-17 contributes to the pathology of AS, genetic studies have 
shown a strong genetic association with a series of polymorphisms in the IL23R gene, including 
R381Q. This polymorphism confers protection from AS (148), and it was experimentally 
corroborated that the R381Q polymorphism impairs IL-23–dependent IL-17 production by TH17 
cells in vitro. (166). These results suggest that genetically determined down-modulation of type 
17 immunity provides protection against AS. Additional evidence indicating that IL-17 is 
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pathologic in AS comes from the observations that serum levels of IL-17 and IL-23, and 
circulating TH-17 and γδ T cells, are increased in AS patients compared to controls (167,168). 
Additionally, in mice, IL-23 overexpression induces an AS-like disease mediated by increased 
IL-17 production (39), providing supportive evidence that type 17 immunity is pathologic in AS. 
Further understanding of IL-17R signaling may contribute to the development of better therapies 
for this and other autoimmune diseases. 
 
1.9.5 Noninfectious Uveitis 
Noninfectious uveitis is a form of intraocular inflammation that remains a major cause of vision 
loss. Uveitis is an organ-specific T cell–driven autoimmune disease of an immune-privileged 
site. Both TH17 and TH1 cells are thought to contribute to tissue damage in the intraocular tissue 
(169). Moreover, upregulation of IL-23 and IL-17 occurs in patients with active uveitis (170), 
suggesting that IL-17 signaling plays an inflammatory role in the pathogenesis of uveitis. 
Furthermore, the use of anti-IL-17 blocking therapy is approved as second-line treatment for AS, 
suggesting that excessive IL-17 signaling is pathologic in AS. 
 
1.9.6 Crohn’s Disease 
Crohn’s disease (CD) is an inflammatory bowel disease (IBD) characterized by increased 
inflammation in the gastrointestinal track, decreased nutrient absorption and significant 
disruption of the intestinal epithelial barriers. Associations between polymorphisms in the IL23R 
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gene and the risk of adult and pediatric CD suggested a link between type 17 immunity and CD 
(171). Furthermore, biopsy samples from patients with CD showed an increased expression of 
IL-17, IL-23, IL-22, and IL-6 compared to control patients, suggesting that these cytokines are 
involved in the pathogenesis of this disease (172). Mechanistically, IL-17 has both pro- and anti-
inflammatory roles as described in animal models of IBD. In some models, IL-23 administration 
exacerbates disease, and inhibition of IL-23 is and subsequent decrease in IL-17 is protective.  In 
contrast to its inflammatory role, IL-17 has a protective role in a model of T cell-mediated 
intestinal inflammation (69). This dichotomy between IL-23 and IL-17 in mediating 
pathogenesis of IBD is because in colitis, the intestinal epithelial barrier is preserved by IL-17-
dependent expression of occludin and claudin-1, two major tight junction proteins (69). The IL-
17-dependent induction of tight junctions preserves the epithelium integrity and limits IBD. 
Consistent with the protective role of IL-17 in colitis, clinical trials of anti-IL-17 and anti-IL-17R 
showed no improvement, and even exacerbated disease (173). These findings emphasize that IL-
17R signaling is an important inflammatory mediator, but that it also contributes to tissue-
specific functions such as maintenance of intestinal epithelial integrity. 
 
1.10 STATEMENT OF THE PROBLEM 
Our understanding of IL-17-mediated functions in the immune response is driving several 
advances in the treatment of human disease. Infectious and autoimmune diseases are regulated 
by IL-17 signaling. For autoimmune diseases, therapies have already been employed to block IL-
17 cytokine, and some studies have investigated blocking the IL-17 receptor directly as a more 
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specific therapeutic. However, IL-17R downstream signaling is incompletely understood. The 
identification of novel downstream intermediates of the IL-17 receptor can contribute to our 
understanding of the effects of blocking IL-17R and inform the development of more specific 
therapies to control IL-17-mediated inflammation. In this thesis, I aimed to identify novel 
signaling intermediates of IL-17R, and to describe the molecular mechanisms by which two of 
these intermediates regulate IL-17 signaling.  
 
1.11 SUMMARY 
In this thesis, I discovered several genes that potentially regulate IL-17 signaling. I describe the 
screening and general characterization of these genes in Chapter 3. Among the candidates, I 
decided to focus on ABIN-1 (Tnip1) and caveolin-1 (Cav1) in an attempt to describe their 
mechanisms of action within the IL-17 signal transduction setting.  
ABIN-1 is an A20-binding protein, and both human genetic studies and experimental 
animal models demonstrated the relevance of ABIN-1 in inhibiting the inflammatory pathways 
involved in the onset of psoriasis (129,134,174,175). Since IL-17 signaling is associated with 
psoriasis and inhibited by A20, I asked whether ABIN-1 was also a downstream inhibitor of the 
IL-17 signaling pathway. Chapter 4 provides data to demonstrate that ABIN-1 inhibits tonic and 
IL-17-induced signaling, and in turn, IL-17 signaling induces degradation of ABIN-1. These data 
suggest a novel regulatory mechanism by which ABIN-1 functions in the IL-17 signaling 
pathway. 
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Among its numerous intracellular functions, caveolin-1 regulates inflammation by 
interacting with TNFR1 and TLR4, thereby regulating some of their downstream effectors 
(176,177).  Since proteins that regulate and interact with TNFR1 and TLR4 often also regulate 
IL-17R signaling, I explored the hypothesis that Cav1 regulates IL-17R signaling. Chapter 5 
describes preliminary findings that suggest caveolin-1 may indeed be a positive regulator of IL-
17 signaling. 
In summary, this thesis describes my studies of the different molecular mechanisms and 
proteins that regulate IL-17R signaling. My results contribute to the characterization of 
downstream intermediate molecules of IL-17R signaling, and provide insight into novel 
molecular targets for developing future therapies to control IL-17-mediated inflammation. 
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2.0  CHAPTER TWO: MATERIAL AND METHODS 
2.1 ANTIBODIES 
The antibodies used for western blot and immunoprecipitation analysis are listed on table 2.1 
along with the sources, the dilution used to detect proteins and notes regarding the incubation.  
2.2 CELL LINES 
HEK293T cells, ST2 cells and MEFs were cultured in α-MEM (Sigma, St Louis MO) containing 
10% fetal bovine serum (FBS) with 1% L-glutamine and 1% antibiotics (Invitrogen).   
2.3 DERIVATION OF TAIL FIBROBLASTS 
Mice were sacrificed following all the regulations established by the Institutional Animal Care 
and Use Committee (IACUC) from the University of Pittsburgh. Tails from 5- 15 weeks old 
mice were cut and stored in α-MEM (Sigma, St Louis MO) containing 10% fetal bovine serum 
(FBS) with 1% L-glutamine and 2% antibiotics (Invitrogen) on ice or at 4ºC until the tails were 
processed.  
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All the post-collection processing of the tails was performed in a tissue culture hood 
under sterile condition. Tails were cut with a razor blade into the smallest pieces attainable in a 
tissue culture plate. Next, the pieces of tail were resuspended in 2 mL PBS with PenStrep and 
collagenase (total concentration = 1000U/mL). Tails were digested in collagenase for 30 minutes 
at 37ºC, and tubes containing the tails were mixed every 5 minutes to ensure correct collagenase 
treatment. When incubation was over, the tubes were spun at 1200 RPM for 5 minutes and 
washed twice with HBSS. After washing, 3 mL of trypsin was added, and tails were incubated 
for additional 20 minutes at 37ºC. After incubation, trypsin was neutralized with 3 mL of media 
(20% FBS) and centrifugated for 5 minutes. The supernatant was removed, the pellet 
resuspended in 5 mL of complete media (α-MEM containing 20% fetal bovine serum (FBS) with 
1% L-glutamine and 2% antibiotics) and transferred into T25 tissue culture flasks. The tissue 
pieces were kept until layers of fibroblasts were visible at the bottom of the flask. After 3 days, 
more media was added on top of the culture, and 2-3 days later the media with the unattached 
cells and tissue was discarded, and replaced with fresh media. After fibroblast were confluent on 
the original flask, they were split into larger areas and cultured. To immortalize cells, fibroblasts 
were transfected with SV40 T antigen (24-well plate) and cultured for few passages until growth 
advantage was visible. Aliquots of all cells were frozen and stored in liquid nitrogen.  
2.4 PLASMIDS 
Plasmids expressing E-tag ABIN-1 and the human ABIN-1 promoter were provided by Dr. Rudi 
Beayert (University of Ghent, Belgium) and Dr. Brian Aneskievich (University of Connecticut). 
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These plasmids and the Lcn2 promoter were previously described (Heyninck 2003, Gurevich 
2012, Shen 2006}. Other plasmids in this study were cloned using primers from table 2.2.  
2.5 SMALL INTERFERING RNA 
All small interfering RNAs (siRNAs) used in this project were purchased from Dharmacon (GE, 
Lafayette CO) and they are listed in tables 2.3 and 2.4.  
2.6 TRANSFECTION 
Transfections to knockdown specific genes were performed using siRNAs purchased from 
Dharmacon. Cells were plated in either 12-, 24- or 6-well plates in αMEM medium with 10% 
FBS and 1% L-glutamine. No antibiotic was added to the medium. Next day in the morning, 
cells were siRNA Transfected with 5μM siRNA prepared in 1X siRNA transfection buffer 
(Dhamacon), Dharmafect reagent (Dhamacon) and OptiMEM medium. Mix was prepared 
following vendor’s instructions. Twenty-four hours later, the medium was changed for fresh 
medium. Next day, cells were stimulated and harvested as indicated for each specific experiment. 
In all cases efficiency of knock-down was confirmed by qPCR and western blotting.  
Transient transfections to overexpress a specific gene were performed using Fugene HD 
(Promega, Madison WO) or Lipojet (SignaGen, Rockville MD). Cells were plated the day before 
the transfection in antibiotic free αMEM (Fugene HD transfection) or complete αMEM (Lipojet 
transfection). Mixes were prepared following vendor’s instructions. Briefly, plasmids coding for 
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the gene of interest were mix with the appropriate reagent and incubated for up to 10 minutes at 
room temperature. Mix was added drop-by-drop to cells and left there for 24h before stimulation 
and harvesting of cells.   
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2.7 LUCIFERASE ASSAY 
Luciferase assays were performed as described (Shen 2006). ST2 (0.05x106) or fibroblasts 
(0.05x106) cells were plated in a 12-well plate using antibiotic free αMEM the day before the 
transfection. Transfections were performed as described above, mixing the plasmid of interest or 
empty vector, 100-500 ng promoter reporter-luciferase and 5ng renilla-luciferase. Next day after 
transfection, cells were stimulated for 6-8h with IL-17 and harvested. Cells trypsinized for 5 
minutes, trypsin was neutralized, and cells were transferred into a 1.5mL tube. Tubes were spun 
for 5 min at 3000g and the supernatant removed. The cell pellet was resuspended in 50μL lysis 
buffer (1% NP40, 150mM NaCl, 50mM Tris pH 8.0, 2mM NaF, supplemented with fresh 1mM 
Na2VO4, 50mM PMSF, 10mM β-glycerophosphate disodium salt and a protease inhibitor 
cocktail (Sigma-Millipore)) and incubated for 20 minutes in ice. After lysis, tubes were spun for 
20 minutes at 20000g at 4ºC. After spinning, 15μL of supernatant was added to each well of a 
white 96-well plate for luciferase(Fisher) assay, and the plate was inserted in the Veritas 
microplate Luminometer. The luminometer automatically mixed the cell lysated with Dual-Glo® 





ST2 cells were plated 24-48h before treatment in complete αMEM medium. Inhibitors and 
conditions used are described in table 2.5. All these drugs were purchased from EMD Millipore. 
2.9 RNA ISOLATION AND QUANTIATIVE REVERSE TRANSCRIPTASE PCR 
RNA was extracted using RNAeasy Kits (74106, Qiagen) and cDNA was made to perform 
qPCR. Primers used for qPCR analysis were purchases from Qiagen. The lists of primers are in 
tables 2.6 and 2.7. Relative gene expression was normalized to Gapdh and to the relevant 
control. All primers were purchased from Qiagen.  
 
2.10 ELISA 
ELISA analyses were performed using kits were from eBioscience (IL-6; 88-7064-88) or from 
R&D systems (Lcn2; MLCN20, & CXCL1; DY453).  
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2.11 IMMUNOPRECIPITATION AND IMMUNOBLOTTING 
Cells were lysed on ice for 20 minutes in lysis buffer (1% NP40, 150mM NaCl, 50mM Tris pH 
8.0, 2mM NaF) supplemented with 1mM Na2VO4, 50mM PMSF, 10mM β-glycerophosphate 
disodium salt and a protease inhibitor cocktail (Sigma-Millipore). Samples were boiled (5-15 
minutes) in running buffer and immunoblotted. Band intensity was analyzed using AlphaView 
SA Version:3.4.0 (Protein Simple, San Jose CA).  
2.12 INTRAPERITONEAL INJECTION OF MICE AND CARDIAC PUNCTURE 
All mice were handled according to the University of Pittsburgh Institutional Animal Care and 
Use Committee (IACUC) guidelines. To study the IL-17-induced cytokine response in serum, 
age- and sex-matched mice were intraperitoneally injected with PBS alone or with a combination 
of IL-17 (1μg per mouse) and TNFα (200ng per mouse) in PBS. All mice were awake during the 
injection, and remained awake in their cage for 4 hours. After the end of 4 hours mice were 
sacrificed using CO2. Immediately after each mouse stopped breathing and moving, the rear paw 
was pinched to confirm that the animal was dead. If the mouse did not react to pinching, blood 
was collected using a 1mL syringe with a 26G needle by inserting the needle in the area 
immediately below the sternum, and slightly to the left of the mouse. A volume of 300μL to 
900μL of blood was collected per mouse and gently transferred into a 1.7mL Eppendorf tube. 
Tubes were rested on horizontal position at 4ºC during overnight. Next day, the tubes were spin 
at 4000g for 10 minutes at 4ºC. 80μL to 300μL of serum (supernatant) per sample were collected 
and transferred to new tubes. Samples were stored at -20ºC until they were used for IL-6, 
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CXCL1 and Lcn2 ELISA analysis. For IL-6 and CXCL1 analysis, the samples required no 
dilution and were reused to measured different cytokines. For Lcn2, the samples required a large 
( > 1:1000) dilution since there seems to be a high background.   
2.13 STATISTICS 
To assess significance, we used Student’s t test, ANOVA with post hoc Tukey’s analysis, or 
linear regression. P < 0.05 was considered significant. Error bars reflect the means ± SEM of 
biological replicates within individual experiments or pooled data, as indicated in legends. All 
experiments were repeated a minimum of twice. We use R (R Foundations for Statistical 
Computing) to perform linear regression to model the effect of duration of IL-17-stimulation on 
ABIN-1 mRNA or protein.  
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Table 2.1: List of antibodies used in this thesis. 
Antibody company Catalog# Dilution Species Notes 
4G10 Millipore 05-1050 1:1000 Mouse ON/4C 
A20 Cell Sig. 5630 1:1000 Rabbit   
ABIN1  Invitrogen 37-6100 1:1000 Mouse 1h/RT – Unreliable 
ABIN1 Sta. Cruz SC-134660  1:1000 Rabbit ON/4C – Works well 
ABIN1 Cell Sig. 4664S IP Rabbit 2h antibody/4C -> 2h 
Protein A agarose/4C 
Act1 Sta. Cruz SC-11444 1:1000 Rabbit ON/4C 
anti-E-tag Cell Sig. 13419 1:2000 Rabbit Overnight/4C or 1h/RT 
Anti-GFP Sta. Cruz SC-8334 1:1000 Rabbit ON/4C 
Anti-goat 
HRP 
Pierce 431402 1:5000 Rabbit  1h/RT 
Anti-IL-
17RA 
RD   1:500 Goat 1h/RT 
B-TrCP Cell Sig. 11984 1:1000 Rabbit ON/4C 
Caveolin1 BD 610406 1:1000 Mouse ON/4C 
CYLD Sta. Cruz SC-25779 1:1000 Rabbit It does not work 
CYLD  Cell Sig. 8462T 1:1500 Rabbit ON/4C – works great 
E-FITC Abcam Ab19399       
ERK-
Phospho 
Cell Sig. 9106S 1:1000 Mouse ON/4C 
FLAG M2 Sigma  F1804 1:1000 mouse Overnight/4C 
GSK3B Cell Sig. 9315 1:1000 Rabbit   
HA Sigma H3663-200UL 
(H-274) 
1:2000 mouse  Overnight/4C 
IkBa(C-21) Sta. Cruz sc371 1:1000 Rabbit 1h/RT 
IKBa-
Phospho 
Cell Sig. 9246L 1:1000 Mouse Block ON/4C 
IKKalpha Cell Sig. 11930 1:1000 Mouse ON/4C – Do not reuse 
IKKbeta Cell Sig. 2678 1:1000 Rabbit Block in Milk ON/4C  
IKKepsilon Cell Sig. 3416P 1:1000 Rabbit ON/4C 
IL-17RC  R&D AF2270 1:500 Goat ON/4C 
JNK-Phospho Cell Sig. 9251S 1:1000 Rabbit ON/4C 
MYC Cell Sig.   1:1000 Mouse Overnight/4C 
Otulin Sta. Cruz sc-162789 1:200 Goat   
p38-phopho Cell Sig. 9211S 1:1000 Rabbit ON/4C 
P-GSK3B Cell Sig. 9336S 1:1000 Rabbit Block in milk (1h) - 
ON/4C 
P-IKKα/β Cell Sig. 2697 1:1500 Rabbit 1h/RT – TBST, block ON 
Poly-
ubiquitin 
ENZO BML-PW8805  1:200 Mouse Overnight/4C 
Syk Cell Sig. 13198  1:1000 Rabbit ON/4C 




Cell Sig. 4531 1:1000 Rabbit Overnight/4C 
total ERK Cell Sig. 9102 1:2000 rabbit ON/4C 
total JNK Cell Sig. 9252 1:1000 rabbit ON/4C 
total p38 Cell Sig. 9212 1:1000 Rabbit ON/4C  
TRAF3 Sta. Cruz sc-949 1:1000 Rabbit ON/4C 
TRAF6 Sta. Cruz sc-7221 1:1000 Rabbit  It works for IP and WB 
Ubiquitin 
(P4D1) 
Sta. Cruz sc8017 1:200 Mouse Antibody in BSA  
α-Tubulin-
HRP 
Abcam Ab40742 1:20000   ON/4C or RT/1h 
Anti-Goat Sta. Cruz SC-2020 1:5000 Donkey  
IKBζ Cell Sig. 92445 1:1000 Rabbit  






























































Table 2.3: Murine siRNA used in this project. 
 Gene Catalog # 
1 Tnip1 (ABIN-1) L-047652-01 
2 Tnfaip3 (A20) L-058907-02 
3 Non-targeting mock D-001810-10-20 
4 Traf3ip2(ACT1) L-059885-01 
5 Fam105b(Otulin) L-067300-01 
6 Cyld L-055575-01 
7 Caveolin-1 L-058415-00 
8 Cdc27 (AnaPC3) L-167064-00 
9 USP15 L-040417-01 
10 Sykb L-041084-00 
11 Otub7b (Cezanne) L-050018-01 
12 IRAK2 L-060091-00 
13 Parp10 L-164453-00 
14 Btrc (Btrcp1) L-044048-00 








Table 2.4: Human siRNA used in this project. 
 Gene Catalog # 
1 TNIP1 (ABIN-1) L-016358-00 
2 Tnfaip3 (A20) L-009919-00 
3 Traf3ip2(ACT1) L-004311-01 
4 FAM105B (OTULIN) L-018991-02 
5 CYLD L-004609-00 
6 CAV1 L-003467-00 
7 CDC27 (AnaPC3) L-003229-00 
 
 
Table 2.5: Small molecule inhibitors used in this project. 
Abbreviations: pt: pre-treatment. 
 
Inhibitor Catalog # Working 
concentration 
Time of treatment Reference 
MG132 474790-
100UG 
20μM 30 min pt & various with 
IL-17 
(75) 
Staurosporine 569396 100nM 20 min pt & 2h with IL-17 (75) 
IKK inhibitor 
VII 
401486 10μM 30 min pt & 2h with IL-17 (19) 
Bay 11-7082 196870-
10MG 
100μM 1h pt 
& various with IL-17 
(178,179) 
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Table 2.6: Murine primers used for quantitative RT-PCR. 























Table 2.7: Human primers used for quantitative RT-PCR. 












3.0  CHAPTER THREE: SCREENING OF IL-17 RECEPTOR SIGNALING 
INTERMEDIATES 
3.1 BACKGROUND  
Inflammation is a process initiated by inflammatory molecules like interleukin-17 (IL-17, IL-
17A), lipopolysaccharide (LPS) or tumor necrosis factor alpha (TNFα) and mediated by their 
respective receptors: IL-17R, TLR4 or TNFR1. During mucosal infections, these receptors 
promote inflammation as a necessary process to protect the host. Upon stimulation with TNFα, 
LPS or IL-17, receptor signaling cascades are activated, ultimately resulting in activation of the 
Nuclear factor-kappa B (NF-κB) pathway (16,66,180–182). IL-17 promotes expansion and 
recruitment of neutrophils and monocytes, and cooperates with LPS and TNFα to drive 
expression of β-defensins and anti-microbial peptides. Inappropriate activation of the NF-κB 
signaling pathway is implicated in the pathogenesis of chronic inflammation and autoimmunity. 
Mechanistically, IL-17R and TLR4 signaling converge on the ubiquitination and activation of 
TRAF6, which in turns recruits TAK1 to subsequently activate the IKK complex, comprising 
two catalytic kinase subunits (IKKα/β) and a homodimer of the scaffolding regulatory subunit 
(IKKγ/NEMO). TNFR1 and IL-17R signaling converge at the level of the IKK complex 
downstream in the NF-κB pathway. 
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As described in chapter 1, IL-17R signaling activates primarily three effector pathways, 
NF-κB, CAAT enhancer binding protein beta (C/EBPβ) and mitogen-activated protein kinase 
(MAPK). In contrast, TLR4 and TNFR1 signaling each involve other downstream effector 
pathways (figure 3.1). Specifically, the TLR4 receptor binds several ligands, the most studied 
being LPS from gram-negative bacteria. Moreover, TLR4 signaling involves two proximal 
adaptors: MYD88 and TRIF (183). On the cell surface, MYD88-dependent signaling recruits the 
IRAK-TRAF6-TRAF3 complex, leading to NF-κB or AP-1 activation (184).  Once TLR4 is 
internalized in vesicles, TRIF-signaling is initiated. TRIF-dependent signaling activates TBK1, 
in turn activating transcription factors interferon-responder factors (IRFs). TRIF signaling also 
mobilizes TRAF6 to activate MAPK and NF-κB signaling (185). 
Like TLR4, TNFR1 signals differently depending on the localization of the ligand-
receptor complex. When TNFα binds to the trimeric TNFR1 complex on the cell surface, it 
forms complex I that activates MAP3Ks and JNK, which subsequently activate the transcription 
factor AP-1. Next, after linear ubiquitination of adaptor proteins, complex I activates the IKK 
complex and NF-κB signaling to induce cell survival. The internalization of the whole signaling 
complex forms complex II or the Death-Inducing Signaling Complex (DISC). DISC-mediated 
signaling induces cell death. These events are coordinated by different signaling intermediates 
including TRADD, TRAF2 or FADD (186). Despite the differences among these signaling 
pathways, some TLR4- and TNFR1-activated genes overlap with IL-17 target genes, and all of 
these pathways have the ability to individually activate NF-κB signaling. Furthermore, several 
intermediates from TLR4 and TNFR1 signaling also participate in IL-17R signaling. Therefore, 
their signaling intermediates partially overlap, with some intermediates from TLR4 and TNFR1 
pathways playing roles in IL-17R signaling.  
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Comparing the IL-17R signaling pathway to TLR4 and TNFR1 signaling pathways 
provides potential insight into potentially novel intermediates of IL-17 signaling. Therefore, 
since not all intermediates of TLR4 or TNFR signaling are necessarily used by the IL-17R, I 
screened candidate genes that I hypothesized have a role in IL-17 signaling. I selected the 
candidate genes based on the following criteria: involvement in the (i) regulation of signaling 
downstream of the TLR or TNFR families of cytokine receptors, (ii) regulation of NF-κB 
signaling, and (iii) regulation of ubiquitination of signaling proteins by having a E3-ligase or 
deubiquitinase (DUB) activity. Details of these candidate genes are provided in Table 3.1. 
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Table 3.1 : List of candidate genes and properties considered relevant for this study. 
 
Gene 













(ABIN-1) Both EGFR Inhibits 
Binds 
pUb. Blocks NEMO (187) 




TRAF6 pUb (188) 
Otud7a TNFR1 N.D. Inhibits DUB RIP1’s DUB (189) 
Parp10  TNFR1 IL-1R Inhibits Binds pUb. 
Block pUb of 
NEMO (190) 
Cdc27 N.D. N.D. N.D. E3-ligase 










Otulin TNFR1 N.D. Inhibits Linear DUB 
DUB linear 
Ub. (194) 
Usp15 N.D. TGFβ / BMPR N.D. DUB DUB mono-Ub (195) 
Cav1  Both N.D. Inhibits / activates  No 
Binds TLR4 / 
TNFR1 (196) 
Syk Both  N.D. Activates N.D. N.D. (197)(77) 
Abbreviations: DUB: deubiquitinases; TLR: Toll-Like Receptor; Ub: ubiquitin/ubiquitination; 





Figure 3.1: Candidate genes regulate other inflammatory pathways. 
TNFα and TLR signaling shared some intermediates with IL-17R signaling. Upon ligand binding, these 
inflammatory signals converge in their activation of NF-κB. I investigated the role of some intermediates from these 
pathways on IL-17R signaling. TNFα: Tumor Necrosis Factor-α; TNFR1: TNF-Receptor 1; TRADD: TNFR-
Associated Death Domain; TLR4: Toll-Like Receptor-4; MyD88: Myeloid differentiation primary response 88; IL-
17R: Interleukin-17 receptor; ACT1: NF-κB Activator 1; Lcn2: Lipocalin 2; IL-6: Interleukin-6. 
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3.2 RESULTS  
3.2.1 Screening of candidate genes that may regulate IL-17R signaling 
To identify new intermediates in the IL-17R signaling cascade, I silenced ten candidate genes 
using an siRNA knockdown approach (Figure 3.2-A-B). Controls were Traf3ip2 (ACT1), 
Tnfaip3 (A20), and mock or non-targeting siRNA. Traf3ip2 is a positive regulator of IL-17 
signaling, and its knockdown decreases the production of IL-17-dependent IL-6. On the other 
hand, knockdown of the negative regulator of IL-17 signaling, Tnfaip3, increases IL-6 
production at baseline and after IL-17 stimulation. The ten candidates fell into three groups: (i) 
possible negative regulators or inhibitors of IL-17 signaling (Tnip1, Cyld, and Otulin), (ii) 
possible positive regulators or activators (Cdc27, Cav1, and Syk), and (iii) genes with no evident 
regulatory activity in IL-17 signaling (Otud7b, Irak2, Usp15 and Parp10) (Figure 3.2-A-B). 
Knockdown of each gene was considered successful if gene silencing was above 20%, as 






Figure 3.2: Screening of candidate genes that may regulate IL-17R signaling. 
 (A-B) Knockdown of some, but not all, candidates impacted IL-17R signaling. ST2 cells were transfected with the 
indicated siRNAs and stimulated with IL-17 for 3h. IL-17-dependent IL-6/Il6 expression was quantified by (A) 
ELISA or by (B) qPCR. (A-B) Absolute values of IL-6/Il6 expression were transformed into fold induction by 
comparing the values from each treatment with the values from mock-unstimulated cells. Knockdown of candidate 
genes was repeated at least twice. * p < 0.05 – Two-way ANOVA. (C) Degree of knock-down of candidate genes. 
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Knock-down was confirmed by measuring gene expression of targeted genes in ST2 cells after siRNA treatments. 
Most knock-downs resulting in at least a 20% decrease of gene expression. 
3.2.2 Inflammatory stimuli control expression of Tnip1 and Cav1 genes 
Because signaling pathway can regulate the expression of their own by downstream 
intermediates (e.g. Tnfaip3/A20 is a feedback negative regulator of IL-17R signaling (19)), I 
tested whether the genes from the siRNA screen that impacted IL-17R were also downstream of 
IL-17, TNFa, or LPS signaling.  Specifically, I stimulated ST2 cells with these ligands and 
measured gene expression by qPCR. IL-17 stimulation did not regulate the expression of Cdc27, 
Cyld or Otulin.  However, IL-17 stimulation increased expression of Tnip1 1.5-2.5-fold, and 
decreased Cav1 expression to 0.5-0.8-fold of baseline (figure 3.3-A).  Stimulation with TNFα 
(figure 3.3-B) or TNFα combined with IL-17 (figure 3.3-C) had similar effects as IL-17 alone 
(figure 3.3-A). TLR4 stimulation with LPS downregulated Il-17rd expression but no other genes 
(figure 3.3-D).  Thus, these data show that IL-17R or TNFR signaling regulates Tnip1 (ABIN-1) 





Figure 3.3: Inflammatory stimuli control expression of Tnip1 and Cav1 genes. 
ST2 cells were plated and 24 hours later stimulated with (A) 200ng/mL IL-17, (B) 10ng/mL TNFα, (C) IL-
17+TNFα or (D) 100ng/mL LPS at the indicated times.  Expression of selected candidate genes was measured by 
qPCR. This experiment was repeated twice, and this representative data is from one experiment.              
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3.2.3 Cyld regulates IL-17 receptor signaling. 
Cyld siRNA increased IL-17-dependent production of IL-6 without affecting its baseline 
expression (figure 3.2-A), suggesting that Cyld may inhibit IL-17 signaling. To test whether 
Cyld regulates the expression of other IL-17-target genes, I knocked-down Cyld using siRNA in 
ST2 cells and measured gene expression by qPCR.  The knockdown of Cyld enhanced 
production of Lcn2, Ccl20, and Cxcl1 both at baseline and under IL-17-stimulated conditions, 
but had no detectable effect on the expression of Nfkbiz (encoding IκBζ) (figure 3.4-A). To 
determine whether CYLD also inhibits IL-17 signaling in primary human cells, I knocked-down 
CYLD in primary human fibroblast-like synoviocytes (FLS) from a rheumatoid arthritis patient. 
Compared to other candidate genes that inhibit IL-17 signaling in murine cells, CYLD and 
TNFAIP3 were the only genes to affect IL-17-dependent IL-6 production (figure 3.4-B). Lastly, 
to confirm the inhibitory role of Cyld in IL-17 signaling, I stimulated murine embryonic 
fibroblasts (MEF) derived from Cyld+/+ or Cyld-/- mice and measured IL-6 production by ELISA.  
Although these fibroblasts responded to IL-17, there was no significant difference between the 
Cyld+/+ and Cyld-/-  cells (figure 3.4-C).  In summary, the knockdown of Cyld in murine ST2 and 
human FLS cells increased IL-17-dependent IL-6 production, suggesting that Cyld inhibits IL-17 
signaling. However, MEFs from Cyld+/+ and Cyld-/- mice had no difference in their response to 
IL-17, which suggests that if Cyld inhibits IL-17 signaling, this function may be a tissue-specific. 




Figure 3.4: Cyld regulates IL-17 receptor signaling. 
 (A) Lcn2, Cxcl1, and Ccl20 are inhibited by Cyld downstream of IL-17. ST2 cells were transfected with siRNA 
targeting Cyld or non-targeting Mock siRNA, and 48 hours later cells were stimulated with 200 ng/mL IL-17 for 3 
hours. Expression of IL-17-dependent genes was assessed by qPCR. This experiment was performed three times, 
and these data are from one representative experiment. P < 0.05, two-way ANOVA test.  (B) Cyld regulates the IL-
17 response in human fibroblast-like synoviocytes (FLS). Human FLS obtained from the joints of a patient with 
rheumatoid arthritis were cultured. After three passages, FLS were transfected with human siRNAs targeting the 
indicated human genes (x-axis). Forty-eight hours after transfection, FLS were stimulated with human 200ng/mL 
 64 
IL-17A for 4 hours, and IL6 mRNA was determined by qPCR. This experiment was performed once. (C) Cyld-/- 
MEFs respond to IL-17A. MEFs derived from Cyld+/+ or Cyld-/- mice were incubated with 200ng/mL IL-17A or 
culture medium only at the indicated times.  IL-6 production was measured by ELISA, and this experiment was 
performed once. 
3.2.4 Otulin regulates IL-17-dependent Ccl20 expression. 
Because OTULIN removes linear poly-ubiquitin chains from NEMO in TNF-dependent NF-κB 
signaling, I further explored whether Otulin regulates the expression of other IL-17-target genes. 
I knocked down Otulin in ST2 cells and measured gene expression by qPCR. In contrast to Cyld, 
Otulin only regulated Ccl20 expression under IL-17-stimulated conditions without affecting 
Lcn2, Cxcl1 or Nfkbiz expression (figure 3.5-A). These data suggest that Otulin may function 













Figure 3.5: Otulin regulates IL-17-dependent Ccl20 expression. 
 (A) Otulin regulates IL-17-dependent Ccl20 expression. ST2 cells were treated with siRNA targeting Otulin or 
scrambled/non-targeting siRNA, and forty-eight hours later cells were stimulated with 200ng/mL IL-17A (3h). 
Expression of IL-17-dependent genes was assessed by qPCR. These data are from one representative experiment of 
three different experiments. P < 0.05, Two-way ANOVA test.  
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3.3 DISCUSSION  
Binding of IL-17 to IL-17R triggers a cascade of events depicted in figure 1.4. Briefly, ACT1 
and TRAF6 are recruited to activate the IKK complex and to induce NF-κB signaling. Here, I 
tested ten candidate genes that are known regulators of TNFR- or TLR-dependent NF-κB 
activation, and that control ubiquitination of downstream intermediates of TNFR or TLR 
signaling. My results showed that Tnip1, Cyld, and Otulin inhibited IL-17 signaling, while Cav1, 
Cdc27 and Syk activated it. The molecular mechanism of action of these novel intermediates is 
yet to be described, but a preliminary model could be proposed based the current literature and 
these results. 
Prior work has demonstrated that A20 (encoded by Tnfaip3) inhibits TRAF6-mediated 
signaling downstream of TLR-, TNFR- and IL-17R by removing ubiquitin (19,198,199). Taking 
the A20 deubiquitinase activity into consideration, I decided to study Cyld and Otulin, genes that 
encode for two other deubiquitinases. CYLD binds NEMO (200) and TRAF6 to inhibit TNFR1 
signaling by regulating deubiquitination of K63-linkages (94,96) (97). In vivo murine models 
have shown that Cyld has a major anti-inflammatory role in the hematopoietic compartment. 
Cyld-/- macrophages are hyper-responsive to TLR4 stimulation (201) and monocytic osteoclast-
progenitors have increased RANK-mediated signaling, which decreases osteoclastogenesis. 
Additionally, CYLD deubiquitinates and subsequently inactivates TRAF6 downstream of RANK 
signaling (202).  In addition to macrophages and monocytes, Cyld-/- T cells are also defective 
because of dysregulated TCR signaling. Thus, immature T cell numbers are increased in thymus 
(203), while mature cells are hyperreactive to TCR signaling by decreased deubiquitination of 
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TAK1 and increased NF-κB signaling (204). Altogether, these defects cause excessive 
inflammation and the development of autoimmune-like disease resembling inflammatory bowel 
disease (201). Far fewer functions of CYLD have been studied in non-hematopoeitic cells, and 
my results suggest that Cyld inhibits IL-17R signaling in a murine cell line (ST2 cells) and in 
primary human fibroblast. Further characterization of the molecular mechanism by which CYLD 
regulates IL-17R signaling should consider deubiquitination of TRAF6 and NEMO as the 
regulatory step mediated by CYLD.  
OTULIN removes linear ubiquitination, opposing the function of linear-ubiquitin 
assembly complex (LUBAC) formed by HOIL, sharpin and the catalytic subunit HOIL-1-
interacting protein (HOIP). Mechanistically, after TNFα stimulation, LUBAC and OTULIN are 
recruited to the TNFR1-signaling complex. The recruitment of OTULIN is mediated by its 
binding to HOIP, which depends on the phosphorylation of OTULIN at tyrosine-56 (205). Once 
in this complex, Otulin deubiquitinates NEMO and RIPK2 to inhibit NF-κB activation (98); 
however, no studies have yet indicated whether linear ubiquitination plays a role downstream of 
IL-17R signaling. Thus, my finding that Otulin has specific inhibitory roles regulating Il6 and 
Ccl20, but not other IL-17-target genes, needs to be taken with caution. Perhaps linear 
ubiquitination has a role downstream of IL-17R signaling, but this needs to be tested, and while 
OTULIN could mediate linear deubiquitination of IL-17 signaling intermediates, Otulin may also 
have other roles that are yet to be discovered. Thus far, mutations in Otulin, in human and mice, 
have been shown to cause autoimmunity and fatal inflammation, which was associated with 
defective anti-inflammatory function of Otulin in myeloid cells (100). 
Altogether, my data suggest that Cyld and Otulin have inhibitory roles downstream of IL-
17R signaling in stromal cells. However, a growing body of evidence suggests that the main anti-
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inflammatory functions of these two genes lay in the non-hematopoietic compartment. Thus, 
their functions in IL-17R signaling may be a secondary protective anti-inflammatory mechanism 
or a novel system of differentially regulating IL-17 target gene expression. More details about 
the mechanism of inhibition mediated by Tnip1 (ABIN-1) downstream of IL-17R signaling are 
explained in the next chapter.  
Regarding the activators of IL-17R signaling discovered in this screening, Cav1, Syk and 
Cdc27 (encoding for anaphase-promoting complex 3 /AnapC3), only Cav1 expression was itself 
regulated by IL-17R signaling. Although a promising finding, the Cdc27-mediated activation of 
IL-17R is hard to reconcile with the current knowledge of Cdc27. The anaphase-promoting 
complex is a multi-protein structure of E3-ligases and scaffolding proteins that mediates 
progression of the cell cycle through mitosis and the G1 phase of the cell cycle. AnapC3 
promotes ubiquitination of K11-, K48-, and K63-pUb chains in different target proteins such as 
the cell-division cycle protein 20 (CDC20) to regulate cell cycle signaling (191). Although 
AnapC3 has not been linked to inflammatory signaling, AnapC5 and AnapC7 from the same 
complex contribute to A20-mediated inhibition IL-17R signaling (192). In a yeast two-hybrid 
screen, Anapc7 was a frequent interacting partner of IL-17RC, which led to the discovery that 
AnapC5 also interacts with IL-17RC and IL-17RA. Furthermore, AnapC5 interacts with A20 and 
contributes to the inhibition of IL-17R signaling (192). Since AnapC3 is part of the same 
complex with AnapC5 and AnapC7, I included it in my siRNA screening of candidate genes. 
Thus, Cdc27 knockdown decreased IL-17 signaling, suggesting that Cdc27 is an activator of 
signaling. However, since the main function of Cdc27 is controlling the cell cycle (206), a 
possible explanation is that dysregulation of the cell cycle affected IL-17 signaling as a 
secondary mechanism. Syk activates IL-17R signaling, by facilitating ubiquitination of TRAF6 
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(77), confirming the findings from my screening, and providing a molecular mechanism. Thus, I 
decided to further explore the link between Cav1 and IL-17R signaling because this relationship 
has not been studied and presents opportunities to discover new functions for Cav1. More data 
about regulation of IL-17R signaling by Cav1 is presented in chapter 5 of this thesis.   
Although the data from this chapter are insufficient to derive a detailed molecular 
mechanism of action integrating these intermediates, I hypothesize based on published findings 
that CYLD and Otulin inhibit IL-17R signaling by deubiquitinating TRAF6, TAK1, or NEMO. 
Meanwhile, ABIN-1 binds NEMO (92), an interaction that can contribute to the inhibitory 
signaling of DUBs. In regard to the positive acting molecules, AnapC3 may indirectly regulate 
IL-17R signaling by controlling cell cycle progression, whereas Syk binds TRAF6 (77) to 
activate IL-17 signaling. Caveolin-1 activates signaling by a mechanism that is partially 
described in chapter 5. Altogether, findings from this chapter provide the basis for the work 




4.0  CHAPTER FOUR: IL-17R SIGNALING TRIGGERS DEGRADATION OF THE 
CONSTITUTIVE NF-κB INHIBITOR ABIN-1 
4.1 BACKGROUND  
Interleukin-17A (IL-17) is produced by lymphocytes and acts on tissue fibroblasts and epithelial 
cells to activate inflammatory gene expression. IL-17 is required to clear extracellular pathogens, 
particularly fungi such as Candida albicans (207). However, dysregulated or excessive IL-17 
signaling is associated with the onset of autoimmune diseases such as psoriasis and ankylosing 
spondylitis, among others. Recently, IL-17 blocking therapies have shown considerable efficacy 
in treating psoriatic patients, and are now being evaluated for many other conditions (34).  
The mechanisms of IL-17 signaling are still incompletely defined. Produced by Th17 
cells as well as a variety of innate lymphocyte subsets, IL-17 and its receptor belong to a 
subclass of cytokines with distinct structural properties, compared to other cytokine 
superfamilies such as TNF and IL-1. Upon IL-17 binding to its receptor, numerous signaling 
intermediates are engaged to transduce downstream events. A key early event is activation of the 
Act1 and TRAF6 E3 ubiquitin ligases. These in turn activate a sequence of downstream 
signaling intermediates, culminating in degradation of the IκB inhibitor and nuclear translocation 
of the NF-κB transcription factor (11,208)(209). Consequently, genes with promoters containing 
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NF-κB-binding elements are upregulated by IL-17 stimulation, with IL-6 (Il6) and Lipocalin-2 
(Lcn2) being prototypical IL-17 target genes (210).  
To date, the mechanisms that constrain the IL-17 pathway are not well understood, which 
is an important clinical issue in light of the autoimmune potential of this cytokine. Recently, we 
showed that the ubiquitin editing enzyme A20 inhibits IL-17 signaling by de-ubiquitinating 
TRAF6 and thereby limiting NF-κB and MAPK activation (19). Moreover, IL-17 upregulates 
A20 expression, establishing a negative feedback loop that restricts IL-17-driven inflammation. 
A20 is encoded by TNFAIP3, a genetic locus frequently associated with human autoimmune 
diseases. 
In order to understand how IL-17 controls autoimmunity, we evaluated other genetic loci 
connected to IL-17-driven autoimmune conditions. The A20-binding inhibitor of NF-κB 
activation 1 (ABIN-1) is an A20-binding protein encoded by the TNIP1 gene. ABIN-1 deficiency 
is associated with psoriasis in human genome wide association analyses (GWAS) 
(128,129,134,174). Additionally, mice with keratinocytes lacking ABIN-1 are more sensitive to 
imiquimod-induced dermatitis, a common model of psoriasis (175). Since IL-17 signaling is 
associated with psoriasis and inhibited by A20, we hypothesized that ABIN-1 might also serve as 
a downstream inhibitor of the IL-17 signaling pathway.  
Here, we demonstrate that Tnip1 restricts the basal expression of IL-17 target genes such 
as Il6 in fibroblasts and stromal cells. Tnip1 also negatively regulates IL-17-induced production 
of Il6, Lcn2 and other NF-κB-dependent genes, but not all IL-17-inducible genes are affected. 
Although ABIN-1 is known to interact with A20, we found that A20 is fully dispensable for 
ABIN-1-mediated inhibition of IL-17 signaling. Additionally, IL-17 induced expression of Tnip1 
mRNA by activating in its proximal promoter. Surprisingly, however, ABIN-1 protein levels are 
 72 
reduced following IL-17 signaling, an event that is mediated by proteasomal degradation. 
Additionally, we found that phosphorylation protects ABIN-1 from degradation. Thus, IL-17 
signaling serves to release the ABIN-1-controlled brake on inflammation, revealing a new 
regulatory circuit in the IL-17 inflammatory pathway. 
 73 
 
4.2 RESULTS  
4.2.1 Tnip1 inhibits both basal and IL-17-induced gene expression 
To delineate the role of Tnip1 in IL-17-mediated signaling, we assessed IL-17 signaling in 
immortalized MEFs lacking Tnip1 (211). Cells were treated with IL-17 over a 24 h period, and 
IL-6 in culture supernatants was assessed by ELISA. At baseline, Tnip1-/- fibroblasts secreted 
significantly more IL-6 than Tnip1+/+ cells (figure 4.1-A). Similarly, Tnip1-/- cells treated with 
IL-17 expressed more IL-6 than IL-17-stimulated Tnip1+/+ cells. Consistent with these findings, 
elevated expression of Il6 mRNA was observed in Tnip1-/- MEFs, both at baseline and after IL-
17 stimulation (figure 4.1-B). These results indicate that Tnip1restricts both tonic and IL-17-
dependent IL-6 expression. To confirm that Tnip1 limits IL-6 expression levels and to rule out 
the possibility that this effect was restricted to a particular MEF line, Tnip1-/- fibroblasts were 
reconstituted with ABIN-1 by transfection. Cells were then stimulated with IL-17 for 3 h and Il6 
mRNA was measured by qPCR. Consistent with its role as an inhibitor of inflammatory 
signaling, reconstitution with ABIN-1 decreased Il6 production compared to cells transfected 
with a control vector (figure 4.1-C).   
To verify the inhibitory activity of Tnip1 in another setting, we silenced Tnip1 with 
siRNA in ST2 cells, a mouse bone marrow stromal cell line that responds robustly to IL-17 
(figure 4.1-D) (212). Indeed, knockdown of Tnip1 led to increased expression of IL-6 both at 
baseline and following IL-17 stimulation (figure 4.1-E). Levels of Il6 mRNA were similarly 
enhanced upon Tnip1 knockdown, as was expression of other IL-17-target genes including Lcn2 
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and Cxcl1 (figure 4.1-F).  However, not all IL-17-induced genes were impacted by Tnip1 
deficiency; for example, Ccl20 and Nfκbiz (encoding IκBζ) are IL-17-target genes that are 
restricted by A20 but not by Tnip1 (figure 4.2.1-F) (19). Together, these results demonstrate that 
Tnip1 is a negative regulator of tonic and IL-17-induced signaling, selectively controlling 
expression of a subset of IL-17-target genes. 
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Figure 4.1: Tnip1 inhibits tonic and IL-17-dependent gene expression in mesenchymal cells. 
 (A) Kinetics of Tnip1-mediated inhibition of IL-6 expression. Tnip1+/+ or Tnip1-/- fibroblasts were treated with IL-
17 (200ng/ml) for the indicated times, and IL-6 in conditioned supernatants was measured by ELISA. Data are 
presented as mean values; *P<0.05, 2 way ANOVA with Sidak's multiple comparisons test analyzing all groups. 
Data are representative from 3 independent experiments. (B) Tnip1 restricts Il6 basal expression. Tnip1+/+ or Tnip1-/- 
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fibroblasts were treated with IL-17 for 3 h, and Il6 mRNA was assessed by qPCR and normalized to Gapdh. 
*P<0.05, 2 way ANOVA with Sidak's multiple comparisons test compared to untreated Tnip1+/+ sample. (C) Tnip1 
reconstitution inhibits Il6 expression. Tnip1-/- fibroblasts were transiently transfected with a Tnip1-expressing 
plasmid or empty vector (E.V.). After 24 h, cells were treated with IL-17 for 3 h and Il6 was assessed by qPCR. 
Data are presented as the fold-induction of Il6 in IL-17-stimulated cells compared to unstimulated. Data are 
normalized to untreated cells transfected with the same plasmid. *P<0.05, 2 way ANOVA with Sidak's multiple 
comparisons test compared to Tnip1-/- untreated. (D) Tnip1 knockdown efficiency. ST2 cells were transfected with 
siRNA targeting Tnip1 or a scrambled siRNA (mock) control. Tnip1 (ABIN1) expression was assessed by qPCR 
(left) and Tnip1 protein by immunoblotting (right). *P<0.05, 2 way ANOVA with Sidak's multiple comparisons test 
compared to mock, unstimulated cells. (E) Tnip1 silencing enhances tonic and IL-17-induced IL-6 production. ST2 
cells were transfected with the indicated siRNAs. 48 h later cells were stimulated with IL-17 for 3 h, and secreted 
IL-6 was assessed by ELISA. *P<0.05, 2 way ANOVA with Sidak's multiple comparisons test compared to mock 
unstimulated cells. (F)  Tnip1 silencing enhances tonic and IL-17-induced expression of some but not all IL-17 
target genes. ST2 cells from panel (E) were analyzed for the expression of the indicated genes by qPCR. *P<0.05, 
2 way ANOVA with Sidak's multiple comparisons test compared to mock unstimulated cells.  Panels B-F, data are 
representative of 3 independent experiments. 
 
4.2.2 ABIN-1 inhibits IL-17R signaling independently of A20 
Since ABIN-1 was identified based on its ability to bind A20, we asked whether ABIN-1-
mediated inhibition of IL-17R signaling is dependent on A20 (213). To determine whether A20 
was required for the inhibitory activity of ABIN-1, we knocked down Tnip1 in Tnfaip3-/- 
fibroblasts by RNA silencing. As shown, reduced expression of Tnip1 led to enhanced Il6 and 
Lcn2 expression, both at baseline and after IL-17 stimulation, similar to wild-type MEFs and 
ST2 cells (figure 4.2-A). In an independent approach to address the role of A20 in ABIN-1 
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activity, we co-transfected Tnfaip3-/- MEFs with ABIN-1, together with a luciferase reporter 
driven by the Lcn2 promoter (63). Cells were stimulated with IL-17 for six hours and luciferase 
activity was assessed. As we previously reported (19), Tnfaip3-/- fibroblasts showed only a 
modest responsiveness to IL-17, probably because baseline NF-κB is constitutively high in the 
absence of A20 (19). Nonetheless, Lcn2-promoter activity was markedly reduced upon 
transfection of ABIN-1 or A20, confirming that A20 is dispensable for the inhibitory function of 
ABIN-1 (figure 4.2-B). As a third method to assess the role of A20, we transfected ST2 cells 
with the Lcn2 luciferase reporter with either a full-length ABIN-1 or a truncated mutant lacking 
the A20-binding domain (but retaining the NF-κB inhibitory C-terminal domain) (figure 4.2-C) 
(214). In response to IL-17, both the full-length and the truncated forms of ABIN-1 inhibited IL-
17-dependent Lcn2-promoter activation (figure 4.2-C). Collectively, these findings demonstrate 





Figure 4.2: ABIN-1 inhibits IL-17 signaling independently of A20. 
 (A) ABIN-1 knockdown in Tnfaip3-/- fibroblasts maintains enhanced Il6 and Lcn2 expression. Tnfaip3-/- MEFs were 
transfected with ABIN-1 or mock siRNA and Il6 and Lcn2 expression were assessed by qPCR. (B) IL-17-induced 
Lcn2-promoter activation is inhibited in Tnfaip3-/- cells by ABIN-1. Tnfaip3-/- MEFs were transfected with the Lcn2-
promoter together with plasmids expressing ABIN-1 or A20. After 24 h, cells were treated with IL-17 for 6 h and 
luciferase activity was measured. (C) An ABIN-1 mutant lacking the A20 binding domain inhibits IL-17-dependent 
Lcn2-promoter activation. Left: Schematic representation of ABIN-1 protein (FL, full length) and the 444-647 
mutant lacking the A20 binding site. Right: ST2 cells were transfected with the Lcn2-promoter reporter together 
with FL or 444-647 forms of ABIN-1. 24 h later, cells were stimulated with IL-17 for 6 h and luciferase activity 
measured. *P<0.05, 2 way ANOVA with Tukey's multiple comparisons test compared to cells transfected with E.V. 
and treated with IL-17 in (C) and (B), or with cells treated with Mock siRNA and stimulated with IL-17 in (A). Data 
are representative of 3 independent experiments. 
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4.2.3 ABIN-1 regulates IL-17-induced NF-κB signaling 
ABIN-1 is known to inhibit NF-κB in the context of TNFα stimulation (91,92,215), and the 
above results suggested ABIN-1 suppressed NF-κB-dependent genes in the IL-17 pathway as 
well. An early step in the canonical NF-κB signaling pathway is phosphorylation of the inhibitor 
I κBα, which leads to its degradation by the proteasome, releasing NF-κB for nuclear 
translocation. Moreover, the gene encoding IκBα is induced in an NF-κB-dependent manner, 
establishing a negative feedback loop (216). To determine whether ABIN-1 targets NF-κB in the 
IL-17 signaling cascade, we assessed IL-17-dependent IκBα degradation in Tnip1-/- fibroblasts. 
In Tnip1-/- cells transfected with a control (empty) vector (E.V.), IκBα was degraded within 15 
minutes following IL-17 stimulation and remained at low levels for as long as 60 minutes post-
stimulation (figure 4.3-A, lanes 5-8). In contrast, in Tnip1-/- fibroblasts reconstituted with ABIN-
1, IκBα was restored to basal levels by 60 minutes (figure 4.3-A, lane 4).  Therefore, there is 
prolonged activation of NF-κB signaling when ABIN-1 is deficient. These data indicate that 
ABIN-1 inhibits IL-17-dependent NF-κB signaling upstream of IκBα degradation.   
To confirm that ABIN-1 inhibits NF-κB, we knocked down ABIN-1 in ST2 cells and 
evaluated NF-κB activation by IL-17. In ST2 cells transfected with a control (mock) siRNA, 
IκBα returned to normal levels 60 minutes after IL-17 stimulation (figure 4.3-B, lane 4). 
However, when ABIN-1 was reduced, cells deficient in this molecule could not re-establish pre-
treatment levels of IκBα (figure 4.3-B, lane 8). These data suggest that ABIN-1 is required to 
inhibit IL-17-dependent NF-κB signaling upstream of IκBα. 
To further define the mechanism by which ABIN-1 inhibits IL-17 signaling, we 
measured IL-17-dependent Lcn2 promoter activation in ST2 cells transfected with full-length 
ABIN-1 or a mutant with a non-functional ubiquitin binding domain (UBAN) (214). Whereas the 
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full-length ABIN-1 inhibited IL-17-dependent Lcn2 promoter activation, the UBAN mutant did 
not impair basal signaling and only partially inhibited IL-17 signaling (figure 4.3-C). Thus, 
ABIN-1 negatively regulates NF-κB activation in response to IL-17 signaling through IκBα. 





Figure 4.3: ABIN-1 inhibits IL-17-dependent NF-κB activation. 
 (A) Tnip1-/- fibroblasts exhibit prolonged activation of IL-17-dependent NF-κB signaling. Tnip1-/- MEFs were 
transfected with ABIN-1 or empty vector (E.V.), rested for 24 h, and stimulated with IL-17 (200 ng/ml) for the 
indicated times. IκBα degradation was assessed by immunoblotting of total cell lysates. (B) ABIN-1 knockdown 
prolongs activation of IL-17-induced NF-κB. ST2 cells were transfected with Tnip1 or mock siRNAs for 48 h and 
treated with IL-17 for the indicated times. Whole cell lysates were immunoblotted for IκBα. Results are 
representative of 3 independent experiments. (C) The ubiquitin binding domain (UBAN) contributes to the 
inhibitory function of ABIN-1. ST2 cells were transfected with the Lcn2-promoter reporter together with and ABIN-
1 or mutant lacking the UBAN domain (DF485/486NA). 24 h later, cells were treated with IL-17 for 6 h and 
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luciferase activity was measured. Data are representative of 3 experiments. *P<0.05, 2 way ANOVA with Tukey's 
multiple comparisons test.  
4.2.4 IL-17 signaling differentially regulates Tnip1 mRNA and ABIN-1 protein 
IL-17 induces several known signaling inhibitors to establish feedback signaling loops, including 
IκBα, A20 and regnase-1/MCPIP1, all of which are regulated by NF-κB. Tnip1 is also a known 
NF-κB target gene, raising the possibility that IL-17 might also induce its expression (217). 
Accordingly, we measured Tnip1 mRNA by qPCR following IL-17 stimulation. A linear 
regression model showed that IL-17 significantly, albeit modestly, induced Tnip1 mRNA over 
time, resulting in ~2-fold increased levels over two hours (figure 4.4-A). This induction was NF-
κB-dependent, as expression was blocked in the presence of an IKK inhibitor (figure 4.4-B). 
Moreover, IL-17 induction of TNIP1 occurred at the level of the promoter, as verified in ST2 
cells transfected with the full-length (6 kB) TNIP1 proximal promoter (218,219) (figure 4.6-A-
B). Transfection of C/EBPβ or NF-κB p65, transcription factors regulated by IL-17, was also 
sufficient to drive TNIP1 promoter activation (figure 4.6-C). These data support the hypothesis 
that IL-17 induces Tnip1 mRNA through its proximal promoter, via C/EBPβ and NF-κB. 
In probing regulation of the ABIN-1 protein, we were surprised that expression of ABIN-
1 was markedly and reproducibly decreased after ~60 minutes of IL-17 stimulation (figure 4.4-
C). A similar trend was seen in MEFs (figure 4.7-A-B). To determine whether the reduced 
ABIN-1 levels were due to proteasomal degradation, cells were treated with IL-17 in the 
presence of the proteasome inhibitor MG132. Blocking proteasome function prevented ABIN-1 
protein degradation after IL-17 treatment, which was most notable at the early (15 minutes) time 
point (figure 4.4-D). These data indicate that, even though the ABIN-1 promoter is activated by 
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IL-17, ABIN-1 is inducibly degraded in an IL-17-dependent manner. This unexpected finding 




Figure 4.4: IL-17 signaling upregulates Tnip1 mRNA by downregulates ABIN-1. 
 (A) Tnip1 mRNA is upregulated by IL-17. ST2 cells were stimulated with IL-17 for the indicated times, and Tnip1 
mRNA was analyzed by qPCR. Relative mRNA expression was assessed by linear regression modeling (P = 
0.0085). Data are pooled from 5 independent experiments. (B) NF-κB regulates Tnip1 mRNA. ST2 cells were 
pretreated with IKK inhibitor VII for 30 min or DMSO and treated with IL-17 for 3h. mRNA was analyzed by 
qPCR. *P < 0.05 2 way ANOVA with Tukey’s multiple comparisons test comparing to untreated sample. Data are 
representative of 3 experiments. (C) ABIN-1 protein is downregulated upon IL-17 signaling. Left: ST2 cells were 
treated with IL-17 (200 ng/ml) and whole cell lysates were analyzed by immunoblotting. Lanes 7-8: cells were 
transfected with mock or ABIN-1 siRNA to confirm the identity of ABIN-1 band. Right: Relative protein band 
intensities were compared to time of stimulation and analyzed by linear regression. Data are pooled from 6 
independent experiments. (D) ABIN-1 is degraded by the proteasome. Left: ST2 cells were pretreated with 
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proteasome inhibitor MG-132 for 30 min or DMSO and treated with IL-17 for the indicated times. Whole cell 
lysates were analyzed by immunoblotting. Right: Relative protein band intensities were compared to time of 
stimulation and analyzed by linear regression. Data pooled from 4 independent experiments and presented as mean 
+/- standard error. 
4.2.5 ABIN-1 is phosphorylated in an IL-17-dependent manner 
As early as five minutes after IL-17 stimulation, a second band was observed above the ABIN-1 
band (figure 4.4-C), suggesting that ABIN-1 may be phosphorylated. To determine if ABIN-1 
was phosphorylated, I immunoprecipitated endogenous ABIN-1 after 15 minutes of IL-17 
stimulation and treated the fraction with alkaline phosphatase, which should remove all 
phosphate groups from the immunoprecipitated form of ABIN-1. Then, observing SDS-PAGE 
mobility of ABIN-1 I indirectly determine its phosphorylation status (figure 4.5-A, lane 2). The 
comparison of the buffer-only treated sample in lane 1 with lane 2 demonstrates that ABIN-1 is 
phosphorylated after 15 minutes of IL-17 stimulation (figure 4.5-A). In the case of IκBα, IL-17-
mediated phosphorylation leads to proteasomal degradation. Since we observed a degradation of 
ABIN-1 after IL-17 stimulation, we tested if kinase activity had a role in this degradation. 
Interestingly, the use of the pan-kinase inhibitor staurosporine enhanced ABIN-1 degradation 
after IL-17 stimulation (figure 4.5-B, lanes 7-12) compared to control (figure 4.5-B, lanes 1-6). 
This result confirms that phosphorylation of ABIN-1 is induced by IL-17 signaling and regulated 
by intracellular kinase activity. Since the IKK complex is downstream of IL-17 signaling, and 
plays a fundamental role in regulating signaling, we tested if the IKK complex can phosphorylate 
ABIN-1 in an overexpression system. Indeed, overexpression of IKKβ together with ABIN-1 
was sufficient to phosphorylate ABIN-1 (figure 4.5-C, lanes 2 and 3). Lastly, to determine if 
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IKK complex kinase activity is required to regulate phosphorylation and degradation of ABIN-1, 
we treated ST2 cells with the pan-IKK inhibitor Bay11-7082. Consistent with our previous 
staurosporine treatment, treatment of ST2 cells with Bay11-7082 was sufficient to enhance 
protein degradation (figure 4.5-D, lanes 3 & 4). Overall, these data suggest that ABIN-1 is 
phosphorylated after IL-17 stimulation, which may be mediated by the IKK complex. 
Interestingly, in contrast to the case of IκBα in which phosphorylation leads to degradation, 




Figure 4.5: IL-17 induces a phosphorylation-independent mobility shift in ABIN-1. 
 (A) ABIN-1 is phosphorylated fifteen minutes after IL-17 stimulation. ST2 cells were stimulated with IL-17 and 
endogenous ABIN-1 protein was immunoprecipitated and treated with alkaline phosphatase (ALKP) to remove all 
phosphate groups. IP fractions were analyzed by WB. This image is representative of 3 independent experiments. 
(B) Kinase activity is necessary to repress ABIN-1 phosphorylation. ST2 cells were pre-treated with staurosporine 
(SPP) for 20 minutes before IL-17 was added to the medium at the indicated times. Whole cell lysates (WCL) were 
analyzed by WB. This image is representative of 2 independent experiments. (C) IKKβ kinase can phosphorylate 
ABIN-1. HEK293T cells were transfected with E-ABIN-1 and IKKβ-FLAG plasmids. WCLs were analyzed by 
WB. This image is representative of 2 independent experiments. (D) The IKK complex activity prevents ABIN-1 
degradation. ST2 cells were pre-treated with Bay11-7082 for 60 minutes before IL-17 was added for 30 minutes. 
WCLs were analyzed by WB. This image is representative of 2 independent experiments. 
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4.2.6 IL-17 induces TNIP1 promoter 
Since Brian Aneskievich group has robustly shown that NF-KB signaling induces TNIP1 
promoter, we tested if IL-17 stimulation induced TNIP1 promoter. Using different fragments of 
the human TNIP1 promoter fused to luciferase (figure 4.6-A) we determined that the human 
TNIP1 promoter is induced 2.5-fold after IL-17 stimulation (figure 4.6-B).  To determine if NF-
KB and CEBPB act on the TNIP1 Promoter, I transfected C/EBPB or p65 together with the 
luciferase reporter. Interestingly, both transcription factors activated the TNIP1 Promoter (figure 














Figure 4.6: IL-17 induces TNIP1/ABIN-1 promoter activation. 
 (A) NF-κB binding sites are necessary to activate the TNIP1/ABIN-1 promoter. Schematic 
representation of different TNIP1/ABIN-1 promoters used in figure (B). (B) TNIP1/ABIN-1-
promoter is activated by IL-17 and both distal and proximal sites are required for this activation. 
ST2 cells were transfected with the human TNIP1/ABIN-1-promoters from figure (A) and 
stimulated with IL-17 for 6h before luciferase activity was measured.  (C) C/EBPβ and NF-κB 
(p65) activate TNIP1/ABIN-1 promoter. The -6kb TNIP1/ABIN-1 promoter was transfected in 
ST2 cells together with the C/EBPβ and p65 expressing plasmids. Luciferase activity was 




4.2.7 IL-17 regulates degradation of ABIN-1 
To confirm that IL-17 induces ABIN-1 degradation in a different cell line, I stimulated wild-type 
murine fibroblasts with IL-17 and measured ABIN1 protein in whole cell lysate from these cells. 
Consistent with my findings from figure 4.4, ABIN1 protein was degraded after IL-17 
stimulation (figure 4.7-A-B). To determine whether degradation was controlled by IL-17 
stimulation, I stimulated ST2 cells with IL-17 for one hour and washed cytokine out using a 
citrate pH 4.0 buffer, and I replace the medium with cytokine free media. Four hours after 
removal of IL-17, ABIN-1 levels were restored to basal conditions (figure 4.7 C-D), 








Figure 4.7: IL-17 downregulates ABIN-1 protein in mouse fibroblasts. 
 (A) ABIN-1 is downregulated in wild-type fibroblasts. Murine fibroblasts (MEFs) derived from ABIN-1+/+ mice 
were stimulated with IL-17 and ABIN-1 protein was assessed by WB. (B) Linear regression was used to model the 
effect of time of IL-17 stimulation on ABIN-1 protein expression in MEFs. ABIN-1 protein was significantly 
decreased and directly associated with time of stimulation (P = 0.0403). Data are from seven independent 
experiments and are presented as mean +/- standard error. (C) ABIN-1 protein levels returned to baseline four hours 
after removal of IL-17 from the environment.  ST2 cells were treated with IL-17 for 1hour and the medium was 
removed, and the cytokine washed out from the cells using a citrate buffer pH 4.0. Cells were immediately incubated 
in complete medium for the indicated times and whole cell lysate was analyzed by western blot. This image is 
representative of three independent experiments. (D) Band density analysis of (C). Densitometry analysis of ABIN-1 
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expression after IL-17 stimulation and at various times after removal of IL-17. Data from three independent 
experiments are presented as mean +/- standard error.  
4.2.8 Degradation of ABIN1 is not regulated by βTrCP1 
To determine the mechanism of degradation of ABIN1, I investigated the effect of SCFβTrCP 
complex on degradation of ABIN1. SCFβTrCP functions downstream of IL-17 signaling to induce 
degradation of ACT1 and IΚBα, thus I hypothesized that SCFβTrCP could also mediates 
degradation of ABIN1. However, knockdown of βTrCP1 and βTrCP2 together to disrupt the 
SCFβTrCP complex did not affect the IL-17-dependent degradation of ABIN1. These data suggest 












Figure 4.8: SCFβTrCP complex does not regulate ABIN-1 degradation. 
(A) ABIN-1 degradation does not require β-TrCP1 and β-TrCP2 expression. ST2 cells were transfected with double 
siRNA for β-TrCP1 (Fbxw1a) and β-TrCP2 (Fbxw11) for 48h until cells were stimulated with IL-17A for indicated 
times. This experiment was repeated three times. (B) Knockdown of β-TrCP1 and β-TrCP2 was successful. ST2 
cells from (A) were also analyzed by qPCR to assess gene expression and knockdown efficiency. Expression of both 
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genes was significantly decreased in cells treated with specific siRNA than cells treated with mock siRNA. P = 0.05 
– t-test.    
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4.3 DISCUSSION 
Sustained IL-17 receptor signaling is associated with psoriasis and other autoimmune conditions 
(34,220–222). Accordingly, it is not surprising that there are negative regulators that act on the 
IL-17 signaling cascade to prevent the over-exuberant inflammatory responses that underlie 
tissue pathology. Notably, many of these inhibitory pathways converge on NF-κB activation 
(11). The development of autoimmunity is associated with polymorphisms in genes that 
influence NF- κB activity, such as TNFAIP3 (encoding A20), NFKBIA (encoding IκBα) and 
TNIP1 (encoding ABIN-1) (223,224). In prior work, we found that A20 is part of a feedback 
loop that restricts IL-17-mediated TRAF6 ubiquitination, which is required for NF-κB and 
MAPK activation; that finding prompted the present analyses of the A20-binding protein ABIN-
1 (19). Because of its A20-binding capacity, it is frequently assumed that ABIN-1 functions 
involve A20 (213,225,226). Indeed, ABIN-1 co-expression with A20 was shown to induce 
destabilization of the IKK complex and inhibition of NF-κB signaling in a lower chordate model 
organism (227). Similarly, ABIN-1 cooperates with A20 to inhibit antiviral signaling or TNF-
regulated NF-κB signaling (92,228). In contrast, our data show that ABIN-1 acts independently 
of A20 in the context of IL-17 receptor signal transduction. 
Most of what is known about ABIN-1 comes from studies of TNFα or LPS. ABIN-1 
controls signaling by several reported mechanisms, including (i) inhibiting IKK complex activity 
by binding to NEMO (IKKγ) (92), (ii) inhibiting ubiquitination and degradation of p105 to block 
p50 production in the non-canonical NF-κB pathway (215), and (iii) by associating with and 
blocking TNF receptor adaptors such as RIP and TRAF2 (225).  ABIN-1 requires its ubiquitin 
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binding domain (UBAN) for its function, as a D485N mutation within the UBAN suppressed 
binding to K63- or linear-poly-ubiquitin chains. In vivo, this mutation caused systemic 
inflammation and autoimmunity (229). This phenotype was considered to be LPS-mediated, but 
involvement of IL-17 was not explored. Here, we demonstrate that the same mutation in the 
UBAN eliminates ABIN-1-mediated inhibition of tonic and IL-17-dependent signaling, raising 
the possibility that some effects of the D485N mutation could be ascribed to IL-17. 
An unexpected finding in this study was the dichotomy by which IL-17 regulates ABIN-1 
mRNA versus protein. We consistently found that IL-17 triggered modest upregulation of ABIN-
1 mRNA. Consistent with its mRNA induction, IL-17 activates the ABIN-1 proximal promoter. 
NF-κB regulates the gene promoter activity of ABIN-1, inducing its mRNA as a late expression 
gene, compared to the A20 expression after TNFα stimulation (218,230). These data thus 
suggested that ABIN-1 is part of a similar negative feedback loop, analogous to other IL-17 
signaling inhibitors such as A20 and MCPIP1/Regnase-1 (19,81). Indeed, in HeLa cells NF-κB 
was found to induce expression of ABIN-1, while ABIN-1 in turn repressed NF-κB activity 
(218). However, the impact of IL-17 on ABIN-1 protein levels contrasted strikingly and 
unexpectedly with its transcriptional activation, since the net effect of IL-17 was downregulation 
of ABIN-1 protein levels. Interestingly, the phenomenon of ABIN-1 degradation after an 
inflammatory stimulus is evident in the published literature, although it has never, to our 
knowledge, been remarked upon. For example, ABIN-1 levels decreased after TLR and TNFα 
stimulation of bone marrow derived macrophages with approximately the same kinetics as we 
observed with IL-17 signaling (229). Additionally, studies in human psoriatic skin lesion 
biopsies showed increased ABIN-1 mRNA, but decreased protein, indicating that this 
phenomenon occurs in a setting where both IL-17 and ABIN-1 are known to be clinically 
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relevant (134). Mice in which ABIN-1 is conditionally deleted in keratinocytes develop more 
severe skin inflammation than control mice after imiquimod-induced dermatitis, which is 
associated with increased expression of IL-17 target genes such as Cxcl1 and Ccl20 (175). These 
findings therefore confirm the physiologic connection between ABIN-1 and IL-17.  
How do we reconcile the observation that IL-17 and other stimuli induce ABIN-1 
transcription yet triggers protein loss? We speculate that the answer lies in the persistence of the 
stimulus and the kinetics of activation. In the early phase of inflammatory signaling, ABIN-1 
protein is degraded within 1-2 hours, which serves to enhance inflammation. Simultaneously 
ABIN-1 mRNA expression is upregulated by NF-κB and C/EBPβ, replenishing at least 
somewhat the pool of translated ABIN-1. In washout experiments, we found that ABIN-1 protein 
levels return to baseline approximately four hours after IL-17 withdrawal (data not shown), thus 
returning the cell to a constitutively inhibited state. However, when IL-17 was able to signal 
continuously, ABIN-1 degradation was maintained. Thus, the inhibitory activity of Tnip1 is 
compromised during ongoing stimulation. This might explain the observation that in patients 
with psoriasis there is elevated mRNA, but decreased protein, for ABIN-1 (134). Psoriasis is 
linked to several inflammatory cytokines, with a predominant role for IL-17A signaling, based in 
part on the success of anti-IL-17A and anti-IL-17RA biologic drugs (220)(127,231,232). 
Therefore, the idea that ABIN-1 is both a tonic inhibitor of inflammation and a negative 
regulator of IL-17 signaling fits well with our data and with findings in pre-clinical mouse 
models and human studies (134,174,175).  
Interestingly, during early IL-17 stimulation, ABIN-1 was phosphorylated. In contrast to 
IκBα, which has less degradation when phosphorylation is inhibited, blocking phosphorylation of 
ABIN-1 increased ABIN-1 degradation. These data suggest that phosphorylation-mediated by 
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the IKK complex induces ABIN-1 degradation by a mechanism that has yet to be discovered. We 
suggest that there are two possible mechanisms by which the IKK complex can mediate ABIN-1 
degradation: (i) the IKK complex directly phosphorylates ABIN-1, which promotes ABIN-1 
interaction with stabilizing proteins, and/or restricting the access of an E3-ligase that would K48-
ubiquitinate ABIN-1 to induce its proteasomal degradation, or (ii) the IKK complex 
phosphorylates a different enzyme, like an E3-ligase that would target ABIN-1, inactivating its 
function, therefore, indirectly protecting ABIN-1. Future experiments to describe in more detail 
the link between phosphorylation and degradation of ABIN-1 will lead to a better understanding 
of the IL-17-mediated regulation of ABIN-1. 
There are certainly other examples of inhibitors that are downregulated by the signals that 
they regulate. In the case of IL-17, the proximal adaptor Act1 is degraded following 
phosphorylation to temper all downstream signaling events (75), and IκBα is degraded following 
phosphorylation to unmask the NF-κB nuclear import signal (233). IL-17 is just one of multiple 
immune effectors that can initiate ABIN-1 degradation and presumably thereby enhance 
inflammation. Moreover, IL-17 functions synergistically with many of these cytokines, 
particularly TNFα (11,234). Thus, ABIN-1 appears to regulate signaling at the intersection of 
these inflammatory stimuli, namely the IKK complex.  
We show that ABIN-1 degradation is at least partially mediated by the proteasome, with 
no apparent contribution of caspases or the lysosome (data not shown). These data have possible 
implications for therapeutic interventions. Therapeutics targeting the proteasome are used for 
cancer (235), and might be useful in diseases where ABIN-1 is implicated, i.e., those where 
TNIP1 SNPs are found. Another therapeutic opportunities involves settings where over-
production of ABIN-1 activators such as IL-17 or TNFα (e.g., autoimmunity, microbiome 
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dysbiosis) might lead to under-expression of ABIN-1 and chronic inflammation. Clearly more 
work needs to be done to further dissect the role of this important, but enigmatic molecule in the 
context of inflammation. 
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5.0  CHAPTER FIVE: IL-17R SIGNALING IS ACTIVATED BY CAVEOLIN-1 
5.1 BACKGROUND 
Caveolin-1 is an integral membrane scaffolding protein, which organizes signaling proteins 
within a specific region of the plasma membrane, the caveolae (236). Caveolin-1 is the main 
structural protein of the caveolae that shapes the inner surface of the plasma membrane in a 
flask-like structure (237). Caveolin-1 is widely express in endothelial cells, smooth muscle cells, 
skeletal muscle cells, fibroblasts, type-I alveolar cells, fat cells, brain and spinal cord neurons, 
and glial cells (238,239). Caveolin-1 primary functions include: lipid and cholesterol transport, 
tumor suppression, endocytosis, exocytosis, and signal transduction in the cell (240–242). 
Caveolin-1 functions are determined by caveolin-1 location (figure 5.1) and by the nature of the 
protein that interacts with caveolin-1. For instance, Caveolin-1 interacts with TLR4 and TNFR1 
through their specific binding motifs to regulate inflammatory signaling (176,177,243–
246)(196,247). Furthermore, caveolin-1 inhibits TLR4 signaling in macrophages, and activates 
TLR4 signaling in endothelial cells (177). Additionally, caveolin-1 regulates TNFR1 subcellular 
localization and TNFR1 signaling by both regulating the trafficking of the receptor and 
activating signaling by binding to TRAF2 (243).  Altogether, these findings suggest that 
caveolin-1 acquires specific functions by interacting with different proteins. 
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In addition to regulating formation of signaling complexes, caveolin-1 also plays a role 
inducing receptor desensitization. The dopamine 1 receptor (D1R) interacts with caveolin-1, and 
the caveolin-1 binding site in D1R mediates receptor desensitization through a mechanism that is 
not fully understood (248).  However, in the same study, cells transfected with a mutant 
containing mutations in the caveolin-1 binding site, D1R failed to internalize or to transduce 
signal, which suggests that caveolin-1 mediates receptor surface localization and desensitization 
(248). Likewise, desensitization of the IL-17R is induced via phosphorylation and degradation of 
ACT1 after persistent IL-17 stimulation (75). This suggests that desensitization of IL-17R can 
happen when proteins that transduce its signaling are removed. Thus, I also explore in this 
chapter whether caveolin-1 is regulated by IL-17R signaling. 
The IL-17R signaling cascade is initiated upon binding of IL-17 to the extracellular 
portion of the heterodimeric receptor formed by subunits IL-17RA and IL-17RC (249). Since IL-
17RA is the most important signaling subunit, it is the focus of this work (250).  IL-17RA has 
two extracellular fibronectin-III-like (FN) domains, FN1 and FN2,  which bind IL-17 (13). After 
IL-17 engages IL-17R, ACT1 is recruited to the intracellular domain of IL-17R to initiate 
signaling. ACT1 promotes IL-17R signaling by forming different functional complexes 
downstream of IL-17R (14,59). Because caveolin-1 initiates similar signaling complexes in other 
cytokine receptor signaling, it is possible that it could be playing a role in IL-17R (177,196,243). 
However, whether caveolin-1 regulates IL-17R signaling by forming a complex with the IL-17R 
has not been studied. For this reason, I tested the hypothesis that the caveolin-1/IL-17R complex 
regulates IL-17R signaling; data supporting this hypothesis are presented in this chapter. 
In this chapter, I report that the IL-17RA subunit of the IL-17R complex has a caveolin-1 
binding site in the FN1 domain of the extracellular portion of the receptor. Furthermore, I present 
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data demonstrating that caveolin-1 also regulates IL-17R signaling and activation of NF-κB. 
These findings suggest that caveolin-1 activates IL-17R signaling by a mechanism that involves 




Figure 5.1: Intracellular trafficking of caveolin-1. 
Diagram representing the different routes of caveolin-1 inside a cell. (1) Caveolin-1 (in red) is inserted co-
translationally into the ER membrane, and has both N- and C-terminal domains in the cytoplasm (red path). 
Caveolin-1 traffics to the Golgi via intracellular vesicles (251). (2) In the Golgi, caveolin-1 oligomerizes (252), 
which is required to transit to the plasma membrane (red path). Once in the plasma membrane, caveolin-1 is 
incorporated into caveolae, and (3) caveolin-1 is internalized and recycled. (4) Caveolin-1 from internalized vesicles 
enters the cytoplasm by interacting with lipids and forming lipid particles. Soluble caveolin-1 can return to the 
vesicles (return blue arrow) or go to the endoplasmic reticulum (ER). In the lumen of the ER, soluble caveolin-1 
binds High-density lipoprotein (HDL)-like particles that are secreted by the cell (253). (5) Alternatively, caveolin-1 
can bypass the ER and stay in the cytosol (green path) as part of lipid droplets (254). (6) Lastly, soluble caveolin-1 




5.2.1 IL-17RA has a putative caveolin-1 binding site in the FN1 extracellular domain.   
To determine if IL-17R can potentially bind to caveolin-1, I scanned the protein sequences of IL-
17RA and IL-17RC for the presence of putative caveolin-1 binding sites (255). Interestingly, I 
identified that the extracellular portion of the IL-17R subunit A (IL-17RA) has a putative Cav-1 
binding site between aa142 and aa149 (WRFSFSHF) (figure 5.2-A). In addition to IL-17RA, IL-
17RC also has a consensus caveolin-1-binding sequence (not shown), but since IL-17RA is the 
major signaling subunit of IL-17R signaling, I focused on the study of IL-17RA and caveolin-1 
interaction. A sequence alignment between human and murine IL-17RA revealed that the 
caveolin-1 binding site was conserved across both species. This evolutionary piece of evidence 
supports my hypothesis that this binding domain is functional, and therefore maintained through 
evolution (figure 5.2-A). The caveolin-1 putative binding site is within the FN1 domain of IL-
17RA, which has been previously described as one of the two domains involved in engaging the 
IL-17 ligand (13). Since the FN1 domain is important for the binding of IL-17, I analyzed the 
previously published crystal structure of IL-17RA to determine whether the putative caveolin-1 
binding site would interfere with the binding of IL-17 to IL-17RA (9,256). I found that the 
putative caveolin-1 binding site is on the opposite side of the ligand binding pocket, suggesting 
that binding to caveolin-1 would not interfere with binding to IL-17 (figure 5.2-B). These 
analyses suggest that caveolin-1 may bind to the FN1 domain in IL-17RA, and set the stage to 




Figure 5.2: IL-17RA has a putative caveolin-1-binding site in the FN1 extracellular domain. 
 (A) Alignment and identification of caveolin-1 binding site. Consensus sequence used to scan protein sequence of 
IL-17RA was AXAXXXXA where A is an aromatic residue (Y, W, F) and X any amino acid. (B) Crystal structure 
of the extracellular portion of the IL-17RA (brown) bound to IL-17A homodimer (pink and blue). Green is 
highlighting the putative caveolin-1 binding site. PDB file: 3JVF_C. from (256). 
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5.2.2 IL-17RA interacts with caveolin-1 via FN1 domain.  
To determine whether caveolin-1 interacts with IL-17RA via the FN1 domain, I used an 
overexpression system in HEK293T cells. I sub-cloned a mutant form of IL-17RA that expresses 
a truncated IL-17RA-FN2 protein, which lacks the FN1 domain (Figure 5.3-A). Using a co-
immunoprecipitation assay, I observed that the full-length of IL-17RA interacted with caveolin-
1. Interestingly, the truncated IL-17RA- FN2 protein did not interact with caveolin-1 (figure 5.3-
B), suggesting that the FN1 domain is necessary for the IL-17RA/caveolin-1 interaction.  These 
results confirm the in silico findings and demonstrate that caveolin-1 interacts with IL-17RA 
through the FN1 domain of IL-17RA. To determine that the putative caveolin-1-binding domain 
contained in the FN1 domain regulates IL-17RA/caveolin-1 interaction, I made a mutant of IL-
17RA to use in a similar immunoprecipitation assay as above. The IL-17RA mutant plasmid had 
two of the three phenylalanine (F) of the caveolin-1-binding site substituted with alanine, and I 
called this construct delta F144A/F149A (figure 5.4-A). Immunoprecipitated caveolin-1 
associated with full-length IL-17RA similar as shown in figure 5.3-A, however, the association 
with the IL-17RA delta F144A/F149A was diminished (figure 5.4-B). Altogether, these results 
suggest that the predicted caveolin-1-binding site can mediate, at least partially, the association 
of IL-17RA with caveolin-1. Further characterization with a mutant of all three phenylalanines 




Figure 5.3: IL-17RA FN1 domain interacts with caveolin-1. 
(A) Schematic diagram of murine IL-17RA showing the full-length (FL) and fibronectin-III-like (FN) domains. 
These constructs were sub-cloned from constructs made by Kramer et al. 2007 and inserted in a vector containing an 
HA-tag. (B) IL-17RA interacts with caveolin-1 via FN1 domain. HEK293T cells were transfected with the indicated 
plasmids and lysed 24 hours later. Cell lysates were incubated with an anti-MYC antibody to immunoprecipitate 
caveolin-1-myc protein and interacting partners. Immunoprecipitates and whole cell lysates were analyzed by 
western blotting. The immunoprecipitation of caveolin-1 with full-length IL-17RA is representative of four 
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independent experiments. The immunoprecipitation of caveolin-1 with truncated IL-17RA-FN2 is representative of 




Figure 5.4: IL-17RA/caveolin-1 interaction is partially mediated by two phenylalanine residues. 
 (A) Schematic diagram of murine IL-17RA showing the full-length (FL) and mutant in two of the three relevant 
amino acids of the caveolin-1-binding site (ΔF144A/F149A). These constructs were cloned by inserting the double 
mutation using PCR. (B) IL-17RA interacts with caveolin-1 via caveolin-1-binding domain. Similar as in (B), 
HEK293T cells were transfected and lysed 24 hours later. Caveolin-1-myc protein was immunoprecipitated to 
determine interaction with FL or mutant IL-17RA-HA. Immunoprecipitates and whole cell lysates were analyzed by 
western blotting. This experiment was repeated twice. 
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5.2.3 Caveolin-1 partially facilitates the surface localization of IL-17RA. 
Caveolin-1 regulates surface localization of TNFR1, which influences receptor signaling 
(176,247). Additionally, caveolin-1 regulates intracellular trafficking of signaling proteins to 
different intracellular compartments (257–260). To determine whether caveolin-1 regulates 
surface localization of IL-17RA, I analyzed IL-17RA receptor levels on the surface of Cav1-/- 
fibroblasts by flow cytometry. Compared to wild-type Cav1+/+ mice fibroblasts, cells deficient in 
Cav1 had lower surface expression of IL-17RA (figure 5.5-A-B). Interestingly, surface IL-17RA 
did not change in ST2 cells after knockdown of Cav1 (not shown), although IL-17R signaling 
decreased (figure 3.2). These results suggest that acute knockdown of caveolin-1 is enough to 
interrupt intracellular signaling, but is not enough to disrupt the pool of receptor that is already 
on the surface. Altogether, these data demonstrate that caveolin-1 regulates intracellular 










Figure 5.5: Caveolin-1 may partially facilitate the surface localization of IL-17RA. 
 (A) Cav1-/- fibroblasts exhibit less IL-17RA on the surface. Flow cytometry analysis of expression of IL-17RA on 
the surface of Cav1+/+ (blue) or Cav1-/- (red) tail fibroblasts. (B) MFI analysis from 3 independent experiments show 
a statistically significant difference between the surface expression of IL-17RA on Cav1-/- and Cav11+/+ fibroblasts. 




5.2.4 Caveolin-1 overexpression increases IL-17R signalling.  
 I reported in chapter 3 that caveolin-1 knockdown impaired IL-17R signaling. To confirm that 
IL-17R signaling is regulated by caveolin-1, I transiently transfected ST2 cells to overexpress 
Myc-tagged caveolin-1. Consistent with findings from chapter 3, caveolin-1 overexpression 
increased production of IL-17-dependent IL-6, Lcn2 and CXCL1 in the supernatant of cultured 
ST2 cells (figure 5.6-A). Expression of caveolin-1 in ST2 cells was verified by immunoblotting 
whole cell lysates with anti-MYC antibody (figure 5.6-B). These findings indicate that 






Figure 5.6: Caveolin-1 increases IL-17R signaling. 
 (A) IL-17-dependent expression of IL-6, Lcn2 and CXCL1 are increased after overexpression of caveolin-1. ST2 
cells were transiently transfected with caveolin-1, 24 hours later these cells were stimulated with IL-17 for 24 hours. 
The supernatant of the cells was analysed for the indicated protein by ELISA. Results representative of four 
independent experiments. Statistics: one-way ANOVA – p < 0.05. (B) Ectopic expression of caveolin-1 was 
successful in ST2 cells. The same cells from (A) were lysed and their whole cell content was analysed by western 
blotting. 
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5.2.5 Lack of caveolin-1 decreases activation of IL-17-dependent NF-κB signaling. 
Activation of NF-κB is among the main effector cascades triggered by IL-17R signaling (261–
263). To determine if caveolin-1 regulates IL-17-dependent NF-κB signaling, I assessed IκBα 
degradation in Cav1-/- and Cav1+/+ (WT) fibroblasts after IL-17 stimulation. As expected, IκBα 
was degraded 15-30 minutes after IL-17 treatment, and returned to basal levels by 60 minutes 
(figure 5.7-A). Interestingly, IκBα degradation following IL-17 treatment was compromised in 
Cav1-/- fibroblasts compared to WT fibroblasts (figure 5.7-A-B). These results suggest that in 









Figure 5.7: Lack of caveolin-1 increases activation of IL-17-dependent NF-κB signaling. 
 (A) Cav1-/- fibroblasts exhibit reduced NF-κB signaling. Tail fibroblasts from Cav1+/+ or Cav1-/- mice were 
stimulated with IL-17A for the indicated time. Whole cell lysates were analyzed by western blotting. This 
experiment is representative of two independent experiments. (B) Caveolin-1-/- fibroblasts exhibit less degradation 
IκBα after IL-17 stimulation. The ratios of IκBα to loading control (actin) were normalized to the densitometry at 
time zero for each cell type. This plot has summary data from both biological replicates (A). 
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5.2.6 IL-17 stimulation dynamically regulates caveolin-1 protein expression. 
 I previously noted in chapter 3 that levels of caveolin-1 mRNA were decreased upon IL-17 
stimulation in ST2 cells. These results are consistent with another report indicating that 
inflammatory signaling, including IL-17 stimulation, decreased caveolin-1 mRNA in endothelial 
cells (139). To confirm the regulatory effect of IL-17 on caveolin-1 protein levels, I assessed 
caveolin-1 protein in whole cell lysates of ST2 cells stimulated with IL-17. Consistent with our 
findings about mRNA, caveolin-1 protein levels were also decreased after IL-17 stimulation 





Figure 5.8: IL-17 stimulation downregulates caveolin-1 expression.  
 (A) Caveolin-1 protein decreases after IL-17 stimulation. ST2 cells were stimulated at the indicated times and cells 
were harvested and analyzed by western blotting. This is a representative experiment from 4 biological replicates.  
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5.2.7 Role of caveolin-1 in the synergic effect of IL-17 and TNFα in vivo. 
To investigate that role of caveolin-1 in IL-17R signaling in vivo, I used Cav1+/+ and Cav1-/- mice 
that I injected with IL-17 and TNFα combined. Because Li and colleagues demonstrated that a 
single intraperitoneal (i.p.) injection with IL-17 combined with TNFα increases IL-6 and CXCL1 
in serum of mice after four hours (59), I used a similar assay to determine the role of caveolin-1 
in IL-17R signaling in vivo. Age and gender matched mice were i.p. injected and blood was 
collected four hours after the injection. The content of IL-6 and CXCL1 was quantified in serum 
by ELISA. Since there was no statistically significant difference between male and female mice, 
their measurements were combined. To confirm that the technique was well performed, I 
injected ACT1-deficient mice to analyze same cytokines in the blood serum (figure 5.10-C-D). 
Consistent with findings from Li and colleagues, ACT1-deficient mice had no response to IL-17 
in synergy with TNFα, but the wild-type control mice had a statistically significant increase of 
IL-6 and CXCL1 in serum after the injection of IL-17+TNFα.  When Caveolin-1-deficient mice 
were injected, although there was an increased in IL-6 after the injection, the baseline levels of 
IL-6 were also elevated respect to wild-type mice. Multiple comparison analysis of the 4 
different groups (wild-type vs knock-out, and PBS vs IL-17+ TNFα injected) resulted in no 
statistically difference among these for groups. However, between mice injected with IL-17+ 
TNFα, there was difference that almost reached to significance (p = 0.06), suggesting that 
caveolin-1-deficient mice had a higher production of IL-6 compared to wild-type (figure 5.9-A). 
The levels of CXCL1 in serum followed a similar pattern, but with differences that reached to 
statistically significance.  Caveolin-1-deficient mice injected with IL-17+ TNFα exhibited more 
CXCL1 in their serum than wild-type controls, however, I should also indicate that there was an 
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increased production of CXCL1 in mice injected with PBS compared to wild-type controls 
(figure 5.9-B). These data indicate that production of IL-6 and CXCL1 was increased in 
caveolin-1-deficient mice before any stimulation, and that these mice do not phenocopy ACT1-



















Figure 5.9: Caveolin-1-deficient mice exhibit increased baseline inflammation. 
Cav1-/- mice were injected with IL-17A (1mg/mouse) combined with TNFα (200ng/mouse), and four hours later the 
mice were sacrificed, and blood was collected by cardiac puncture. Blood serum was used to measure (A) IL-6 and 
(B) CXCL1. There was not significant difference between genders, so these plots show results for both male and 








Figure 5.10: ACT1-deficient mice are non-responsive to IL-17R signaling. 
 (A) IL-6 and (B) CXCL1 measured in the serum of ACT1-deficient mice. There was not significant difference 
between genders, so these plots show both male and female mice combined. Statistics:  two-way ANOVA – 
Uncorrected Fisher’s LSD test p = 0.05. 
 122 
5.3 DISCUSSION 
Caveolin-1 regulates inflammatory signaling by binding to receptors like TLR4 or TNFR1 to 
promote their interaction with downstream intermediate molecules (177,196,243). In this 
chapter, I present findings that suggest that caveolin-1 can also regulate IL-17R signaling. Upon 
IL-17 binding to IL-17R, signaling is activated by the recruitment of ACT1 to the IL-17R 
intracellular SEFIR domain (59). ACT1 is an E3-ligase that ubiquitinates both itself and TRAF6 
to initiate downstream IL-17R signaling, and is also a scaffolding protein that mediates the 
binding and functional interaction of adaptor proteins with IL-17R (60). ACT1 is an example of 
the crucial role of scaffolding proteins in the activation of IL-17R signaling. In this chapter, I 
present results showing that caveolin-1 interacts with IL-17R through a putative caveolin-1 
binding site located within the FN1 extracellular domain of IL-17R, and that downregulation or 
overexpression of caveolin-1 in ST2 cells, respectively, decreased or increased IL-17R signaling. 
Additionally, caveolin-1-/- fibroblasts had less IL-17R on the cell surface, but ST2 cells with 
caveolin-1 knockdown have no changes in surface levels of IL-17R (not shown). Based on these 
data, I can provisionally conclude that IL-17R signaling is positively regulated by caveolin-1. 
TLR4 has a putative caveolin-1 binding site located in the C-terminal portion of its 
cytoplasmic domain (196,264), whereas TNFR1 has a putative caveolin-1 binding site located in 
the transmembrane/cytoplasmic region of the receptor (247). Combined with my results 
regarding the putative caveolin-1 binding site in IL-17R, I conclude that caveolin-1 binds these 
three inflammatory receptors through a consensus sequences like AXXAXXXA, where A is an 
aromatic residue and X is any other residue (255). Interestingly, these binding sites are in 
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different domains of the three receptors, suggesting that binding to caveolin-1 could have distinct 
functions depending on the specific receptor domain with which these interactions occur. 
Furthermore, my data indicate that mutation of two out of the three aromatic residues decreased 
the association of IL-17RA with caveolin-1 (figure 5.4-B), suggesting that this putative 
caveolin-1-binding site may indeed mediate this association. Further analysis of the subcellular 
distribution of this mutant of IL-17RA are yet to be performed.  
My studies showing that binding to caveolin-1 may regulate signaling and sub-cellular 
localization of IL-17R, are reminiscent of similar findings with TNFR1.  Knockdown of 
caveolin-1 in human endothelial cells decreases TNFR-signaling and total TNFR1 protein levels, 
due to lysosomal degradation; however, the cell-surface levels of TNFR1 do not change (247). 
Likewise, knockdown of caveolin-1 in murine ST2 cells impaired IL-17R-signaling without 
changing the surface levels of IL-17R. Although the total IL-17R protein levels after caveolin-1 
knockdown in ST2 cells are yet to be determined, the decreased surface levels of IL-17R 
observed in caveolin-1-/- fibroblasts, compared to WT fibroblasts, suggest that caveolin-1 
facilitates intracellular trafficking of IL-17R. I speculate that absence of caveolin-1 re-distributes 
IL-17R to lysosomes for degradation. Lastly, I hypothesize that caveolin-1 is acting as a 
scaffolding protein inside the cell, interacting with IL-17R and a complex of other proteins. 
Consequently, caveolin-1 may prevent IL-17R lysosomal degradation before the receptor gets to 
the surface of the plasma membrane.   
Caveolin-1 can not only regulate signaling by associating with IL-17R, but it can also 
mediate signaling by activating downstream receptor signaling molecules, such as TRAF 
proteins (243,265). My data indicated that knockdown of caveolin-1 decreased, while 
overexpression of caveolin-1 increased, IL-17 signaling. This is partially mediated by activation 
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of NF-κB upstream of IκBα. In a previous report, caveolin-1 activated TLR4 signaling in 
endothelial cells via caveolin-1-Y14 phosphorylation (177). Moreover, caveolin-1 interacted 
with TLR4 and stabilized the TLR4/MYD88 complex to activate NF-κB signaling (177). For 
future work, questions remain regarding whether phosphorylation of caveolin-1-Y14 plays a role 
in regulating of IL-17R signaling, and whether this phosphorylation site regulates the interaction 
of caveolin-1 with IL-17R.   
Finally, a preliminary analysis of the effect of caveolin-1 in IL-17R signaling in vivo 
indicates that caveolin-1 and ACT1 have different functions. My data with fibroblasts and ST2 
cells suggested that caveolin-1 could positively regulate IL-17R signaling, an effect that is 
similar to the function of ACT1 in cells. However, in contrast in vivo, caveolin-1-deficient mice 
had an increased production of IL-6 and CXCL1 in baseline and in stimulated conditions while 
ACT1-deficient mice had no increase in these cytokines. In sum, these data suggest that although 
caveolin-1 regulates IL-17R signaling in cells in culture, caveolin-1 functions are broader in 
organisms.  Additionally, caveolin-1 and ACT1 have no redundant functions, suggesting that a 
possible function of caveolin-1 in IL-17R signaling involves regulation of the receptor 
localization rather than control of signaling.  
In summary, this study expands the understanding of the mechanism of activation of IL-
17R signal transduction, and reveals a role for caveolin-1 in IL-17R localization and signaling. 
Future investigations of the role of caveolin-1 in the regulation of IL-17R signaling may provide 
insight into activation and intracellular trafficking of IL-17R. 
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6.0  CHAPTER SIX: SUMMARY AND DISCUSSION, FUTURE DIRECTIONS AND 
CONCLUDING REMARKS  
6.1 SUMMARY AND DISCUSSION 
IL-17 receptor signaling is both an important line of defense against pathogens and a significant 
contributor to inflammation in autoimmune diseases. The downstream intracellular signaling of 
the IL-17 receptor (IL-17R) requires activation of intermediate proteins that transduce signals 
through a cascade of events, involving protein-protein interactions and post-translational 
modifications like phosphorylation and ubiquitination of target proteins (reviewed in (11,34)). 
Together, these molecular events organize the stabilization of mRNA transcripts, and/or the 
activation of terminal effectors like the NF-κB transcription factor that induces gene expression. 
In this thesis, I sought to define the molecular mechanisms by which the ubiquitin-binding 
protein ABIN-1 and the membrane-bound scaffolding protein caveolin-1 regulate IL-17R signal 
transduction. Additionally, I provide evidence for deubiquitinases CYLD and Otulin having 
potential regulatory roles in IL-17 signaling. 
In chapter 3, I reported results of an siRNA screen for candidate genes that could regulate 
IL-17R signaling. From the literature, I selected ten candidate genes that fell into one or more of 
the following categories: (i) genes known to regulate NF-κB downstream of TLR4 or TNFR1 
signaling, (ii) genes that regulate signaling pathways via ubiquitination, and (iii) genes linked to 
 126 
IL-17-dependent autoimmune diseases.  Among these, I found five genes with possible 
regulatory effects on IL-17R signaling. Two of these genes, caveolin-1 and anaphase-promoting 
complex (AnapC3 or Cdc27), were possible activators, as their knockdown reduced IL-17-
mediated signaling. I chose not to pursue the study of AnapC3 (Cdc27)-mediated activation of 
IL-17R signaling because this effect is likely to be a consequence of disrupting the cell cycle, a 
major known function of AnapC3 (206). The other activator was caveolin-1, a multifunctional 
scaffolding protein. Caveolin-1 regulates various intracellular signaling pathways, including 
signaling by receptor and non-receptor tyrosine kinases, G-protein coupled receptors (GPCR), 
and TNFR1 and TLR4 (266). Since caveolin-1 is known to regulate trafficking and signaling of 
several surface receptors (267,268), I further explored the specific role of caveolin-1 downstream 
of IL-17R. Additionally, IL-17 stimulation of ST2 cells down-regulated caveolin-1 mRNA and 
protein, suggesting the presence of a feedback loop. Three other putative intermediates 
discovered from this screen showed inhibitory activity on IL-17R signaling: ABIN-1, CYLD, 
and Otulin. CYLD and Otulin are deubiquitinases, while ABIN-1 binds poly-ubiquitinated K63-
linkages with its ubiquitin-binding domain homologous to that of NEMO (IKKγ), a critical 
component of the IKK complex of NF-κB signaling. I decided to focus further investigation on 
determining the role of ABIN-1 in IL-17R signaling for the following reasons: (i) Among ABIN-
1, Otulin and CYLD, ABIN-1 (TNIP1) is the only gene that has been genetically associated with 
psoriasis, a complex autoimmune skin disease that is successfully treated by blocking IL-17R 
signaling, (ii) ABIN-1 binds to NEMO and A20, two key intermediates of NF-κB signaling, (iii) 
ABIN-1 inhibits TNF-dependent NF-κB signaling (91,92). 
In chapter 4, I presented data that suggest a molecular mechanism of action for ABIN-1 
in IL-17R signaling. ABIN-1 is a tonic inhibitor of inflammatory signaling functioning at the 
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level of NEMO and the IKK complex (92) (figure 6.1). I discovered that ABIN-1 can inhibit IL-
17R signaling independently of A20 and dependent on a functional ubiquitin-binding domain 
(figures 4.2 & 4.3). Although ABIN-1 mRNA is induced by NF-κB (217), the levels of ABIN-1 
protein did not return to baseline until four hours after removal of IL-17 stimulation (figure 4.7). 
To our knowledge, this is the first study that has described that ABIN-1 protein is degraded after 
IL-17 stimulation. Furthermore, several studies have reported that ABIN-1 transcript levels 
increase after TNFα stimulation, but no studies were done to query the protein levels (217,269). 
My data, presented in figure 4.4, show that while ABIN-1 mRNA levels increase after IL-17 
stimulation, surprisingly, there is a decrease in ABIN-1 protein. This decrease in ABIN-1 protein 
levels is particularly important in the “RNAseq era”. Technological advances have improved our 
capacity to analyze gene induction on a large-scale by measuring mRNA. These data emphasize 
the principle that, even when mRNA levels are increased, protein levels are not necessarily 
altered concomitantly. I was able to reconcile ABIN-1 mRNA induction, degradation of ABIN-1 
protein, and ABIN-1 inhibitory function by suggesting that ABIN-1 serves as a constitutive 
brake on signaling. Thus, as a tonic inhibitor of inflammatory signaling, ABIN-1 would 
somehow need to be degraded to permit activation of IL-17-dependent NF-κB signaling. In turn, 
activation of NF-κB would induce ABIN-1 mRNA, as part of a feedback signaling circuit. 
Furthermore, I speculate that while IL-17R signaling remains activated, ABIN-1 protein 
continues to be degraded, which could explain a previous observation that ABIN-1 protein is 
decreased in skin biopsies of psoriatic patients, a disease that is characterized by increased IL-17 
signaling (134). Further studies are of course necessary to elucidate the complete molecular 
mechanism by which ABIN-1 is degraded and how IL-17R signaling contributes to this 
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degradation. Nonetheless, I speculate that molecular events like phosphorylation and 
ubiquitination of ABIN-1 mediated by IL-17R signaling will be part of this mechanism. 
Furthermore, in chapter 4, I explored the mechanism by which IL-17 induces 
phosphorylation and degradation of ABIN-1. Specifically, I investigated whether these two 
processes are related, as is the case for another tonic inhibitor of NF-κB, IκBα. To initiate 
signaling, IκBα is first phosphorylated at serine 32 (Ser 32) and serine 36 (Ser 36), and then 
K48-ubiquitinated, and finally degraded (270). For IκBα, these three processes are sequentially 
dependent on each other, as shown by substitution of Ser32/36 with alanine residues to originate 
an IκBα protein that does not undergo signal-induced degradation (271). To test the relationship 
between phosphorylation and degradation of ABIN-1, I used staurosporine, a pan-kinase 
inhibitor, to non-specifically block intracellular phosphorylation. Surprisingly, inhibiting 
phosphorylation of ABIN-1 increased ABIN-1 degradation (figure 4.5-B), leading me to 
conclude that intracellular phosphorylation activity protects ABIN-1 from degradation. 
 To characterize further the phosphorylation of ABIN-1 and to delineate the kinase 
responsible for its phosphorylation, I inhibited the IKK kinase complex, as it is known to 
function downstream of IL-17R signaling (261). Consistent with the staurosporine experiment, 
inhibition of both IKKα and IKKβ together enhanced degradation of ABIN-1 even before 
stimulation (figure 4.5-D). Based on my results, I speculate that IL-17 induces phosphorylation 
of ABIN-1 at one or more sites (tyrosine (Y), serine (S) or threonine (T) residues). S and T  
residues are commonly seen as part of the PEST (Proline-Glutamic-Serine-Threonine)  signal 
sequence that promotes protein degradation (272). However, no PEST signal sequence was 
found in ABIN-1 (not shown), suggesting that phosphorylation of ABIN-1 has a role other than 
inducing protein degradation. Together, these data suggest that kinase activity of the IKK 
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complex prevents degradation of ABIN-1. However, important questions remain, including: (i) 
does the IKK complex directly phosphorylate ABIN-1? and (ii) is degradation of ABIN-1 
dependent on, or independent of, its phosphorylation? These and other remaining questions are 
discussed later in this chapter. In summary, I found that IL-17R signaling induces ABIN-1 
phosphorylation, but further studies are required to map the phosphorylation site in ABIN-1 and 
to identify the specific kinase that catalyzes the phosphorylation.  
In addition, in chapter 4, I provide evidence that IL-17-dependent ABIN-1 degradation 
occurs at least partly via the proteasome, a process that requires K48-ubiquitination. The SCF-β-
TrCP complex, containing Skp1, Cullin-1, β-TrCP1 and β-TrCP2 proteins, is known to mediate 
K48-ubiquitination of IκBα to target it for proteasomal degradation (273). Based on  published 
reports that the SCF-β-TrCP complex is activated downstream of IL-17R signaling to target 
IκBα and ACT1 for degradation (75,274), I hypothesized  that the SCF-β-TrCP complex (formed 
by β-TrCP1 and β-TrCP2 as aforementioned) regulates degradation of ABIN-1. However, 
knocking-down β-TrCP1 and β-TrCP2 to disrupt the SCF-β-TrCP complex had no effect on 
ABIN-1 degradation (figure 4.8), suggesting that this complex does not mediate ABIN-1 
ubiquitination and degradation. Nevertheless, possible caveats are that the incomplete 
knockdown of ABIN-1 siRNA was insufficient to fully restrict the β-TrCP complex activity 
(knockdown efficiency was 60%, and protein levels were not tested). Another explanation may 
relate to the half-life of β-TrCP1, which was reported to be between three to ten hours in two 
different cell lines (275). To-date, the half-life of β-TrCP2 is unknown.  Consequently, if the β-
TrCP complex half-life exceeds 48 hours, siRNA treatment may not have sufficiently reduced 
the existing pool of β-TrCP protein, and thus not interrupted ABIN-1 ubiquitination and 
degradation. Alternatively, a different E3-ligase may be activated by IL-17R signaling to induce 
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K48-ubiquitination and degradation of ABIN-1. If the latter is the case, it would be important to 
identify this ligase and to identify the other signaling intermediates that are targeted by it. In the 
future directions sections of this chapter, I discuss how to address some of these remaining 
questions in more detail.  
In chapter 5, I presented results to support the hypothesis that caveolin-1 activates IL-17R 
signaling. Caveolin-1 regulates intracellular signaling by binding to various signaling 
intermediates and restricting or promoting their function in the context of TLR4 and TNFR1 
signaling (176,177,196). One possibility that seemed promising is that caveolin-1 binds to IL-
17R. I proposed this possibility because I discovered in silico that both subunits of the 
heterodimeric receptor IL-17R (formed by IL-17RA/IL-17RC) contain a putative caveolin-1 
binding site in the FN1 (Fibronectin III-like 1) domain of their extracellular region (figure 5.1). I 
experimentally confirmed the functionality of this caveolin-1 binding site in IL-17RA, the most 
important signaling subunit of the IL-17 receptor (14,16).  Indeed caveolin-1 associates with IL-
17RA upon overexpression of both proteins in HEK293T cells (figure 5.2). Interestingly, a 
truncated form of IL-17RA, lacking the FN1 domain that encompasses the putative caveolin-1-
binding site, did not associate with caveolin-1. To my knowledge, these preliminary results are 
the first report that caveolin-1 associates with IL-17RA, and set the groundwork for more in-
depth analysis of this pathway.  
In chapter 5, I also observed that fibroblasts deficient in caveolin-1 express lower levels 
of IL-17RA on the cell surface as shown by flow cytometry (figure 5.3). Caveolin-1 is well-
known to regulate receptor trafficking to the cell surface and signaling of receptors such as the 
bone morphogenic protein receptor II (BMPRII), transforming growth factor beta receptor I 
(TGF-βRI), D2 dopamine receptor (Drd2) and TNFR1 (176,248,258,259,276). Accordingly, it is 
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tempting to speculate that there is reduced IL-17 signal transduction due to the decreased levels 
of IL-17RA on the cell surface. As a preliminary conclusion, I propose that caveolin-1 facilitates 
signaling and surface localization of IL-17R by direct binding to IL-17RA. However, it must be 
pointed out that this conclusion only partially explains my results, because IL-17RA on the cell 
surface was unchanged in ST2 cells following caveolin-1 knockdown (not shown). ST2 cells are 
a bone marrow stromal cell line that robustly responds to IL-17 stimulation (212). Nonetheless, 
as I showed in chapter 3, ST2 cells in which caveolin-1 was knocked down exhibited a decreased 
response to IL-17 stimulation as measured by IL-6 production (figure 3.1). Thus, in addition to 
regulating IL-17RA surface localization, these data suggest that caveolin-1 may also have a 
direct signaling role downstream of IL-17R signaling.  
In addition to regulating surface localization of receptors, caveolin-1 also regulates 
signaling of  TLR4 and TNFR1 (176,277). In chapter 5, I also described the finding that 
caveolin-1 functions downstream of IL-17R signaling (figure 5.4). To corroborate this finding, I 
overexpressed caveolin-1 in ST2 cells and measured IL-17-dependent IL-6 production. 
Consistent with the knockdown experiments, overexpression of caveolin-1 increased IL-17R 
signaling (figure 5.4). Together, these data suggest that IL-17R is positively activated by 
caveolin-1 in our experimental system. Moreover, adaptor molecules in the IL-17R signaling 
cascade like ACT1 or TRAF6 may interact with caveolin-1. For instance, TRAF6 interacts with 
caveolin-1 downstream of IL-1β receptor signaling, another inflammatory pathway (265), and 
my in silico analyses revealed a putative caveolin-1 binding site in the sequence of ACT1 (not 
shown). It is therefore tempting to hypothesize that caveolin-1 may also interact with ACT1 or 
TRAF6 downstream of IL-17R signaling to facilitate the formation of signaling complexes. 
Additionally, I also discovered evidence of mutual regulation between caveolin-1 and IL-17R 
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signaling.  A similar mechanism of mutual regulation between IL-17R signaling with ACT1 has 
been reported (75). Specifically, in chapters 3 and 5, I showed that IL-17 stimulation decreased 
caveolin-1 mRNA (figure 3.3) and protein (figure 5.6) in ST2 cells. These data suggest that 
caveolin-1 is downregulated because of the activation of IL-17R signaling.  Furthermore, 
Yamaguchi et al. described that stimulation of keratinocytes with IL-17 or TNFα decreased 
caveolin-1 mRNA, which supports my findings. The authors of that study correlated their 
findings in keratinocytes with decreased caveolin-1 mRNA in skin biopsies of patients with 
psoriasis (127,139). However, Yamaguchi et al. did not investigate whether caveolin-1 regulates 
IL-17 signaling, and to my knowledge, this thesis is the first report describing a mutual 
regulation between caveolin-1 and IL-17R signaling. Moreover, to test further the role of 
caveolin-1 in IL-17R signaling, caveolin-1-/- cells could be reconstituted with a plasmid 
expressing a dominant negative mutant of caveolin-1 protein.  Phosphorylation of caveolin-1 at 
tyrosine-14 has been shown to mediate its signal transduction function, and mutations of this 
residue originate a dominant negative form of caveolin-1 (177,278). Thus, I hypothesize that 
caveolin-1-/- cells reconstituted with this dominant negative tyrosine-14 mutant of caveolin-1 
would have decreased IL-17 signaling. Finally, extending the hypothesis to in vivo models, 
absence of caveolin-1 could potentially reduce IL-17-mediated inflammation. To test this 
hypothesis, I suggest using caveolin-1-/- mice in models of IL-17-mediated inflammation like the 
mouse model of multiple sclerosis (MS) and/or the imiquimod-induced psoriasis-like disease 
model. Thus, work presented here identified that both ABIN-1 and caveolin-1 function 
downstream of IL-17R, by different mechanisms. 
IL-17R signaling synergizes with other signaling receptors, like TNFR1 (212,279–281). 
Integration of all the responses from various receptors determines how cells respond to multiple 
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stimuli. ABIN-1 and caveolin-1 act downstream of both IL-17R (this thesis) and TNFR 
(174,211,229) so ABIN-1 and caveolin-1 could mediate receptor cross-talk. For example, ABIN-
1 and caveolin-1 protein levels are down-regulated by IL-17. ABIN-1 is degraded for as long as 
IL-17 is stimulating its receptor (figure 4.7), while caveolin-1 protein levels dynamically change 
during IL-17 stimulation (figure 5.6). Degradation of ABIN-1 can prime cells to having an 
enhanced response to a secondary stimulation with TNFα, but dynamic changes in caveolin-1 
can modulate the final signaling response. An approach to understanding the contribution of 
ABIN-1 and caveolin-1 in the cross-talk between signaling pathways is to build computational 
models of these signaling networks. Computational models have previously been used to 
determine the cross-talk of pathways via NF-κB signaling (reviewed in (282)). Experimental data 
from my studies on ABIN-1 and caveolin-1 could be used as input to build and calibrate a model 
of the IL-17 response. Kinetics of down-regulation, target gene expression, and the status of 
different proteins from the IL-17R pathway can be also used as inputs for this model. Additional 
data should be accumulated regarding the role of ABIN-1 and caveolin-1 in TNFR1 signaling, 
and added to this computational model. Furthermore, this model could be used to suggest new 
hypotheses regarding IL-17R signaling, and to understand the cross-talk between TNFα and IL-
17 pathways. 
The addition of my findings to the IL-17R signaling pathway are illustrated in figure 
6.1(figure 6.1). In this model, I depict that ABIN-1 and caveolin-1 are constitutively expressed 
prior to IL-17 stimulation. At baseline, ABIN-1 inhibits the IKK complex, while caveolin-1 
facilitates localization of IL-17R to the cell surface. Upon IL-17 stimulation, ACT1 is recruited 
to the receptor and caveolin-1 may contribute to ACT1-dependent signaling by possible 
stabilization of the ACT1/IL-17R complex, leading to activation of NF-κB. As a distal signaling 
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event upon receptor activation, IL-17R signaling induces degradation of ABIN-1 to increase NF-
κB activation. In this model, caveolin-1 is downregulated due to the activation of IL-17R 
signaling. Furthermore, downregulation of caveolin-1 restricts IL-17-mediated inflammation and 
helps to dampen inflammatory signaling, while IL-17 continues to stimulate the receptor. 
In summary, my thesis described a screen of novel intermediates of IL-17R signaling, 
and is the first study to propose mechanistic roles for ABIN-1 and caveolin-1 acting downstream 
of IL-17R signaling.  Here, I described a potential mechanism by which the ubiquitin-binding 
domain of ABIN-1 regulates baseline and IL-17-stimulated signaling in an A20-independent 
manner. In the case of my preliminary studies on caveolin-1, my data suggest that caveolin-1 
promotes IL-17 signaling as well as regulates surface localization of the receptor (IL-17RA). 
Together, the results described in this thesis contribute to the characterization of downstream 




Figure 6.1: Schematic representation of IL-17R signaling  
Proposed roles of ABIN-1 and caveolin-1 are included in this model as described in this thesis. 
The red arrows with flat ends indicate inhibition and the black arrows with pointed ends indicate 
induction or activation. Dotted black arrows indicate feedback regulation, dotted red arrows 
 136 
represent phosphorylation events, and double arrows indicate the interaction of caveolin-1 with 
the extracellular domain of IL-17RA.  
6.2 FUTURE DIRECTIONS 
The work presented in this thesis illuminates some aspects of the regulation of IL-17R signaling, 
while generating many other possible avenues of investigation. Questions remain regarding the 
molecular mechanism of phosphorylation and degradation of ABIN-1, as well as the specific role 
of caveolin-1 in activation of IL-17R signaling. Potential in vivo relevance of these signaling 
molecules could be tested in murine models of IL-17-related diseases to investigate the 
physiological relevance of ABIN-1 and caveolin-1 in IL-17R signaling.  Since a goal of studying 
signaling is to provide the basis for therapy, I propose exploration of small molecules and 
peptides for studying, and for possible therapeutic regulation of, IL-17R signaling.  
6.2.1 Molecular approaches to study ABIN-1 in IL-17R signaling. 
A possible avenue to extending my studies involves the identification of the kinase(s) and 
E3-ligase(s) responsible for phosphorylation and ubiquitination of ABIN-1 downstream of IL-
17R signaling. Achieving this aim would be useful in determining what other proteins interact 
with ABIN-1 (its “interactome”) after IL-17 stimulation in ST2 cells. The Gaffen lab has widely 
used this cell line to study IL-17R signaling (15,19,283). Using mass spectrometry can provide 
insight into the identity of proteins that bind to ABIN-1 upon IL-17 stimulation. Understanding 
the interactome of ABIN-1 as regulated by IL-17R signaling could provide information about the 
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mechanism by which ABIN-1 regulates IL-17R signaling and vice-versa. Specifically, I 
speculate that this approach could help to narrow the list of possible kinase(s) or E3-ligase(s) that 
regulate ABIN-1 after IL-17 stimulation. Specific findings from this mass spectrometry analysis 
could be validated in other relevant cells that respond to IL-17, like murine keratinocytes or 
human oral epithelial cells (35,284). 
An additional future direction could be to identify the role of β-TrcP proteins in 
ubiquitination and degradation of ABIN-1 by using β-TrCP1-deficient fibroblasts. As I discussed 
above, siRNA knockdown of β-TrcP1 and β-TrcP2 could have been incomplete in disrupting the 
functional β-TrcP complex. Thus, using β-TrcP1-deficient fibroblasts, which have impaired 
degradation of IκBα (285), could help to determine if ABIN-1 is K48-ubiquitinated by the SCF-
β-TrcP complex after IL-17 stimulation. 
In addition, in vitro analyses could be used to investigate ABIN-1 phosphorylation and 
ubiquitination in cells. Endogenous ABIN-1 could be incubated in an assay in vitro with 
recombinant IKKβ protein to assess if ABIN-1 can be phosphorylated by the IKK complex. If so, 
these results would strengthen our findings in stromal cells (chapter 4). A similar assay could be 
used with other kinases. Possible limitations of this approach include the source of purified 
active protein and the requirement to immunoprecipitate sufficient quantities of endogenous 
ABIN-1 protein. These limitations could be addressed by purifying overexpressed protein from 
HEK293T cells.  All in all, this assay would provide evidence that ABIN-1 could be 
phosphorylated (or not) by the tested kinases.  Lastly, since the ABIN-1-phosphorylating kinase 
could have different roles within a cell, the relevance of these findings should be validated in IL-
17-responding cells like ST2 cells, keratinocytes, or epithelial cells. 
In vivo approaches to study caveolin-1 in IL-17R signaling 
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How might one apply the findings from this thesis to a physiological relevant model? I 
propose to analyze the relationship between caveolin-1 with IL-17R signaling using murine 
models of autoimmune diseases like psoriasis or multiple sclerosis (MS) (127,286). Caveolin-1-/- 
mice have been previously used with the autoimmune encephalitis (EAE) model, a murine model 
of MS that has been shown to depend on IL-17 signaling (142,287–289). Specifically, results 
from two studies using caveolin-1-/- mice in the EAE model are consistent with my hypothesis 
that caveolin-1 promotes IL-17R signaling in stromal cells. Wu et al showed that caveolin-1-/- 
mice developed less disease than wild-type mice (290). They explained that their results were a 
consequence of a decreased expression of adhesion proteins (ICAM and VCAM) in endothelial 
cells of caveolin-1-/- mice, which increased the selectivity of the blood-brain barrier and 
decreased trafficking of T cells into the central nervous system (CNS) (291). In a different study, 
Lutz et al. confirmed that caveolin-1-/- mice develop less MS-like disease severity by 
demonstrating that caveolin-1-/- endothelium had a significant reduction in transcellular and 
paracellular migration of TH1 cells, but not of TH17 cells. Accordingly, they found similar 
numbers of TH17 cells in the CNS of wild-type and caveolin-1-/- mice used in the EAE model. 
Lastly, they attributed the decrease in EAE severity in caveolin-1-/- mice to a decrease in TH1 
cells in the CNS (292). These two studies confirm a role of caveolin-1 in the development of 
EAE. Together, these findings raise the question of why there is a decreased disease severity if 
IL-17-producing cells do get into the CNS? Putting their findings in the context of my results, it 
is tempting to speculate that the lack of caveolin-1 in glial cells – which are responsible for the 
development of IL-17-dependent EAE (142) — makes them less responsive to IL-17R signaling. 
To test my hypothesis that caveolin-1 activates IL-17R signaling in vivo, mice with a deletion of 
caveolin-1 in glial cells could be used in the EAE model.  Another model to test for an IL-17-
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dependent disease with the caveolin-1-/- mice is the murine imiquimod-induced psoriasis-like 
disease model (284,293). This model of psoriasis-like disease has not been tested in caveolin-1-/- 
mice, nor has it been used to study the specific role of caveolin-1 in the non-hematopoietic 
compartment. Thus, I recommend performing the imiquimod murine model with bone marrow 
chimeras.  
To better understand the cell types involved in using caveolin-1 as a signaling 
intermediate, murine studies incorporating a bone marrow chimera approach in the imiquimod-
induced psoriasis-like disease model could be used. If the hypothesis that caveolin-1 activates 
IL-17R signaling is correct, caveolin-1-/- mice would develop less imiquimod-induced psoriasis-
like disease, perhaps comparable to a control group of ACT1-/- mice that are less susceptible to 
developing disease (121). Next, to corroborate that the role of caveolin-1 is in the non-
hematopoietic compartment, a bone marrow chimera approach could be added. Based on my 
hypothesis, I predict that the recipient caveolin-1-/- mice would be less susceptible to developing 
a psoriasis-like disease. Results from such in vivo experiments would bolster our understanding 
of the regulation of IL-17R signaling mediated by caveolin-1, and further demonstrate its 
potential clinical utility as a target. 
6.2.2 Pharmacological approaches to study ABIN-1 and caveolin-1 in IL-17R signaling. 
Another compelling area for future investigation at the molecular level is the study of IL-
17-dependent ABIN-1 degradation using specific proteasome inhibitors.  In my studies, I used 
MG132, a non-specific inhibitor of proteasomal degradation, which partially inhibited ABIN-1 
degradation. Perhaps using a more specific inhibitor could be more effective blocking ABIN-1 
degradation. Several new inhibitors of the proteasome are in clinical trials as therapy for 
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neoplasia (235), and these could be tested for their effectiveness in inhibiting IL-17R signaling. 
This in vitro study could lead to the identification of effective drugs to block degradation of 
ABIN-1. The inhibitor IκBα is also degraded via the proteasome; thus, blocking IκBα and ABIN-
1 proteasomal degradation could enhance inhibition of IL-17R signaling. These experiments, 
using a pharmacological approach in vitro, could set the groundwork to test these specific 
proteasome inhibitors for IL-17-mediated autoimmune diseases.     
To study the role of oligomerization of proteins to caveolin-1 in IL-17R signaling, I 
propose to use the commercially available peptide that specifically inhibits protein binding to 
caveolin-1, known as the WL 47-dimer  (294). WL 47 is a small, high-affinity, selective 
disrupter of caveolin-1 oligomerization. It was identified in a screen using a phage-displayed 
library for selection of novel binding peptides targeting residues from the caveolin-1 
oligomerization domain. From this screen, WL 47 had the highest affinity for caveolin-1. Thus, 
in principle, this peptide works by binding to the site of the caveolin-1 oligomerization domain, 
displacing other proteins. This peptide could be used in IL-17-responding cells to determine if it 
interrupts IL-17R signaling. I speculate that disrupting the IL-17RA and caveolin-1 interaction 
may decrease IL-17-dependent production of IL-6. Furthermore, if this peptide safely inhibits IL-
17R signaling, it could prove to be a promising new molecule to investigate IL-17R signaling.  
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6.3 CONCLUDING REMARKS 
This thesis contributes to our understanding of the mechanisms of activation and inhibition of IL-
17R signaling. I demonstrated that ABIN-1, an ubiquitin binding protein, inhibits IL-17R 
signaling in a ubiquitin-binding-dependent manner (chapter 4). Interestingly, IL-17R signaling 
triggered the degradation of ABIN-1, which I hypothesize is a necessary step to allow signaling 
to proceed.  I also demonstrate that caveolin-1, a scaffolding protein best known for binding 
most G-protein-coupled receptors, binds to the IL-17R and positively activates signal 
transduction. I showed evidence supporting a hypothesis that caveolin-1 functions both as an IL-
17R chaperone that facilitates the surface localization of the receptor and as a signaling adaptor 
protein that functions downstream of IL-17R, albeit by an unknown mechanism. Future work 
validating the function of ABIN-1 and caveolin-1 in the non-hematopoietic compartment in vivo 
is still needed. These findings add a baseline inhibitor, ABIN-1, and an activator, caveolin-1, to 
the set of molecules that could be targets for therapies to control IL-17-mediated inflammation.  
 142 
BIBLIOGRAPHY  
1.  Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of 
inflammatory diseases. Cell Signal. 2013 Dec;25(12):2335–2347.  
2.  McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. 
Trends Immunol. 2006 Jan;27(1):17–23.  
3.  Somma D, Mastrovito P, Grieco M, Lavorgna A, Pignalosa A, Formisano L, et al. 
CIKS/DDX3X interaction controls the stability of the Zc3h12a mRNA induced by IL-17. 
J Immunol. 2015 Apr 1;194(7):3286–3294.  
4.  Hartupee J, Liu C, Novotny M, Li X, Hamilton T. IL-17 enhances chemokine gene 
expression through mRNA stabilization. J Immunol. 2007 Sep 15;179(6):4135–4141.  
5.  Henness S, Johnson CK, Ge Q, Armour CL, Hughes JM, Ammit AJ. IL-17A augments 
TNF-alpha-induced IL-6 expression in airway smooth muscle by enhancing mRNA 
stability. J Allergy Clin Immunol. 2004 Oct;114(4):958–964.  
6.  Sun D, Novotny M, Bulek K, Liu C, Li X, Hamilton T. Treatment with IL-17 prolongs 
the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-
regulatory factor SF2 (ASF). Nat Immunol. 2011 Aug 7;12(9):853–860.  
7.  Asahina R, Kamishina H, Kamishina H, Maeda S. Gene transcription of pro-
inflammatory cytokines and chemokines induced by IL-17A in canine keratinocytes. Vet 
Dermatol. 2015 Dec;26(6):426–31, e100.  
 143 
8.  Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang S-K. IL-17 cytokine family. J 
Allergy Clin Immunol. 2004 Dec;114(6):1265–73; quiz 1274.  
9.  Liu S, Song X, Chrunyk BA, Shanker S, Hoth LR, Marr ES, et al. Crystal structures of 
interleukin 17A and its complex with IL-17 receptor A. Nat Commun. 2013;4:1888.  
10.  Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009 
Aug;9(8):556–567.  
11.  Amatya N, Garg AV, Gaffen SL. IL-17 Signaling: The Yin and the Yang. Trends 
Immunol. 2017 May;38(5):310–322.  
12.  Novatchkova M, Leibbrandt A, Werzowa J, Neubüser A, Eisenhaber F. The STIR-domain 
superfamily in signal transduction, development and immunity. Trends Biochem Sci. 
2003 May;28(5):226–229.  
13.  Kramer JM, Hanel W, Shen F, Isik N, Malone JP, Maitra A, et al. Cutting edge: 
identification of a pre-ligand assembly domain (PLAD) and ligand binding site in the IL-
17 receptor. The Journal of Immunology Author Choice. 2007;179:6379–6383.  
14.  Onishi RM, Park SJ, Hanel W, Ho AW, Maitra A, Gaffen SL. SEF/IL-17R (SEFIR) is not 
enough: an extended SEFIR domain is required for il-17RA-mediated signal transduction. 
J Biol Chem. 2010 Oct 22;285(43):32751–32759.  
15.  Ho AW, Shen F, Conti HR, Patel N, Childs EE, Peterson AC, et al. IL-17RC is required 
for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic 
tail. J Immunol. 2010 Jul 15;185(2):1063–1070.  
16.  Maitra A, Shen F, Hanel W, Mossman K, Tocker J, Swart D, et al. Distinct functional 
motifs within the IL-17 receptor regulate signal transduction and target gene expression. 
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7506–7511.  
 144 
17.  Shen F, Li N, Gade P, Kalvakolanu DV, Weibley T, Doble B, et al. IL-17 receptor 
signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain. 
Sci Signal. 2009 Feb 24;2(59):ra8.  
18.  Zhu S, Pan W, Shi P, Gao H, Zhao F, Song X, et al. Modulation of experimental 
autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 
receptor signaling. J Exp Med. 2010 Nov 22;207(12):2647–2662.  
19.  Garg AV, Ahmed M, Vallejo AN, Ma A, Gaffen SL. The deubiquitinase A20 mediates 
feedback inhibition of interleukin-17 receptor signaling. Sci Signal. 2013 Jun 
4;6(278):ra44.  
20.  Oh S, Aitken M, Simons DM, Basehoar A, Garcia V, Kropf E, et al. Requirement for 
diverse TCR specificities determines regulatory T cell activity in a mouse model of 
autoimmune arthritis. J Immunol. 2012 May 1;188(9):4171–4180.  
21.  Adair P, Kim YC, Pratt KP, Scott DW. Avidity of human T cell receptor engineered 
CD4(+) T cells drives T-helper differentiation fate. Cell Immunol. 2016 Jan;299:30–41.  
22.  Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine 
secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173.  
23.  Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. 
Curr Opin Immunol. 2007 Dec;19(6):652–657.  
24.  Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-
23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp 
Med. 2005 Jan 17;201(2):233–240.  
 145 
25.  Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Litvinov IV, Fredholm S, Petersen DL, et 
al. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 
expression in cutaneous T-cell lymphoma. Blood. 2016 Mar 10;127(10):1287–1296.  
26.  Benveniste EN, Liu Y, McFarland BC, Qin H. Involvement of the janus kinase/signal 
transducer and activator of transcription signaling pathway in multiple sclerosis and the 
animal model of experimental autoimmune encephalomyelitis. J Interferon Cytokine Res. 
2014 Aug;34(8):577–588.  
27.  Raychaudhuri SK, Raychaudhuri SP. Janus kinase/signal transducer and activator of 
transcription pathways in spondyloarthritis. Curr Opin Rheumatol. 2017 Jul;29(4):311–
316.  
28.  Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, et al. Th17 cells and IL-
17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp 
Med. 2009 Feb 16;206(2):299–311.  
29.  Geha M, Tsokos MG, Bosse RE, Sannikova T, Iwakura Y, Dalle Lucca JJ, et al. IL-17A 
Produced by Innate Lymphoid Cells Is Essential for Intestinal Ischemia-Reperfusion 
Injury. J Immunol. 2017 Oct 15;199(8):2921–2929.  
30.  Sutton CE, Mielke LA, Mills KHG. IL-17-producing γδ T cells and innate lymphoid cells. 
Eur J Immunol. 2012 Sep;42(9):2221–2231.  
31.  Rubino SJ, Geddes K, Girardin SE. Innate IL-17 and IL-22 responses to enteric bacterial 
pathogens. Trends Immunol. 2012 Mar;33(3):112–118.  
32.  Hamada S, Umemura M, Shiono T, Tanaka K, Yahagi A, Begum MD, et al. IL-17A 
produced by gammadelta T cells plays a critical role in innate immunity against listeria 
monocytogenes infection in the liver. J Immunol. 2008 Sep 1;181(5):3456–3463.  
 146 
33.  Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat 
Rev Immunol. 2010 Jul;10(7):479–489.  
34.  Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to 
therapeutic testing. Nat Rev Immunol. 2014 Sep;14(9):585–600.  
35.  Verma AH, Richardson JP, Zhou C, Coleman BM, Moyes DL, Ho J, et al. Oral epithelial 
cells orchestrate innate type 17 responses to Candida albicans through the virulence factor 
candidalysin. Sci Immunol. 2017 Nov 3;2(17).  
36.  Eberl G. Development and evolution of RORγt+ cells in a microbe’s world. Immunol 
Rev. 2012 Jan;245(1):177–188.  
37.  Chang Y, Kang S-Y, Kim J, Kang H-R, Kim HY. Functional Defects in Type 3 Innate 
Lymphoid Cells and Classical Monocytes in a Patient with Hyper-IgE Syndrome. 
Immune Netw. 2017 Oct 25;17(5):352–364.  
38.  Conti HR, Peterson AC, Brane L, Huppler AR, Hernández-Santos N, Whibley N, et al. 
Oral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans 
infections. J Exp Med. 2014 Sep 22;211(10):2075–2084.  
39.  Sherlock JP, Joyce-Shaikh B, Turner SP, Chao C-C, Sathe M, Grein J, et al. IL-23 
induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T 
cells. Nat Med. 2012 Jul 1;18(7):1069–1076.  
40.  Cho M-L, Kang J-W, Moon Y-M, Nam H-J, Jhun J-Y, Heo S-B, et al. STAT3 and NF-
kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous 
arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol. 2006 May 
1;176(9):5652–5661.  
 147 
41.  Works MG, Yin F, Yin CC, Yiu Y, Shew K, Tran T-T, et al. Inhibition of TYK2 and 
JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and 
the IL-23/IL-17 axis. J Immunol. 2014 Oct 1;193(7):3278–3287.  
42.  Yoshimura T, Takeda A, Hamano S, Miyazaki Y, Kinjyo I, Ishibashi T, et al. Two-sided 
roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression 
of proinflammatory cytokine production including IL-23-induced IL-17 on activated 
CD4+ T cells partially through STAT3-dependent mechanism. J Immunol. 2006 Oct 
15;177(8):5377–5385.  
43.  Olivito B, Simonini G, Ciullini S, Moriondo M, Betti L, Gambineri E, et al. Th17 
transcription factor RORC2 is inversely correlated with FOXP3 expression in the joints of 
children with juvenile idiopathic arthritis. J Rheumatol. 2009 Sep;36(9):2017–2024.  
44.  Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu T-T, et al. Regulatory T-cell 
suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature. 
2009 Mar 19;458(7236):351–356.  
45.  Li P, Spolski R, Liao W, Wang L, Murphy TL, Murphy KM, et al. BATF-JUN is critical 
for IRF4-mediated transcription in T cells. Nature. 2012 Oct 25;490(7421):543–546.  
46.  Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 
2009;27:485–517.  
47.  Gomez-Rodriguez J, Wohlfert EA, Handon R, Meylan F, Wu JZ, Anderson SM, et al. Itk-
mediated integration of T cell receptor and cytokine signaling regulates the balance 
between Th17 and regulatory T cells. J Exp Med. 2014 Mar 10;211(3):529–543.  
 148 
48.  Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, et al. The receptor 
SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor 
pathway and mTOR kinase activation. Immunity. 2010 Jan 29;32(1):54–66.  
49.  Abdollahi E, Tavasolian F, Momtazi-Borojeni AA, Samadi M, Rafatpanah H. Protective 
role of R381Q (rs11209026) polymorphism in IL-23R gene in immune-mediated 
diseases: A comprehensive review. J Immunotoxicol. 2016 May;13(3):286–300.  
50.  Liu M, Hu X, Wang Y, Chen X, Wu J. Association of IL-23 and its receptor gene single-
nucleotide polymorphisms with multiple sclerosis in Chinese southern population. Int J 
Neurosci. 2014 Dec;124(12):904–907.  
51.  Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, et al. 
Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest 
Dermatol. 2008 Jul;128(7):1653–1661.  
52.  Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor receptor-
associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med. 2000 Apr 
3;191(7):1233–1240.  
53.  Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, et al. Cutting edge: 
interleukin 17 signals through a heteromeric receptor complex. J Immunol. 2006 Jul 
1;177(1):36–39.  
54.  Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K, et al. Identification of 
the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol. 2007 
Oct 15;179(8):5462–5473.  
 149 
55.  Taylor PR, Roy S, Leal SM, Sun Y, Howell SJ, Cobb BA, et al. Activation of neutrophils 
by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, 
IL-23, RORγt and dectin-2. Nat Immunol. 2014 Feb;15(2):143–151.  
56.  Bär E, Whitney PG, Moor K, Reis e Sousa C, LeibundGut-Landmann S. IL-17 regulates 
systemic fungal immunity by controlling the functional competence of NK cells. 
Immunity. 2014 Jan 16;40(1):117–127.  
57.  Malynn BA, Ma A. Ubiquitin makes its mark on immune regulation. Immunity. 2010 Dec 
14;33(6):843–852.  
58.  Rong Z, Cheng L, Ren Y, Li Z, Li Y, Li X, et al. Interleukin-17F signaling requires 
ubiquitination of interleukin-17 receptor via TRAF6. Cell Signal. 2007 Jul;19(7):1514–
1520.  
59.  Qian Y, Liu C, Hartupee J, Altuntas CZ, Gulen MF, Jane-Wit D, et al. The adaptor Act1 
is required for interleukin 17-dependent signaling associated with autoimmune and 
inflammatory disease. Nat Immunol. 2007 Mar;8(3):247–256.  
60.  Liu C, Qian W, Qian Y, Giltiay NV, Lu Y, Swaidani S, et al. Act1, a U-box E3 ubiquitin 
ligase for IL-17 signaling. Sci Signal. 2009 Oct 13;2(92):ra63.  
61.  Huang F, Kao C-Y, Wachi S, Thai P, Ryu J, Wu R. Requirement for both JAK-mediated 
PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in 
enhancing cytokine expression in human airway epithelial cells. J Immunol. 2007 Nov 
15;179(10):6504–6513.  
62.  Besse A, Lamothe B, Campos AD, Webster WK, Maddineni U, Lin S-C, et al. TAK1-
dependent signaling requires functional interaction with TAB2/TAB3. J Biol Chem. 2007 
Feb 9;282(6):3918–3928.  
 150 
63.  Shen F, Hu Z, Goswami J, Gaffen SL. Identification of common transcriptional regulatory 
elements in interleukin-17 target genes. J Biol Chem. 2006 Aug 25;281(34):24138–
24148.  
64.  Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008 Feb 
8;132(3):344–362.  
65.  Xiao Y, Jin J, Chang M, Nakaya M, Hu H, Zou Q, et al. TPL2 mediates autoimmune 
inflammation through activation of the TAK1 axis of IL-17 signaling. J Exp Med. 2014 
Jul 28;211(8):1689–1702.  
66.  Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirkwood KL, et al. 
Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is 
mediated by CCAAT/enhancer-binding protein family members. J Biol Chem. 2004 Jan 
23;279(4):2559–2567.  
67.  Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. 
Biochem J. 2002 Aug 1;365(Pt 3):561–575.  
68.  Karlsen JR, Borregaard N, Cowland JB. Induction of neutrophil gelatinase-associated 
lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-
alpha is controlled by IkappaB-zeta but neither by C/EBP-beta nor C/EBP-delta. J Biol 
Chem. 2010 May 7;285(19):14088–14100.  
69.  Lee JS, Tato CM, Joyce-Shaikh B, Gulen MF, Cayatte C, Chen Y, et al. Interleukin-23-
Independent IL-17 Production Regulates Intestinal Epithelial Permeability. Immunity. 
2015 Oct 20;43(4):727–738.  
 151 
70.  Huppert J, Closhen D, Croxford A, White R, Kulig P, Pietrowski E, et al. Cellular 
mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J. 2010 
Apr;24(4):1023–1034.  
71.  Conti HR, Bruno VM, Childs EE, Daugherty S, Hunter JP, Mengesha BG, et al. IL-17 
Receptor Signaling in Oral Epithelial Cells Is Critical for Protection against 
Oropharyngeal Candidiasis. Cell Host Microbe. 2016 Nov 9;20(5):606–617.  
72.  Ramani K, Garg AV, Jawale CV, Conti HR, Whibley N, Jackson EK, et al. The 
Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in 
the Kidney. PLoS Pathog. 2016 Nov 4;12(11):e1005952.  
73.  Bulek K, Liu C, Swaidani S, Wang L, Page RC, Gulen MF, et al. The inducible kinase 
IKKi is required for IL-17-dependent signaling associated with neutrophilia and 
pulmonary inflammation. Nat Immunol. 2011 Aug 7;12(9):844–852.  
74.  Herjan T, Yao P, Qian W, Li X, Liu C, Bulek K, et al. HuR is required for IL-17-induced 
Act1-mediated CXCL1 and CXCL5 mRNA stabilization. J Immunol. 2013 Jul 
15;191(2):640–649.  
75.  Shi P, Zhu S, Lin Y, Liu Y, Liu Y, Chen Z, et al. Persistent stimulation with interleukin-
17 desensitizes cells through SCFβ-TrCP-mediated degradation of Act1. Sci Signal. 2011 
Nov 1;4(197):ra73.  
76.  Zhong B, Liu X, Wang X, Liu X, Li H, Darnay BG, et al. Ubiquitin-specific protease 25 
regulates TLR4-dependent innate immune responses through deubiquitination of the 
adaptor protein TRAF3. Sci Signal. 2013 May 14;6(275):ra35.  
 152 
77.  Wu N-L, Huang D-Y, Tsou H-N, Lin Y-C, Lin W-W. Syk mediates IL-17-induced 
CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6. J 
Invest Dermatol. 2015 Feb;135(2):490–498.  
78.  Zepp JA, Liu C, Qian W, Wu L, Gulen MF, Kang Z, et al. Cutting edge: TNF receptor-
associated factor 4 restricts IL-17-mediated pathology and signaling processes. J 
Immunol. 2012 Jul 1;189(1):33–37.  
79.  Qu F, Gao H, Zhu S, Shi P, Zhang Y, Liu Y, et al. TRAF6-dependent Act1 
phosphorylation by the IκB kinase-related kinases suppresses interleukin-17-induced NF-
κB activation. Mol Cell Biol. 2012 Oct;32(19):3925–3937.  
80.  Jeltsch KM, Hu D, Brenner S, Zöller J, Heinz GA, Nagel D, et al. Cleavage of roquin and 
regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to 
promote T(H)17 differentiation. Nat Immunol. 2014 Nov;15(11):1079–1089.  
81.  Garg AV, Amatya N, Chen K, Cruz JA, Grover P, Whibley N, et al. MCPIP1 
Endoribonuclease Activity Negatively Regulates Interleukin-17-Mediated Signaling and 
Inflammation. Immunity. 2015 Sep 15;43(3):475–487.  
82.  Zhu S, Pan W, Song X, Liu Y, Shao X, Tang Y, et al. The microRNA miR-23b 
suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and 
IKK-α. Nat Med. 2012 Jul;18(7):1077–1086.  
83.  Kramer JM, Yi L, Shen F, Maitra A, Jiao X, Jin T, et al. Evidence for ligand-independent 
multimerization of the IL-17 receptor. J Immunol. 2006 Jan 15;176(2):711–715.  
84.  Schmidt MHH, Furnari FB, Cavenee WK, Bögler O. Epidermal growth factor receptor 
signaling intensity determines intracellular protein interactions, ubiquitination, and 
internalization. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6505–6510.  
 153 
85.  Zhong B, Liu X, Wang X, Chang SH, Liu X, Wang A, et al. Negative regulation of IL-17-
mediated signaling and inflammation by the ubiquitin-specific protease USP25. Nat 
Immunol. 2012 Nov;13(11):1110–1117.  
86.  Wang X, Deckert M, Xuan NT, Nishanth G, Just S, Waisman A, et al. Astrocytic A20 
ameliorates experimental autoimmune encephalomyelitis by inhibiting NF-κB- and 
STAT1-dependent chemokine production in astrocytes. Acta Neuropathol. 2013 
Nov;126(5):711–724.  
87.  Zong S, Li K, Zeng G, Fang Y, Zhao J. The Effects of Interleukin-17 (IL-17)-Related 
Inflammatory Cytokines and A20 Regulatory Proteins on Astrocytes in Spinal Cord 
Cultured In Vitro. Cell Physiol Biochem. 2016 Mar 4;38(3):1100–1110.  
88.  Liu X, He F, Pang R, Zhao D, Qiu W, Shan K, et al. Interleukin-17 (IL-17)-induced 
microRNA 873 (miR-873) contributes to the pathogenesis of experimental autoimmune 
encephalomyelitis by targeting A20 ubiquitin-editing enzyme. J Biol Chem. 2014 Oct 
17;289(42):28971–28986.  
89.  Peng X, Shi X, Zhao J, He J, Li K, Cen Z, et al. The Effects of miR-136-5p-Mediated 
Regulation of A20 in Astrocytes from Cultured Spinal Cord Cultured Cells In Vitro. Cell 
Physiol Biochem. 2017 Mar 28;41(4):1596–1604.  
90.  Wang J, Ouyang Y, Guner Y, Ford HR, Grishin AV. Ubiquitin-editing enzyme A20 
promotes tolerance to lipopolysaccharide in enterocytes. J Immunol. 2009 Jul 
15;183(2):1384–1392.  
91.  Verstrepen L, Carpentier I, Verhelst K, Beyaert R. ABINs: A20 binding inhibitors of NF-
kappa B and apoptosis signaling. Biochem Pharmacol. 2009 Jul 15;78(2):105–114.  
 154 
92.  Mauro C, Pacifico F, Lavorgna A, Mellone S, Iannetti A, Acquaviva R, et al. ABIN-1 
binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J Biol 
Chem. 2006 Jul 7;281(27):18482–18488.  
93.  Heyninck K, De Valck D, Berghe WV, Van Criekinge W, Contreras R, Fiers W, et al. 
The Zinc Finger Protein A20 Inhibits TNF-induced NF-κB–dependent Gene Expression 
by Interfering with an RIP- or TRAF2-mediated Transactivation Signal and Directly 
Binds to a Novel NF-κB–inhibiting Protein ABIN. J Cell Biol. 1999;145:1471–1482.  
94.  Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D, Courtois G. The 
tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. 
Nature. 2003 Aug 14;424(6950):801–805.  
95.  Hayakawa M. Role of K63-linked polyubiquitination in NF-κB signalling: which ligase 
catalyzes and what molecule is targeted? J Biochem. 2012 Feb;151(2):115–118.  
96.  Brummelkamp TR, Nijman SMB, Dirac AMG, Bernards R. Loss of the cylindromatosis 
tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature. 2003 Aug 
14;424(6950):797–801.  
97.  Draber P, Kupka S, Reichert M, Draberova H, Lafont E, de Miguel D, et al. LUBAC-
Recruited CYLD and A20 Regulate Gene Activation and Cell Death by Exerting 
Opposing Effects on Linear Ubiquitin in Signaling Complexes. Cell Rep. 2015 Dec 
15;13(10):2258–2272.  
98.  Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K, et al. Involvement of 
linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol. 2009 
Feb;11(2):123–132.  
 155 
99.  Keusekotten K, Elliott PR, Glockner L, Fiil BK, Damgaard RB, Kulathu Y, et al. 
OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked 
polyubiquitin. Cell. 2013 Jun 6;153(6):1312–1326.  
100.  Damgaard RB, Walker JA, Marco-Casanova P, Morgan NV, Titheradge HL, Elliott PR, et 
al. The deubiquitinase OTULIN is an essential negative regulator of inflammation and 
autoimmunity. Cell. 2016 Aug 25;166(5):1215–1230.e20.  
101.  Huppler AR, Conti HR, Hernández-Santos N, Darville T, Biswas PS, Gaffen SL. Role of 
neutrophils in IL-17-dependent immunity to mucosal candidiasis. J Immunol. 2014 Feb 
15;192(4):1745–1752.  
102.  Brown L, Wolf JM, Prados-Rosales R, Casadevall A. Through the wall: extracellular 
vesicles in Gram-positive bacteria, mycobacteria and fungi. Nat Rev Microbiol. 2015 
Oct;13(10):620–630.  
103.  Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, et al. Th1-Th17 cells 
mediate protective adaptive immunity against Staphylococcus aureus and Candida 
albicans infection in mice. PLoS Pathog. 2009 Dec 24;5(12):e1000703.  
104.  Puel A, Cypowyj S, Maródi L, Abel L, Picard C, Casanova J-L. Inborn errors of human 
IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin 
Immunol. 2012 Dec;12(6):616–622.  
105.  Ling Y, Cypowyj S, Aytekin C, Galicchio M, Camcioglu Y, Nepesov S, et al. Inherited 
IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J Exp Med. 
2015 May 4;212(5):619–631.  
 156 
106.  Glocker E-O, Hennigs A, Nabavi M, Schäffer AA, Woellner C, Salzer U, et al. A 
homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl 
J Med. 2009 Oct 29;361(18):1727–1735.  
107.  Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired 
T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. 
Nature. 2008 Apr 10;452(7188):773–776.  
108.  Kisand K, Bøe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, et al. Chronic 
mucocutaneous candidiasis in APECED or thymoma patients correlates with 
autoimmunity to Th17-associated cytokines. J Exp Med. 2010 Feb 15;207(2):299–308.  
109.  Ripamonti C, Bishop LR, Kovacs JA. Pulmonary Interleukin-17-Positive Lymphocytes 
Increase during Pneumocystis murina Infection but Are Not Required for Clearance of 
Pneumocystis. Infect Immun. 2017 Jul;85(7).  
110.  Myles IA, Fontecilla NM, Valdez PA, Vithayathil PJ, Naik S, Belkaid Y, et al. Signaling 
via the IL-20 receptor inhibits cutaneous production of IL-1β and IL-17A to promote 
infection with methicillin-resistant Staphylococcus aureus. Nat Immunol. 2013 
Aug;14(8):804–811.  
111.  Kleinschek MA, Muller U, Brodie SJ, Stenzel W, Kohler G, Blumenschein WM, et al. IL-
23 enhances the inflammatory cell response in Cryptococcus neoformans infection and 
induces a cytokine pattern distinct from IL-12. J Immunol. 2006 Jan 15;176(2):1098–
1106.  
112.  Zheng M, Horne W, McAleer JP, Pociask D, Eddens T, Good M, et al. Therapeutic Role 
of Interleukin 22 in Experimental Intra-abdominal Klebsiella pneumoniae Infection in 
Mice. Infect Immun. 2016 Jan 4;84(3):782–789.  
 157 
113.  Chan YR, Liu JS, Pociask DA, Zheng M, Mietzner TA, Berger T, et al. Lipocalin 2 is 
required for pulmonary host defense against Klebsiella infection. J Immunol. 2009 Apr 
15;182(8):4947–4956.  
114.  Chen K, Eddens T, Trevejo-Nunez G, Way EE, Elsegeiny W, Ricks DM, et al. IL-17 
Receptor Signaling in the Lung Epithelium Is Required for Mucosal Chemokine 
Gradients and Pulmonary Host Defense against K. pneumoniae. Cell Host Microbe. 2016 
Nov 9;20(5):596–605.  
115.  Bachman MA, Lenio S, Schmidt L, Oyler JE, Weiser JN. Interaction of lipocalin 2, 
transferrin, and siderophores determines the replicative niche of Klebsiella pneumoniae 
during pneumonia. MBio. 2012 Nov 20;3(6).  
116.  Bachman MA, Miller VL, Weiser JN. Mucosal lipocalin 2 has pro-inflammatory and 
iron-sequestering effects in response to bacterial enterobactin. PLoS Pathog. 2009 Oct 
16;5(10):e1000622.  
117.  Domingo-Gonzalez R, Das S, Griffiths KL, Ahmed M, Bambouskova M, Gopal R, et al. 
Interleukin-17 limits hypoxia-inducible factor 1α and development of hypoxic 
granulomas during tuberculosis. JCI Insight. 2017 Oct 5;  
118.  Gopal R, Monin L, Torres D, Slight S, Mehra S, McKenna KC, et al. S100A8/A9 proteins 
mediate neutrophilic inflammation and lung pathology during tuberculosis. Am J Respir 
Crit Care Med. 2013 Nov 1;188(9):1137–1146.  
119.  Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, Slight SR, et al. Influenza A 
inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol. 
2011 Feb 1;186(3):1666–1674.  
 158 
120.  Yao Z, Timour M, Painter S, Fanslow W, Spriggs M. Complete nucleotide sequence of 
the mouse CTLA8 gene. Gene. 1996 Feb 12;168(2):223–225.  
121.  Ha H-L, Wang H, Pisitkun P, Kim J-C, Tassi I, Tang W, et al. IL-17 drives psoriatic 
inflammation via distinct, target cell-specific mechanisms. Proc Natl Acad Sci U S A. 
2014 Aug 19;111(33):E3422–31.  
122.  Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 
and interferon-gamma synergize in the enhancement of proinflammatory cytokine 
production by human keratinocytes. J Invest Dermatol. 1998 Oct;111(4):645–649.  
123.  Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, et 
al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key 
inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011 Mar;131(3):677–
687.  
124.  Liang SC, Tan X-Y, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. 
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance 
expression of antimicrobial peptides. J Exp Med. 2006 Oct 2;203(10):2271–2279.  
125.  Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous 
antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002 Oct 
10;347(15):1151–1160.  
126.  Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, et al. Th17 cytokines 
stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for 
psoriasis pathogenesis. J Invest Dermatol. 2009 Sep;129(9):2175–2183.  
 159 
127.  Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. 
Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014 Jul 
24;371(4):326–338.  
128.  Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan PH, Thappa DM, Negi 
VS. TNFAIP3 and TNIP1 polymorphisms confer psoriasis risk in South Indian Tamils. Br 
J Biomed Sci. 2015;72(4):168–173.  
129.  Li XL, Yu H, Wu GS. Investigating the genetic association of HCP5, SPATA2, TNIP1, 
TNFAIP3 and COG6 with psoriasis in Chinese population. Int J Immunogenet. 2014 
Dec;41(6):503–507.  
130.  Bowes J, Orozco G, Flynn E, Ho P, Brier R, Marzo-Ortega H, et al. Confirmation of 
TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis. 2011 
Sep;70(9):1641–1644.  
131.  Yin X, Cheng H, Wang W, Wang W, Fu H, Liu L, et al. TNIP1/ANXA6 and CSMD1 
variants interacting with cigarette smoking, alcohol intake affect risk of psoriasis. J 
Dermatol Sci. 2013 May;70(2):94–98.  
132.  Finzi E, Harkins R, Horn T. TGF-alpha is widely expressed in differentiated as well as 
hyperproliferative skin epithelium. J Invest Dermatol. 1991 Mar;96(3):328–332.  
133.  Turbitt ML, Akhurst RJ, White SI, MacKie RM. Localization of elevated transforming 
growth factor-alpha in psoriatic epidermis. J Invest Dermatol. 1990 Aug;95(2):229–232.  
134.  Chen Y, Yan H, Song Z, Chen F, Wang H, Niu J, et al. Downregulation of TNIP1 
Expression Leads to Increased Proliferation of Human Keratinocytes and Severer 
Psoriasis-Like Conditions in an Imiquimod-Induced Mouse Model of Dermatitis. PLoS 
ONE. 2015 Jun 5;10(6):e0127957.  
 160 
135.  Campbell L, Gumbleton M. Aberrant caveolin-1 expression in psoriasis: a signalling 
hypothesis. IUBMB Life. 2000 Dec;50(6):361–364.  
136.  Campbell L, Laidler P, Watson REB, Kirby B, Griffiths CEM, Gumbleton M. 
Downregulation and altered spatial pattern of caveolin-1 in chronic plaque psoriasis. Br J 
Dermatol. 2002 Oct;147(4):701–709.  
137.  Ma WY, Zhuang L, Cai DX, Zhong H, Zhao C, Sun Q. Inverse correlation between 
caveolin-1 expression and clinical severity in psoriasis vulgaris. J Int Med Res. 
2012;40:1745–51.  
138.  Zhang F, Li H, Zhou Y, Gu Y, Wang L. Caveolin-1 expression in different types of 
psoriatic lesions: analysis of 66 cases. Indian J Dermatol. 2014 May;59(3):225–229.  
139.  Yamaguchi Y, Watanabe Y, Watanabe T, Komitsu N, Aihara M. Decreased Expression of 
Caveolin-1 Contributes to the Pathogenesis of Psoriasiform Dermatitis in Mice. J Invest 
Dermatol. 2015 Nov;135(11):2764–2774.  
140.  Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. Interleukin-
17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple 
sclerosis. Mult Scler. 1999 Apr;5(2):101–104.  
141.  Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray 
analysis of multiple sclerosis lesions yields new targets validated in autoimmune 
encephalomyelitis. Nat Med. 2002 May;8(5):500–508.  
142.  Kang Z, Wang C, Zepp J, Wu L, Sun K, Zhao J, et al. Act1 mediates IL-17-induced EAE 
pathogenesis selectively in NG2+ glial cells. Nat Neurosci. 2013 Oct;16(10):1401–1408.  
 161 
143.  McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, et 
al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 
17-producing effector T helper cells in vivo. Nat Immunol. 2009 Mar;10(3):314–324.  
144.  El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F, et al. The encephalitogenicity 
of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-
CSF. Nat Immunol. 2011 Jun;12(6):568–575.  
145.  Codarri L, Gyülvészi G, Tosevski V, Hesske L, Fontana A, Magnenat L, et al. RORγt 
drives production of the cytokine GM-CSF in helper T cells, which is essential for the 
effector phase of autoimmune neuroinflammation. Nat Immunol. 2011 Jun;12(6):560–
567.  
146.  Haines CJ, Chen Y, Blumenschein WM, Jain R, Chang C, Joyce-Shaikh B, et al. 
Autoimmune memory T helper 17 cell function and expansion are dependent on 
interleukin-23. Cell Rep. 2013 May 30;3(5):1378–1388.  
147.  Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, et al. Fate mapping of IL-
17-producing T cells in inflammatory responses. Nat Immunol. 2011 Mar;12(3):255–263.  
148.  Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis 
Consortium (TASC), Burton PR, Clayton DG, Cardon LR, Craddock N, et al. Association 
scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. 
Nat Genet. 2007 Nov;39(11):1329–1337.  
149.  Samoilova EB, Horton JL, Hilliard B, Liu TS, Chen Y. IL-6-deficient mice are resistant 
to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and 
differentiation of autoreactive T cells. J Immunol. 1998 Dec 15;161(12):6480–6486.  
 162 
150.  Sutton C, Brereton C, Keogh B, Mills KHG, Lavelle EC. A crucial role for interleukin 
(IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune 
encephalomyelitis. J Exp Med. 2006 Jul 10;203(7):1685–1691.  
151.  Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, et al. Preferential 
recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann 
Neurol. 2009 Sep;66(3):390–402.  
152.  Huang G, Wang Y, Vogel P, Chi H. Control of IL-17 receptor signaling and tissue 
inflammation by the p38α-MKP-1 signaling axis in a mouse model of multiple sclerosis. 
Sci Signal. 2015 Mar 3;8(366):ra24.  
153.  Simpson-Abelson MR, Hernandez-Mir G, Childs EE, Cruz JA, Poholek AC, 
Chattopadhyay A, et al. CCAAT/Enhancer-binding protein β promotes pathogenesis of 
EAE. Cytokine. 2017 Apr;92:24–32.  
154.  Tahir H, Deodhar A, Genovese M, Takeuchi T, Aelion J, Van den Bosch F, et al. 
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, 
Double-Blind Placebo-Controlled Phase 3 Study. Rheumatol Ther. 2017 Dec;4(2):475–
488.  
155.  Blanco FJ, Möricke R, Dokoupilova E, Codding C, Neal J, Andersson M, et al. 
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, 
Active Comparator- and Placebo-Controlled Study. Arthritis Rheumatol. 2017 
Jun;69(6):1144–1153.  
156.  Li G, Zhang Y, Qian Y, Zhang H, Guo S, Sunagawa M, et al. Interleukin-17A promotes 
rheumatoid arthritis synoviocytes migration and invasion under hypoxia by increasing 
 163 
MMP2 and MMP9 expression through NF-κB/HIF-1α pathway. Mol Immunol. 2013 
Mar;53(3):227–236.  
157.  Li G, Zhang Y, Liu D, Qian Y, Zhang H, Guo S, et al. Celastrol inhibits interleukin-17A-
stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through 
suppression of NF-κB-mediated matrix metalloproteinase-9 expression. Int 
Immunopharmacol. 2012 Dec;14(4):422–431.  
158.  Van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid 
arthritis. Nat Rev Rheumatol. 2009 Oct;5(10):549–553.  
159.  McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity. 
2008 Apr;28(4):445–453.  
160.  Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo 
CJJ, Joosten LAB, et al. Treatment with a neutralizing anti-murine interleukin-17 
antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage 
destruction, and bone erosion. Arthritis Rheum. 2004 Feb;50(2):650–659.  
161.  Lubberts E, Joosten LAB, van de Loo FAJ, Schwarzenberger P, Kolls J, van den Berg 
WB. Overexpression of IL-17 in the knee joint of collagen type II immunized mice 
promotes collagen arthritis and aggravates joint destruction. Inflamm Res. 2002 
Feb;51(2):102–104.  
162.  Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-
induced arthritis in IL-17-deficient mice. J Immunol. 2003 Dec 1;171(11):6173–6177.  
163.  Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Köhler D, et al. 
Immunohistologic analysis of zygapophyseal joints in patients with ankylosing 
spondylitis. Arthritis Rheum. 2006 Sep;54(9):2845–2851.  
 164 
164.  Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-
interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing 
spondylitis: a randomised, double-blind, placebo-controlled trial. The Lancet. 2013 Nov 
23;382(9906):1705–1713.  
165.  Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an 
Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015 Dec 
24;373(26):2534–2548.  
166.  Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor 
polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional 
responses. Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9560–9565.  
167.  Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, et al. Increased serum IL-17 and IL-23 in 
the patient with ankylosing spondylitis. Clin Rheumatol. 2011 Feb;30(2):269–273.  
168.  Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 
cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009 Jun 
1;60(6):1647–1656.  
169.  Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, et al. Either a Th17 or a Th1 
effector response can drive autoimmunity: conditions of disease induction affect dominant 
effector category. J Exp Med. 2008 Apr 14;205(4):799–810.  
170.  Chi W, Yang P, Li B, Wu C, Jin H, Zhu X, et al. IL-23 promotes CD4+ T cells to produce 
IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol. 2007 
May;119(5):1218–1224.  
 165 
171.  Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-
wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 
2006 Dec 1;314(5804):1461–1463.  
172.  Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, Paschos E, et al. Linking 
genetic susceptibility to Crohn’s disease with Th17 cell function: IL-22 serum levels are 
increased in Crohn's disease and correlate with disease activity and IL23R genotype 
status. Inflamm Bowel Dis. 2008 Feb;14(2):204–212.  
173.  Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, et 
al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe 
Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled 
trial. Gut. 2012 Dec;61(12):1693–1700.  
174.  Callahan JA, Hammer GE, Agelides A, Duong BH, Oshima S, North J, et al. Cutting 
edge: ABIN-1 protects against psoriasis by restricting MyD88 signals in dendritic cells. J 
Immunol. 2013 Jul 15;191(2):535–539.  
175.  Ippagunta SK, Gangwar R, Finkelstein D, Vogel P, Pelletier S, Gingras S, et al. 
Keratinocytes contribute intrinsically to psoriasis upon loss of Tnip1 function. Proc Natl 
Acad Sci U S A. 2016 Oct 11;113(41):E6162–E6171.  
176.  D’Alessio A, Al-Lamki RS, Bradley JR, Pober JS. Caveolae participate in tumor necrosis 
factor receptor 1 signaling and internalization in a human endothelial cell line. Am J 
Pathol. 2005 Apr;166(4):1273–1282.  
177.  Jiao H, Zhang Y, Yan Z, Wang Z-G, Liu G, Minshall RD, et al. Caveolin-1 Tyr14 
phosphorylation induces interaction with TLR4 in endothelial cells and mediates MyD88-
 166 
dependent signaling and sepsis-induced lung inflammation. J Immunol. 2013 Dec 
15;191(12):6191–6199.  
178.  Rauert-Wunderlich H, Siegmund D, Maier E, Giner T, Bargou RC, Wajant H, et al. The 
IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of 
NFκB transcription factors. PLoS ONE. 2013 Mar 20;8(3):e59292.  
179.  Rasheed Z, Haqqi TM. Endoplasmic reticulum stress induces the expression of COX-2 
through activation of eIF2α, p38-MAPK and NF-κB in advanced glycation end products 
stimulated human chondrocytes. Biochim Biophys Acta. 2012 Dec;1823(12):2179–2189.  
180.  Napetschnig J, Wu H. Molecular basis of NF-κB signaling. Annu Rev Biophys. 2013 Mar 
11;42:443–468.  
181.  Yang J, Zeng X, Ma B. [Effect of NF-kappa B pathway on apoptosis of hepatic carcinoma 
cell line-7721 induced by TNF-alpha]. Ai Zheng. 2002 Sep;21(9):974–978.  
182.  Yi H, Bai Y, Zhu X, Lin L, Zhao L, Wu X, et al. IL-17A induces MIP-1α expression in 
primary astrocytes via Src/MAPK/PI3K/NF-kB pathways: implications for multiple 
sclerosis. J Neuroimmune Pharmacol. 2014 Dec;9(5):629–641.  
183.  Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor 
TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003 Aug 
1;301(5633):640–643.  
184.  Muroi M, Tanamoto K. TRAF6 distinctively mediates MyD88- and IRAK-1-induced 
activation of NF-kappaB. J Leukoc Biol. 2008 Mar;83(3):702–707.  
185.  Sato S, Sugiyama M, Yamamoto M, Watanabe Y, Kawai T, Takeda K, et al. Toll/IL-1 
receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF 
receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct 
 167 
transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor 
signaling. J Immunol. 2003 Oct 15;171(8):4304–4310.  
186.  Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell 
Signal. 2012 Jun;24(6):1297–1305.  
187.  Heyninck K, Kreike MM, Beyaert R. Structure-function analysis of the A20-binding 
inhibitor of NF-kappa B activation, ABIN-1. FEBS Lett. 2003 Feb 11;536(1-3):135–140.  
188.  Keating SE, Maloney GM, Moran EM, Bowie AG. IRAK-2 participates in multiple toll-
like receptor signaling pathways to NFkappaB via activation of TRAF6 ubiquitination. J 
Biol Chem. 2007 Nov 16;282(46):33435–33443.  
189.  Enesa K, Zakkar M, Chaudhury H, Luong LA, Rawlinson L, Mason JC, et al. NF-kappaB 
suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in 
pro-inflammatory signaling. J Biol Chem. 2008 Mar 14;283(11):7036–7045.  
190.  Verheugd P, Forst AH, Milke L, Herzog N, Feijs KLH, Kremmer E, et al. Regulation of 
NF-κB signalling by the mono-ADP-ribosyltransferase ARTD10. Nat Commun. 
2013;4:1683.  
191.  Prinz S, Hwang ES, Visintin R, Amon A. The regulation of Cdc20 proteolysis reveals a 
role for APC components Cdc23 and Cdc27 during S phase and early mitosis. Curr Biol. 
1998 Jun 18;8(13):750–760.  
192.  Ho AW, Garg AV, Monin L, Simpson-Abelson MR, Kinner L, Gaffen SL. The anaphase-
promoting complex protein 5 (AnapC5) associates with A20 and inhibits IL-17-mediated 
signal transduction. PLoS ONE. 2013 Jul 29;8(7):e70168.  
 168 
193.  Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD 
is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR 
family members. Nature. 2003 Aug 14;424(6950):793–796.  
194.  Schaeffer V, Akutsu M, Olma MH, Gomes LC, Kawasaki M, Dikic I. Binding of 
OTULIN to the PUB domain of HOIP controls NF-κB signaling. Mol Cell. 2014 May 
8;54(3):349–361.  
195.  Eichhorn PJA, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, et al. 
USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of 
TGF-β signaling in glioblastoma. Nat Med. 2012 Feb 19;18(3):429–435.  
196.  Wang XM, Kim HP, Nakahira K, Ryter SW, Choi AMK. The heme oxygenase-1/carbon 
monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with 
caveolin-1. J Immunol. 2009 Mar 15;182(6):3809–3818.  
197.  Takada Y, Aggarwal BB. TNF activates Syk protein tyrosine kinase leading to TNF-
induced MAPK activation, NF-kappaB activation, and apoptosis. J Immunol. 2004 Jul 
15;173(2):1066–1077.  
198.  Shi C-S, Kehrl JH. TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 
to control TLR4-induced autophagy. Sci Signal. 2010 May 25;3(123):ra42.  
199.  Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through 
disruption of ubiquitin enzyme complexes. Science. 2010 Feb 26;327(5969):1135–1139.  
200.  Saito K, Kigawa T, Koshiba S, Sato K, Matsuo Y, Sakamoto A, et al. The CAP-Gly 
domain of CYLD associates with the proline-rich sequence in NEMO/IKKgamma. 
Structure. 2004 Sep;12(9):1719–1728.  
 169 
201.  Zhang J, Stirling B, Temmerman ST, Ma CA, Fuss IJ, Derry JMJ, et al. Impaired 
regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis 
in CYLD-deficient mice. J Clin Invest. 2006 Nov;116(11):3042–3049.  
202.  Jin W, Chang M, Paul EM, Babu G, Lee AJ, Reiley W, et al. Deubiquitinating enzyme 
CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin 
Invest. 2008 May;118(5):1858–1866.  
203.  Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, Norbury CC, et al. Regulation 
of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol. 2006 
Apr;7(4):411–417.  
204.  Reiley WW, Jin W, Lee AJ, Wright A, Wu X, Tewalt EF, et al. Deubiquitinating enzyme 
CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T 
cell responses. J Exp Med. 2007 Jun 11;204(6):1475–1485.  
205.  Elliott PR, Nielsen SV, Marco-Casanova P, Fiil BK, Keusekotten K, Mailand N, et al. 
Molecular basis and regulation of OTULIN-LUBAC interaction. Mol Cell. 2014 May 
8;54(3):335–348.  
206.  Yamaguchi M, Yu S, Qiao R, Weissmann F, Miller DJ, VanderLinden R, et al. Structure 
of an APC3-APC16 complex: insights into assembly of the anaphase-promoting 
complex/cyclosome. J Mol Biol. 2015 Apr 24;427(8):1748–1764.  
207.  Conti HR, Gaffen SL. IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen 
Candida albicans. J Immunol. 2015 Aug 1;195(3):780–788.  
208.  Song X, Qian Y. The activation and regulation of IL-17 receptor mediated signaling. 
Cytokine. 2013 May;62(2):175–182.  
 170 
209.  Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune 
demyelinating disease. Trends Immunol. 2011 May;32(5):232–239.  
210.  Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 
function in disease. Immunology. 2010 Mar;129(3):311–321.  
211.  Oshima S, Turer EE, Callahan JA, Chai S, Advincula R, Barrera J, et al. ABIN-1 is a 
ubiquitin sensor that restricts cell death and sustains embryonic development. Nature. 
2009 Feb 12;457(7231):906–909.  
212.  Shen F, Ruddy MJ, Plamondon P, Gaffen SL. Cytokines link osteoblasts and 
inflammation: microarray analysis of interleukin-17- and TNF-alpha-induced genes in 
bone cells. J Leukoc Biol. 2005 Mar;77(3):388–399.  
213.  Heyninck K, De Valck D, Vanden Berghe W, Van Criekinge W, Contreras R, Fiers W, et 
al. The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene 
expression by interfering with an RIP- or TRAF2-mediated transactivation signal and 
directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol. 1999 Jun 
28;145(7):1471–1482.  
214.  Heyninck K, Kreike MM, Beyaert R. Structure–function analysis of the A20-binding 
inhibitor of NF-κB activation, ABIN-1. FEBS Lett. 2003 Feb;536(1-3):135–140.  
215.  Cohen S, Ciechanover A, Kravtsova-Ivantsiv Y, Lapid D, Lahav-Baratz S. ABIN-1 
negatively regulates NF-kappaB by inhibiting processing of the p105 precursor. Biochem 
Biophys Res Commun. 2009 Nov 13;389(2):205–210.  
216.  Sun S-C. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev 
Immunol. 2017 Sep;17(9):545–558.  
 171 
217.  Tian B, Nowak DE, Jamaluddin M, Wang S, Brasier AR. Identification of direct genomic 
targets downstream of the nuclear factor-kappaB transcription factor mediating tumor 
necrosis factor signaling. J Biol Chem. 2005 Apr 29;280(17):17435–17448.  
218.  Gurevich I, Zhang C, Encarnacao PC, Struzynski CP, Livings SE, Aneskievich BJ. 
PPARγ and NF-κB regulate the gene promoter activity of their shared repressor, TNIP1. 
Biochim Biophys Acta. 2012 Jan;1819(1):1–15.  
219.  Gurevich I, Zhang C, Francis N, Struzynsky CP, Livings SE, Aneskievich BJ. Human 
TNFα-induced protein 3-interacting protein 1 (TNIP1) promoter activation is regulated by 
retinoic acid receptors. Gene. 2013 Feb 15;515(1):42–48.  
220.  Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, 
a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. 
Sci Transl Med. 2010 Oct 6;2(52):52ra72.  
221.  Swindell WR, Sarkar MK, Liang Y, Xing X, Gudjonsson JE. Cross-Disease 
Transcriptomics: Unique IL-17A Signaling in Psoriasis Lesions and an Autoimmune 
PBMC Signature. J Invest Dermatol. 2016 Sep;136(9):1820–1830.  
222.  Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and 
therapeutic potential. Clin Sci. 2012 Jun;122(11):487–511.  
223.  Li Y, Cheng H, Zuo X, Sheng Y, Zhou F, Tang X, et al. Association analyses identifying 
two common susceptibility loci shared by psoriasis and systemic lupus erythematosus in 
the Chinese Han population. J Med Genet. 2013 Dec;50(12):812–818.  
224.  Kawasaki A, Ito S, Furukawa H, Hayashi T, Goto D, Matsumoto I, et al. Association of 
TNFAIP3 interacting protein 1, TNIP1 with systemic lupus erythematosus in a Japanese 
population: a case-control association study. Arthritis Res Ther. 2010 Sep 17;12(5):R174.  
 172 
225.  Heyninck K, Denecker G, De Valck D, Fiers W, Beyaert R. Inhibition of tumor necrosis 
factor-induced necrotic cell death by the zinc finger protein A20. Anticancer Res. 1999 
Aug;19(4B):2863–2868.  
226.  Heyninck K, Beyaert R. The cytokine-inducible zinc finger protein A20 inhibits IL-1-
induced NF-kappaB activation at the level of TRAF6. FEBS Lett. 1999 Jan 15;442(2-
3):147–150.  
227.  Yuan S, Dong X, Tao X, Xu L, Ruan J, Peng J, et al. Emergence of the A20/ABIN-
mediated inhibition of NF-κB signaling via modifying the ubiquitinated proteins in a 
basal chordate. Proc Natl Acad Sci U S A. 2014 May 6;111(18):6720–6725.  
228.  Gao L, Coope H, Grant S, Ma A, Ley SC, Harhaj EW. ABIN1 protein cooperates with 
TAX1BP1 and A20 proteins to inhibit antiviral signaling. J Biol Chem. 2011 Oct 
21;286(42):36592–36602.  
229.  Nanda SK, Venigalla RKC, Ordureau A, Patterson-Kane JC, Powell DW, Toth R, et al. 
Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. J Exp Med. 2011 
Jun 6;208(6):1215–1228.  
230.  Tian B, Nowak DE, Brasier AR. A TNF-induced gene expression program under 
oscillatory NF-kappaB control. BMC Genomics. 2005 Sep 28;6:137.  
231.  Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-
interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J 
Med. 2012 Mar 29;366(13):1190–1199.  
232.  Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig 
Drugs. 2013 Aug;22(8):993–1005.  
 173 
233.  Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, et al. 
Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine 
receptor. Immunity. 1995 Dec;3(6):811–821.  
234.  Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol. 2017 May 
18;18(6):612–621.  
235.  Weathington NM, Mallampalli RK. Emerging therapies targeting the ubiquitin 
proteasome system in cancer. J Clin Invest. 2014 Jan 2;124(1):6–12.  
236.  Sargiacomo M, Scherer PE, Tang Z, Kübler E, Song KS, Sanders MC, et al. Oligomeric 
structure of caveolin: implications for caveolae membrane organization. Proc Natl Acad 
Sci U S A. 1995 Sep 26;92(20):9407–9411.  
237.  Han B, Tiwari A, Kenworthy AK. Tagging strategies strongly affect the fate of 
overexpressed caveolin-1. Traffic. 2015 Apr;16(4):417–438.  
238.  Li WP, Liu P, Pilcher BK, Anderson RG. Cell-specific targeting of caveolin-1 to 
caveolae, secretory vesicles, cytoplasm or mitochondria. J Cell Sci. 2001 Apr;114(Pt 
7):1397–1408.  
239.  Virgintino D, Robertson D, Errede M, Benagiano V, Tauer U, Roncali L, et al. 
Expression of caveolin-1 in human brain microvessels. Neuroscience. 2002;115(1):145–
152.  
240.  Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health 
and disease. Physiol Rev. 2004 Oct;84(4):1341–1379.  
241.  Robenek MJ, Severs NJ, Schlattmann K, Plenz G, Zimmer K-P, Troyer D, et al. Lipids 
partition caveolin-1 from ER membranes into lipid droplets: updating the model of lipid 
droplet biogenesis. FASEB J. 2004 May;18(7):866–868.  
 174 
242.  Song J, Bishop BL, Li G, Grady R, Stapleton A, Abraham SN. TLR4-mediated expulsion 
of bacteria from infected bladder epithelial cells. Proc Natl Acad Sci U S A. 2009 Sep 
1;106(35):14966–14971.  
243.  Feng X, Gaeta ML, Madge LA, Yang JH, Bradley JR, Pober JS. Caveolin-1 associates 
with TRAF2 to form a complex that is recruited to tumor necrosis factor receptors. J Biol 
Chem. 2001 Mar 16;276(11):8341–8349.  
244.  Garrean S, Gao X-P, Brovkovych V, Shimizu J, Zhao Y-Y, Vogel SM, et al. Caveolin-1 
regulates NF-kappaB activation and lung inflammatory response to sepsis induced by 
lipopolysaccharide. J Immunol. 2006 Oct 1;177(7):4853–4860.  
245.  Tourkina E, Hoffman S. Caveolin-1 signaling in lung fibrosis. Open Rheumatol J. 2012 
Jun 15;6:116–122.  
246.  Wang XM, Kim HP, Song R, Choi AMK. Caveolin-1 confers antiinflammatory effects in 
murine macrophages via the MKK3/p38 MAPK pathway. Am J Respir Cell Mol Biol. 
2006 Apr;34(4):434–442.  
247.  D’Alessio A, Kluger MS, Li JH, Al-Lamki R, Bradley JR, Pober JS. Targeting of tumor 
necrosis factor receptor 1 to low density plasma membrane domains in human endothelial 
cells. J Biol Chem. 2010 Jul 30;285(31):23868–23879.  
248.  Kong MMC, Hasbi A, Mattocks M, Fan T, O’Dowd BF, George SR. Regulation of D1 
dopamine receptor trafficking and signaling by caveolin-1. Mol Pharmacol. 2007 
Nov;72(5):1157–1170.  
249.  Ho AW, Gaffen SL. IL-17RC: a partner in IL-17 signaling and beyond. Semin 
Immunopathol. 2010 Mar;32(1):33–42.  
 175 
250.  Willis CR, Siegel L, Leith A, Mohn D, Escobar S, Wannberg S, et al. IL-17RA Signaling 
in Airway Inflammation and Bronchial Hyperreactivity in Allergic Asthma. Am J Respir 
Cell Mol Biol. 2015 Dec;53(6):810–821.  
251.  Machleidt T, Li WP, Liu P, Anderson RG. Multiple domains in caveolin-1 control its 
intracellular traffic. J Cell Biol. 2000 Jan 10;148(1):17–28.  
252.  Lisanti MP, Tang ZL, Sargiacomo M. Caveolin forms a hetero-oligomeric protein 
complex that interacts with an apical GPI-linked protein: implications for the biogenesis 
of caveolae. J Cell Biol. 1993 Nov;123(3):595–604.  
253.  Liu P, Li WP, Machleidt T, Anderson RG. Identification of caveolin-1 in lipoprotein 
particles secreted by exocrine cells. Nat Cell Biol. 1999 Oct;1(6):369–375.  
254.  Pol A, Luetterforst R, Lindsay M, Heino S, Ikonen E, Parton RG. A caveolin dominant 
negative mutant associates with lipid bodies and induces intracellular cholesterol 
imbalance. J Cell Biol. 2001 Mar 5;152(5):1057–1070.  
255.  Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP. Identification of peptide and protein 
ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin 
with caveolae-associated proteins. J Biol Chem. 1997 Mar 7;272(10):6525–6533.  
256.  Ely LK, Fischer S, Garcia KC. Structural basis of receptor sharing by interleukin 17 
cytokines. Nat Immunol. 2009 Dec;10(12):1245–1251.  
257.  Sotgia F, Razani B, Bonuccelli G, Schubert W, Battista M, Lee H, et al. Intracellular 
retention of glycosylphosphatidyl inositol-linked proteins in caveolin-deficient cells. Mol 
Cell Biol. 2002 Jun;22(11):3905–3926.  
258.  Syme CA, Zhang L, Bisello A. Caveolin-1 regulates cellular trafficking and function of 
the glucagon-like Peptide 1 receptor. Mol Endocrinol. 2006 Dec;20(12):3400–3411.  
 176 
259.  Wertz JW, Bauer PM. Caveolin-1 regulates BMPRII localization and signaling in 
vascular smooth muscle cells. Biochem Biophys Res Commun. 2008 Oct 31;375(4):557–
561.  
260.  Galbiati F, Volonte D, Brown AM, Weinstein DE, Ben-Ze’ev A, Pestell RG, et al. 
Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-
catenin to caveolae membrane domains. J Biol Chem. 2000 Jul 28;275(30):23368–23377.  
261.  Awane M, Andres PG, Li DJ, Reinecker HC. NF-kappa B-inducing kinase is a common 
mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in 
intestinal epithelial cells. J Immunol. 1999 May 1;162(9):5337–5344.  
262.  Kao C-Y, Chen Y, Thai P, Wachi S, Huang F, Kim C, et al. IL-17 markedly up-regulates 
beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB 
signaling pathways. J Immunol. 2004 Sep 1;173(5):3482–3491.  
263.  Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling 
component of interleukin-17 receptor. J Biol Chem. 2006 Nov 24;281(47):35603–35607.  
264.  Wang P, Zhu F, Tong Z, Konstantopoulos K. Response of chondrocytes to shear stress: 
antagonistic effects of the binding partners Toll-like receptor 4 and caveolin-1. FASEB J. 
2011 Oct;25(10):3401–3415.  
265.  Jagielska J, Kapopara PR, Salguero G, Scherr M, Schütt H, Grote K, et al. Interleukin-1 
assembles a proangiogenic signaling module consisting of caveolin-1, tumor necrosis 
factor receptor-associated factor 6, p38-mitogen-activated protein kinase (MAPK), and 
MAPK-activated protein kinase 2 in endothelial cells. Arterioscler Thromb Vasc Biol. 
2012 May;32(5):1280–1288.  
 177 
266.  Fridolfsson HN, Roth DM, Insel PA, Patel HH. Regulation of intracellular signaling and 
function by caveolin. FASEB J. 2014 Sep;28(9):3823–3831.  
267.  Luttrell LM, van Biesen T, Hawes BE, Koch WJ, Krueger KM, Touhara K, et al. G-
protein-coupled receptors and their regulation: activation of the MAP kinase signaling 
pathway by G-protein-coupled receptors. Adv Second Messenger Phosphoprotein Res. 
1997;31:263–277.  
268.  Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant 
signal transduction molecules. Annu Rev Pharmacol Toxicol. 2008;48:359–391.  
269.  Gallagher J, Howlin J, McCarthy C, Murphy EP, Bresnihan B, FitzGerald O, et al. 
Identification of Naf1/ABIN-1 among TNF-alpha-induced expressed genes in human 
synoviocytes using oligonucleotide microarrays. FEBS Lett. 2003 Sep 11;551(1-3):8–12.  
270.  Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-kappaB regulatory pathways. 
Annu Rev Biochem. 2009;78:769–796.  
271.  Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I kappa B-alpha 
proteolysis by site-specific, signal-induced phosphorylation. Science. 1995 Mar 
10;267(5203):1485–1488.  
272.  Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends 
Biochem Sci. 1996 Jul;21(7):267–271.  
273.  Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. Structure of a beta-
TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the 
SCF(beta-TrCP1) ubiquitin ligase. Mol Cell. 2003 Jun;11(6):1445–1456.  
 178 
274.  Kroll M, Margottin F, Kohl A, Renard P, Durand H, Concordet JP, et al. Inducible 
degradation of IkappaBalpha by the proteasome requires interaction with the F-box 
protein h-betaTrCP. J Biol Chem. 1999 Mar 19;274(12):7941–7945.  
275.  Kuang P, Tan M, Zhou W, Zhang Q, Sun Y. SAG/RBX2 E3 ligase complexes with 
UBCH10 and UBE2S E2s to ubiquitylate β-TrCP1 via K11-linkage for degradation. Sci 
Rep. 2016 Dec 2;6:37441.  
276.  Moreno-Càceres J, Caja L, Mainez J, Mayoral R, Martín-Sanz P, Moreno-Vicente R, et 
al. Caveolin-1 is required for TGF-β-induced transactivation of the EGF receptor pathway 
in hepatocytes through the activation of the metalloprotease TACE/ADAM17. Cell Death 
Dis. 2014 Jul 17;5:e1326.  
277.  Mirza MK, Yuan J, Gao X-P, Garrean S, Brovkovych V, Malik AB, et al. Caveolin-1 
deficiency dampens Toll-like receptor 4 signaling through eNOS activation. Am J Pathol. 
2010 May;176(5):2344–2351.  
278.  Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, et al. Constitutive and 
growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in 
vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol. 2000 
Nov;14(11):1750–1775.  
279.  Honda K, Wada H, Nakamura M, Nakamoto K, Inui T, Sada M, et al. IL-17A 
synergistically stimulates TNF-α-induced IL-8 production in human airway epithelial 
cells: A potential role in amplifying airway inflammation. Exp Lung Res. 2016 
May;42(4):205–216.  
 179 
280.  Lee JW, Wang P, Kattah MG, Youssef S, Steinman L, DeFea K, et al. Differential 
regulation of chemokines by IL-17 in colonic epithelial cells. J Immunol. 2008 Nov 
1;181(9):6536–6545.  
281.  Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on 
macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation 
by soluble receptors and Th2 cytokines. J Immunol. 2001 Nov 15;167(10):6015–6020.  
282.  Basak S, Hoffmann A. Crosstalk via the NF-kappaB signaling system. Cytokine Growth 
Factor Rev. 2008 Aug;19(3-4):187–197.  
283.  Huppler AR, Whibley N, Woolford CA, Childs EE, He J, Biswas PS, et al. A Candida 
albicans Strain Expressing Mammalian Interleukin-17A Results in Early Control of 
Fungal Growth during Disseminated Infection. Infect Immun. 2015 Sep;83(9):3684–
3692.  
284.  Monin L, Gudjonsson JE, Childs EE, Amatya N, Xing X, Verma AH, et al. 
MCPIP1/Regnase-1 Restricts IL-17A- and IL-17C-Dependent Skin Inflammation. J 
Immunol. 2017 Jan 15;198(2):767–775.  
285.  Nakayama K, Hatakeyama S, Maruyama S, Kikuchi A, Onoé K, Good RA, et al. 
Impaired degradation of inhibitory subunit of NF-kappa B (I kappa B) and beta-catenin as 
a result of targeted disruption of the beta-TrCP1 gene. Proc Natl Acad Sci U S A. 2003 
Jul 22;100(15):8752–8757.  
286.  Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV, et al. Genome-
wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet. 
2010 Nov;42(11):991–995.  
 180 
287.  Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, et al. IL-17 plays 
an important role in the development of experimental autoimmune encephalomyelitis. J 
Immunol. 2006 Jul 1;177(1):566–573.  
288.  Hu Y, Ota N, Peng I, Refino CJ, Danilenko DM, Caplazi P, et al. IL-17RC is required for 
IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental 
autoimmune encephalomyelitis. J Immunol. 2010 Apr 15;184(8):4307–4316.  
289.  Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, et al. T 
helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and 
experimental encephalomyelitis. Nat Med. 2010 Apr;16(4):406–412.  
290.  Wu H, Deng R, Chen X, Wong WC, Chen H, Gao L, et al. Caveolin-1 Is Critical for 
Lymphocyte Trafficking into Central Nervous System during Experimental Autoimmune 
Encephalomyelitis. J Neurosci. 2016 May 11;36(19):5193–5199.  
291.  Zhang A, Wang K, Zhou C, Gan Z, Ma D, Ye P, et al. Knockout of microRNA-155 
ameliorates the Th1/Th17 immune response and tissue injury in chronic rejection. J Heart 
Lung Transplant. 2017 Feb;36(2):175–184.  
292.  Lutz SE, Smith JR, Kim DH, Olson CVL, Ellefsen K, Bates JM, et al. Caveolin1 Is 
Required for Th1 Cell Infiltration, but Not Tight Junction Remodeling, at the Blood-Brain 
Barrier in Autoimmune Neuroinflammation. Cell Rep. 2017 Nov 21;21(8):2104–2117.  
293.  Van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, et al. Imiquimod-
induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J 
Immunol. 2009 May 1;182(9):5836–5845.  
 181 
294.  Gilliam AJH, Smith JN, Flather D, Johnston KM, Gansmiller AM, Fishman DA, et al. 
Affinity-Guided Design of Caveolin-1 Ligands for Deoligomerization. J Med Chem. 2016 
Apr 28;59(8):4019–4025.  
 
